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ABSTRACT 
Background. Colorectal cancer (CRC) is a major cause of death for cancer in 
western countries, ranking third in both sexes. Therapeutic developments in the 
past decades have extended life expectancy in patients with advanced disease 
(i.e., stage III), and even for those with distant metastasis (i.e., stage IV). Most 
treatments for advanced disease nowadays include a combination of 
chemotherapy with target therapy. Despite advances, the fact that metastatic 
colorectal cancer remains largely incurable, pushes to pursue a better 
understanding of the factors underlying cancer progression. Nowadays, a major 
field of investigation is the relationship between epithelial tumor cells and the 
surrounding compartment, namely tumor microenvironment, and in particular its 
contribution to cancer progression. 
The tumor microenvironment essentially comprises tumor infiltrating cells, 
vasculature, extracellular matrix, plus other matrix associated molecules. 
Transformed cells can modulate the functions of stromal cells, likely to facilitate 
their own growth and survival. In this Darwinian perspective, outgrowth of cancer 
cells goes together with local changes. Such changes, like clonal ones, are likely 
progressive, from the stage of local invasion, up to regional lymph-node 
colonization and finally to the development of distant metastasis.  
Infiltrating cells are a mix of populations having myeloid or mesenchymal origin, 
including tumor-associated macrophages, myeloid -derived suppressor cells, mast 
cells, monocytes, neutrophils, CD3+ T cells, natural killers, dendritic cells, 
endothelial cells, mesenchymal stem cells and cancer-associated fibroblasts. 
Taken together, all these players are involved in a double-faced game, in which an 
anti-tumor effect (such as that exerted by CD3+ cells in early CRC, [1]) is 
counteracted by a cancer promoting one (e.g., that exerted by macrophages [2]. 
Currently, this cancer-microenvironment match implies contradictory and 
controversial data, largely depending upon the investigated cell population and 
upon the experimental setting. This Ariadnes' thread seems unravelled, mainly 
because of the contemporaneous evolution of both tumor and microenvironment 
cells during multi-stage tumor progression. What is certainly perceived today, is 
that a switch from a genetic to a non-clonal prospective is required to understand 
tumor evolution. Clearly, the dynamic architecture of the stromal compartment and 
the interactions therein, need to be reconciled with the evidences concerning 
genetic irreversible changes in stromal cells. The latter include loss of 
heterozygosis, microsatellite instability (MSI) [3], trisomy of Chromosome 7 in 
connective tissues elements of  CRC [4], and p53 mutations (in the stroma of 
breast carcinoma[5]). These surprising results rise the possibility that the stromal 
compartment contains not only an admixture of  non-neoplastic cells, but also 
cancer cells with an aggressive and invasive phenotype which became able to 
invade the surrounding tissues by mimicking fibroblast morphology. This 
metamorphosis would be possible through the re-use of an embryonic program by 
cancer cells, that is the epithelial to mesenchymal transition (EMT). Originally, in 
a murine model of spontaneous metastatic breast cancer, Weinberg and Coll. 
demonstrated that the highest aggressive potential of cancer cell was reached after 
their transition from an epithelial to a mesenchymal morphology (i.e., EMT), driven 
by Twist1 gene [6]. Twist1 expression and EMT are strictly associated with the 
acquisition of a spindle-like fibroblast morphology, the down-regulation of the 
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epithelial marker E-cadherin and the expression of mesenchymal ones (N-cadherin 
and vimentin), with metastases development, and with the inhibition of the key 
pathway of senescence p16 driven [7]. Currently, many studies demonstrate that 
this embryonic program is activated by a set of transcription factors which act 
pleiotropically. These include Snail, Slug, Zeb1/2, and obviously Twist1. These 
regulators are expressed in various combination in a number of malignant tumor 
types and have been shown in experimental models of carcinoma formation to be 
casually important for programming invasion [8], [9], [10], [11].   
The issues. The multi-step process of metastasis development, recapitulated by 
local invasion, intravasation, extravasation, colonization and growth in distant 
organs, postulates that cells undergoing EMT should be able to complete each 
individual step. However, no experimental evidence of the EMT process has been 
provided for the first step of local invasion (nor for the following ones)  in tissues 
specimens of human malignancies. Similarly, proof of EMT in human epithelial 
cancer cells remains partial, largely derived from murine models, and based on 
ectopic expression of EMT regulators, or on stimulation to achieve transient 
mesenchymal features. Although several studies demonstrate the expression of 
EMT transcription factors in both the tumoral and stromal compartments of different 
cancers [12], [13], [14], they do not directly link this expression to the presence of 
cancer infiltrating cells.  
The experimental work. We moved from the unexplained evidence of genetic and 
chromosomal abnormalities in the stromal compartment of solid tumors, and from 
the role of Twist1 as EMT regulator in cancer cells.  
Moving by microarray data of a pool of CRC cells, we first show that tumor cells 
with a permanent mesenchymal signature, in a stable EMT state, can arise from 
epithelial CRC cells, both in humans and mice. Then we clarify that, within the 
mesenchymal signature, Twist1 plays a crucial role in the migration and invasion of 
CRC tumor cells.  
By a combination of immuno-based and cytogenetic methods we detected in 
human CRC a Twist1+subpopulation of stromal cells, with a mesenchymal 
phenotype. This subpopuation was more represented in MS-stable CRC than in 
less metastatic MS-unstable CRC, and was associated with advanced CRC stage 
and with worse survival. Additionally, we showed that Twist1 transcript is degraded 
in MSI CRC, due to a frameshifted 3’-UTR, and propose that this mechanism 
contributes to the low capability of MSI CRC to exploit EMT to undergo metastasis.   
Finally, we identified Twist1+, stromal cells which share genetic changes with 
epithelial cancer cells, establishing a genetic link between epithelial and 
mesenchymal components of CRC.  
In summary, we provide data from an original cellular model to tissue studies to 
prove the occurrence of EMT in human CRC. We demonstrated the presence of 
tumor cells in the stroma of CRC tumors and we give a method to identify those 
cells undergone to EMT and able to invade the surrounding tissues. Thus, our 
results readdress the study approach to  the stromal compartment from that of a 
recipient of non-neoplastic cells to an incubator of cancer EMT cells able to disrupt 
tissues by mimicking activated fibroblast. 
The experimental demonstration of human CRC in stable EMT, coupled to the 
identification of  previously postulated tumor cells with mesenchymal morphology in 
the stromal compartment, add substantial evidence to EMT, translating a model it 
into a real phenomenon contributing to the metastatic process of human CRC. In a 
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clinical perspective, our study highlights the importance to re-evaluate the target 
therapy of solid tumors from the epithelial compartment to include the 
mesenchymal one. 
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1. INTRODUCTION 
It is now ascertained that human cancer can be characterized by patterns of 
changes in gene expression. Genes that mediate tumorigenesis can be broadly 
characterized as oncogenes, which are activated by alterations; and tumour 
suppressor genes, which are inactivated during tumorigenesis. Oncogenes can 
encode growth factors or their receptors, signalling molecules, regulators of the cell 
cycle, and other factors that regulate cell proliferation and survival. Their 
oncogenicity can be induced by mutations that lead to overactive gene products, 
amplifications that alter copy number, alterations or rearrangements that affect 
promoter function, or modified interactions with regulators of transcription or 
epigenetic modification. Tumour suppressors restrain growth and proliferation, 
passage through the cell cycle, motility, invasion, or other functions related to 
stable differentiation. Genes that encode tumour suppressors are commonly 
inactivated by deletion, mutations, promoter methylation, or other changes in 
regulation. Colorectal cancer (CRC),is a major public health problem in the United 
States and globally. In the United States, it is the third in cancer incidence, and the 
second leading cause of cancer mortality. In 2010, there will be an estimated 
50,000 death associated with this disease. Worldwide, there will be nearly 
1,000,000 of new cases diagnosed in 2008, resulting in about 500,000 deaths. It 
has now been well established that CRC develop gradually over a long period of 
time through the sequential accumulation of genetic alterations that overcome the 
redundant control mechanisms built into each cell. Only a few mutations are 
common to most colorectal tumours, but each tumour has a unique combination of 
genetic alterations. It is possible that no two CRCs are alike, a daunting 
consideration for the rational planning of treatment.  
1.1 Models of CRC Pathogenesis 
It was not immediately obvious that CRCs would be so diverse genetically. The 
initial attempt to characterize multistep carcinogenesis resulted in a novel 
conceptual model in which specific genetic alterations were associated with the 
sequential evolution of the neoplastic phenotype in the colon.  
CRCs develop through an ordered series of events i.e. the so-called “adenoma–
carcinoma sequence”, beginning with the transformation of normal colonic 
epithelium to an adenomatous intermediate and then ultimately adenocarcinoma 
[15]. Multiple genetic events are required for tumour progression. Genomic 
instability is now recognized as an essential cellular feature that accompanies the 
acquisition of these mutations. In CRC, at least three distinct pathways of genomic 
instability have been described, the chromosomal instability (CIN), microsatellite 
instability (MSI), and CpG island methylator phenotype (CIMP) pathways. 
In 1990, Fearon and Vogelstein [16] first proposed a multistep genetic model of 
colorectal carcinogenesis that has come to serve as a paradigm for solid tumour 
progression. Inactivation of the adenomatous polyposis coli (APC) tumour 
suppressor gene occurs first, followed by activating mutations of KRAS (Figure 
1.1). Subsequent malignant transformation is driven by additional mutations in the 
transforming growth factor–β, PIK3CA, and TP53 pathways [15,16,17,18,19,20] 
This model predicts that at least seven distinct mutations are required. Recent 
genome-wide sequencing efforts have calculated as many as 80 mutated genes 
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per colorectal tumour, but a smaller group of mutations (<15) were considered to 
be the true “drivers” of tumorigenesis. [21,22] Although continue to be proposed 
refinements to the original model, three key principles have been today well 
established: a) multiple genetic hits are required, b) there are discrete 
intermediates in the progression to cancer, and c) the temporal acquisition of these 
genetic changes matters. For example, APC mutations serve as the initiating event 
in adenoma formation in human and mouse models. In contrast, mutational 
activation of KRAS cannot initiate cancer in vivo, and only when combined with a 
mutation in APC does mutant KRAS promote tumour progression [23]  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 Multistep genetic model of colorectal carcinogenesis (The Chromosomal 
instability in Colorectal cancer, Gastroenterology, 2010) 
1.1.1 Genomic Instability and CRC 
Baseline mutation rates are insufficient to account for the multiple mutations that 
are required for cancer to develop. The rate of mutations per nucleotide base pair 
is estimated to be as low as 10−9 per cellular generation [24]. As proposed by Loeb 
et al. cancer cells must acquire some form of intrinsic genomic instability, a so-
called “mutator phenotype,” that increases their rate of new mutations [25]. CIN is 
observed in 65%–70% of sporadic CRCs; the term refers to an accelerated rate of 
gains or losses of whole or large portions of chromosomes that results in karyotypic 
variability from cell to cell [26]. The consequence of CIN is an imbalance in 
chromosome number (aneuploidy), subchromosomal genomic amplifications, and a 
high frequency of loss of heterozygosity (LOH). A defect in the DNA mismatch 
repair system leads to a second pathway characterized by instability in stretches of 
DNA microsatellites. The third pathway is designated the CIMP, which exhibits 
gene silencing due to hypermethylation of CpG islands [30]. Because the 
definitions of these three pathways are not mutually exclusive, a tumour can 
occasionally exhibit features of multiple pathways. For example, up to 25% of MSI 
CRCs can exhibit chromosomal abnormalities [31] In addition, whereas CIMP can 
account for most of the MSI-positive/CIN-negative CRCs, up to 33% of CIMP-
positive tumours can exhibit a high degree of chromosomal aberrations[29] 
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Conversely, as many as 12% of CIN-positive tumours exhibit high levels of 
MSI[32]. The significance and implications of these overlapping features are not yet 
fully defined. 
1.1.2 Mechanisms Leading to Chromosomal Instability 
It is now known that more than 100 genes can cause chromosomal instability in the 
yeast Saccharomyces cerevisiae. Although many of these genes have human 
homologues, only a limited number have been implicated in human tumours. 
1.1.2.1Chromosome Segregation Defects and CIN 
The CIN phenotype could result from defects in pathways that ensure accurate 
chromosome segregation. The mitotic checkpoint (also known as the spindle 
assembly checkpoint) is the major cell cycle control mechanism that ensures high 
fidelity of chromosome segregation by delaying the onset of anaphase until all 
pairs of duplicated chromatids are properly aligned on the metaphase plate. 
Defects in checkpoint signalling lead to chromosome mis-segregation and 
subsequent aneuploidy with abnormal numbers of chromosomes being distributed 
to daughter cells. Nearly 100 years ago, Theodor Boveri suggested that malignant 
tumours may arise from a single cell with an abnormal genetic constitution acquired 
as a result of defects in the mitotic spindle apparatus [33]  
Products of the genes mitotic arrest–deficient (MAD) and budding uninhibited by 
benzimidazoles (BUB) operate as checkpoint sensors and signal transducers that 
control sister chromatid separation. Their activation causes inhibition of the 
anaphase-promoting complex/C (APC/C), a large ubiquitin-protein ligase, and cell 
cycle arrest. MAD3/BUBR1, MAD2, and BUB3 associate with the APC/C-activating 
molecule CDC20 to form the mitotic checkpoint complex and induces a 
conformational change in the APC/C, which prevents binding and ubiquitination of 
its substrates [34]. Activation of the APC/C leads to degradation of securin and 
activation of separases, a class of caspase-related proteases. Separase regulates 
a multiprotein complex termed cohesin, which creates physical links between sister 
chromatids that are maintained until late mitosis. Errors in this complex and 
ordered process result in unequal chromosomal segregation. Cahill et al 
demonstrated that cancer cell lines with mutations in hBUB1 and hBUBR1 failed to 
arrest when spindles were depolymerized[35]. Mutations in hBUB1 were dominant 
because exogenous expression of the mutant gene conferred an abnormal spindle 
checkpoint and CIN to chromosomally stable cell lines [36]. To date, hMAD2 and 
hMAD1 mutations have been identified in breast cancer and leukemia, 
respectively, but not in CRC [37,38]. However, mutations in the hZw10, 
hZwilch/FLJ10036, and hRod/KNTC kinetochore proteins that function at the 
spindle checkpoint, and in Ding, which is essential for proper chromosome 
disjunction, have been reported in CRC [39]. Another protein involved in the mitotic 
checkpoint is the centromere-associated protein E (CENP-E), a kinetochore-
associated kinesin-like protein. CENP-E stabilizes the interaction between 
microtubules and kinetochores and stimulates the recruitment and kinase activity of 
BubR1. Fibroblasts derived from mice heterozygous for CENP-E show significantly 
higher rates of aneuploidy than wild-type fibroblasts due to chromosomal mis-
segregation. Another proposed cause of CIN is the abnormal centrosome number 
and function. Centrosomes coordinate mitosis by serving as an anchor for the 
reorganization of cytoplasmic microtubules into a mitotic spindle apparatus. It has 
been proposed that extra centrosomes lead to the formation of multiple spindle 
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poles during mitosis, resulting in the unequal distribution of chromosomes. 
Evidence of a causal relationship between centrosome amplification and cancer 
has recently been provided in flies[42]. Transplantation of larval brain cells with 
extra centrosomes induced the formation of metastatic tumours, suggesting that 
centrosome amplification can initiate tumorigenesis. 
A pathogenic role for centrosome-associated Aurora and Polo-like kinases (Plk) 
has been also identified. There are three human Aurora kinases with distinct 
subcellular localizations and roles. Aurora A (AURKA) is involved in centrosome 
function and duplication, mitotic entry, and bipolar spindle assembly. Aurora A 
overexpression is associated with centrosome amplification, arrested mitosis with 
incomplete cytokinesis, and multinucleation [43] AURKA is amplified and positively 
associated with the degree of CIN in CRC [44] Aurora B is the catalytic component 
of the chromosomal passenger complex that regulates the accurate segregation of 
chromatids at mitosis, histone modification, and cytokinesis. Although its 
involvement in tumorigenesis is less clear, Aurora B overexpression correlates with 
advanced stages in CRC [45] Plk1 to Plk4 are serine/threonine kinases, which 
regulate entry into mitosis, centrosome duplication, transition from metaphase to 
anaphase, and cytokinesis. Two recent studies have provided evidence of a cross-
talk between Plk1 and Aurora A. [46,47] Elevated expression of Plk1 has been 
observed in up to 73% of primary CRCs, and this correlated with tumour invasion, 
lymph node involvement, and Dukes' stage [48].  
1.1.2.2 Telomere Dysfunction and CIN 
Evidences indicate that CIN can be driven by telomere dysfunction. Telomeres are 
DNA-protein complexes that consist of stretches of hexameric repeats (TTAGGG in 
humans) that protect the ends of eukaryotic chromosomes from fusing and 
breaking during segregation. In somatic cells, a portion of telomeric DNA is lost 
after each round of cell division, due to the inability of DNA polymerase to 
completely synthesize the 3′ end of linear chromosomes, also known as the “end-
replication problem.” When a critical short telomere length is reached, DNA 
damage checkpoints trigger cell senescence pathways and apoptosis. Cells that 
fail to undergo senescence enter a crisis-like state characterized by massive cell 
deaths. Cells that survive the crisis checkpoint activate the enzyme complex that 
elongates telomeres called telomerase, or alternatively the Alternative Lengthening 
of Telomeres pathway. 
When the telomere end protection is compromised, chromosomal ends enter in 
breakage-fusion-bridge cycles that can continue for multiple cell generations 
leading to dramatic genome reorganization. Genomic amplification at fragile sites 
can commonly result from breakage-fusion-bridge cycles [49].The importance of 
telomere loss and breakage-fusion-bridge cycles has been demonstrated in vivo. In 
mice deficient in the RNA component of telomerase (Terc−/−), telomere shortening 
led to increased rates of spontaneous tumour development of aberrant crypt foci 
and microadenomas in the gastrointestinal tract [50]. Additionally it has been also 
demonstrated that telomeres are shortened at the stage of high-grade dysplasia 
[51]. Several Authors have reported shorter telomeres rate ranging between 77% 
and 90% in CRC tissues, compared with adjacent normal 
counterparts[52,52,54,55].These observations led to hypothesize that whereas 
telomere shortening promotes the chromosomal instability that drives early 
carcinogenesis, telomerase activation during later stages confers immortality to the 
tumour cells. Consistent with this view, longer telomeres have been identified in 
 5 
tumors staged as Dukes' C and D versus those scored as A and B, and increasing 
telomere length and telomerase expression has been correlated with an increased 
invasiveness.[56]  
1.1.2.3 DNA Damage Response and CIN 
It is well known that DNA damage response machinery protects cells from 
exogenous as well as endogenous genotoxic stress by initiating a cascade that 
culminates in cell cycle arrest to allow sufficient time to repair the damage or, in the 
case of irreparable damage, by inducing senescence or apoptosis. Some DNA 
repair proteins are involved in human cancers, such as the ataxia telangiectasia 
mutated (ATM) and Rad3-related (ATR) protein kinases.[59] Inactivating mutations 
in these genes predispose to specific syndromes, including ataxia-telangiectasia 
(ATM mutations), Seckel (ATR mutations), Li-Fraumeni (TP53 mutations), and 
hereditary breast-ovarian cancer (BRCA1 and BRCA2 mutations) syndromes, all of 
them characterized by an increased susceptibility to cancer  Among the checkpoint 
genes, TP53 has been the only one directly implicated in human CRC, having at 
least a permissive role for development of CIN. Recently, Wang et al identified 
>1000 genes that could cause chromosomal instability based on their homology to 
genes of yeast and Drosophila melanogaster[39]. Today, 100 candidate genes 
were sequenced in a panel of CRCs and,19 mutations in five genes were 
identified, while one of these genes, MRE11, is involved in DNA double-strand 
break repair. 
New insights suggesting a direct relationship between the DNA damage response 
and CIN have been provided by in vivo studies. Haploinsufficiency of histone 
H2AX, an ATM and ATR substrate, can compromise genomic integrity, and in a 
p53-deficient background, enhance tumour susceptibility [60,61] ATM and H2AX 
are closely linked, map to the same cytogenetic region (11q23), and often deleted 
in various human cancers. Mouse embryonic fibroblasts derived from ATM and 
H2AX double-deficient mice show severe genomic instability [62]. In addition, 
Peddibhotla et al reported that deficiency of Chk1, another DNA damage 
checkpoint effector, causes in vivo multiple mitotic defects and displaces Aurora B 
from late mitosis structures, resulting in failure of cytokinesis and multinucleation 
[63]  
1.1.2.4 Cytogenetic of CIN CRC: 'the monosomic and trisomic type' 
CIN CRC show several forms of genomic instability, characterized mainly by 
chromosomal rearrangements and numerical abnormalities at a greatly increased 
rate compared with normal cells [64]. 
Originally, the CIN phenotype was used to describe tumors with a high degree of 
intercellular heterogeneity in chromosome number, ascertained by counts for a 
restricted set of chromosome-specific centromeres [26]. CIN was further employed 
to describe cancers with either aneuploid or polyploid DNA content as measured by 
cytometry or cytogenetics, or multiple gains or deletions of chromosomes or 
chromosome arms, or frequent losses of heterozygosity (LOH) [65]. The first 
cytogenetic observations on cancer cells from colorectal adenocarcinomas were 
described by Dutrillaux [65]. With classical cytogenetic approach he observed two 
distinct patterns of chromosomal anomalies. The first one, called “monosomic 
type”, was characterized by many chromosomes losses, including the losses or 
deletions of chromosomes 18, 17 (short arm = p), 1p, 4, 14, 5 (long arm = q) and 
21. He noticed that this condition frequently evolves towards polyploidy, by 
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duplication of all remaining chromosomes. The second pattern, called “trisomic 
type”, was characterised by the gain of several chromosomes: 7, 12, X, 5 and 8. 
The chromosomal anomalies observed seemed at that time to have no topological 
relationships with oncogenes [65]. Indeed subsequently it became clearer that the 
cancer-specific aneuploidies generate complex, malignant phenotypes, through the 
abnormal dosages of the thousands of genes [66]. 
In general, genomic copy number changes are frequently found in different types of 
cancer and are believed to contribute to their development and progression 
through inactivation of tumour suppressor genes, activation of oncogenes, or more 
subtlly through gene dosage changes [67]. Chromosomal instability is an efficient 
mechanism for causing the physical loss of a wild-type copy of a tumor-suppressor 
gene, such as in CRC: APC, TP53, and SMAD family member 4 (SMAD4), whose 
normal activities oppose the malignant phenotype [68]. The first cytogenetic studies 
on primary CRC tumors suffered by limitations due to the poor quality of the 
preparations. The improvement of molecular cytogenetic studies, performed 
subsequently with the application of fluorescence in situ hybridization (FISH) based 
techniques such as comparative genomic hybridization (CGH) and spectral 
karyotyping (SKY), allowed many groups to show that colorectal carcinomas are 
characterized by multiple patterns of chromosomal imbalances which sequentially 
accumulate during adenoma to carcinoma progression [69].  
Among the first findings, Fearon et al. [70] confirmed a frequent genomic loss in 
CRC at chromosome 18q21. By using comparative genomic hybridization (CGH) 
Korn et al. [71] found that most frequent gains are at 20q13 and with the same 
technique De Angelis et al. [72] determined that gains of 20q and losses of 18q 
were the most frequent aberrations.  
Accumulation of losses in 8p21-pter, 15q11-q21, 17p12-13, and 18q12-21, and 
gains in 8q23-qter, 13q14-31, and 20q13 were found strongly associated with 
adenoma-to-carcinoma progression, independent of the degree of dysplasia [69]. 
Diep et al. by applying different statistical analyses and combining these on a large 
series of genome profiles from reported CRC, were able to identify specific 
chromosomal alterations linked to the different stages of tumor progression. They 
found that losses at 17p and 18 and gains of 8q, 13q, and 20 occur early in the 
establishment of primary CRC whereas loss of 4p is associated with the transition 
from Dukes' A to B–D stages. They observed that deletion of genes located at 
chromosome 4 might therefore contribute to increased aggressiveness of the 
tumor, enabling it to penetrate the muscular layer, and contribute to the 
establishment of advanced stages; moreover loss of chromosome 4 has been 
shown to be associated with poor clinical outcome in a large series of CRC. The 
transition from primary tumor to liver metastasis results correlated with the deletion 
of 8p and gains of 7p and 17q, whereas losses of 14q and gains of 1q, 11, 12p, 
and 19 are late events. 
In a pilot study by Fensterer and coworkers [67] using macrodissected paraffin-
embedded tissue samples, matrix-CGH was performed. The majority of advanced 
tumours displayed 13q-gain and 18q-loss. In locally restricted tumours, only half 
tumours showed a gain on 13q and 7/12 tumours showed a loss on 18q. 
Interphase-FISH and high-resolution arraymapping of the gain on 13q confirmed 
the validity of the arraydata and narrowed the chromosomal interval containing 
potential oncogenes. The amplification on 13q appeared to harbour candidate 
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genes that might confer a more aggressive phenotype to colorectal cancer cells 
[67]. 
Finally, to summarize the numerous investigations performed in the last decade in 
primary colon cancer tumors, including the recent study by Knutsen and co-
workers, comparing the CGH patterns in all of these reports, gains were most 
frequent for 3/3q, 5/5p/5q, 7, 8q, 20/20q, 13, and the X, and losses were most 
frequent for 8p and 18/18q [73]. Searching for the most frequent structural and 
numerical aberrations found in the large intestine adenocarcinoma specimens in 
the Mitelman Database of Chromosome Aberrations in Cancer 
(http://cgap.nci.nih.gov/Chromosomes/Mitelman), among unbalanced 
Chromosomal Abnormalities there are 8q10 i(8)(q10) and 17q10 i(17)(q10); among 
numerical trisomies +7, +13, +20, and +X; among monosomies −4, −5, −8, −10, 
−14, −15, −17, −18, −21, −22, and −Y. The most recurrent aberration found in all 
cytogenetic studies performed, either in primary tumors or in colon cancer cell lines 
or in fixed colorectal cancer tissue blocks is thus 18q (Table Ia). LOH of this region 
indicates an unfavorable outcome in patients with stage II CRC [74]. In the 18q21-
18q21.1 region several tumor suppressor genes have been mapped, including 
SMAD4/DPC4. However, since microsatellite instability was inversely correlated 
with loss of heterozygosity for chromosomes 5q, 17p, and 18q, it has been 
hypothesized that some colorectal cancers (MSI in particular) may arise through a 
mechanism that does not necessarily involve loss of heterozygosity [75].  
 
Table Ia Most frequent Chromosomal aberrations found in CRC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.1.2.5 LOH and CIN 
LOH is considered to be a hallmark of CIN-positive tumors. An average 25%–30% 
of alleles are lost in tumours; it is not unusual to observe losses in 75% of alleles in 
tumour samples. Surprisingly, there are relatively few insights into the mechanisms 
underlying the generation of LOH. Nevertheless, several pathways have been 
implicated, including mitotic nondisjunction, recombination between homologous 
Chromosome loss Chromosome gain Reference
18, 17p, 1p, 4, 14, 5q, 21  7, 12, X, 5, 8 Dutrillaux, 1988 [69]
18q21 Fearon et al., 1990 [70]
20q13 Korn et al., 1999 [71]
18q 20q De Angelis et al., 1999 [72]
18p21-pter, 15q11-q21,
17p12-13, 18q12-21 8q23-ter, 13p14-31, 20q13  Hermsen et al., 2002 [73]
4, 18p, 14q 17p, 17q, 1q11, 12p, 19 Diep et al., 2006 [74]
8p, 18q, 1p22, 4q26, 15q21 20, 8q, 8q28, 16q24.3, 20q13 Camps et al., 2006 [75]
18q 13q Fensterer et al., 2007 [76]
18, 17p, Y, 1p3, 8p 13, 20, 7, X, 12, 6 Muleris et al., 2008 [77]
8p, 18, 18q 3, 3q, 5, 5p, 5q, 7, 8q, 20, 20q, 13, X Knutsen et al., 2010 [78]
4, 5, 8, 10, 14, 15, 17, 18,
21, 22, Y, 18q10 [i(8) Mitelman Database online
(q10)], 17q10 [i (17) (q10)]
7, 13, 20, X 
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chromosomes, and chromosomal deletion. Thiagalingam et al performed a detailed 
molecular and cytogenetic analysis of LOH in the five chromosomes (1,5, 8, 17, 
and 18) most frequently lost in human CRC [76]. The majority of losses on 
chromosome 18 involved the whole chromosome and appeared to be caused by 
mitotic nondisjunction. However, when the losses were limited to a part of a 
chromosome, these appeared to be a consequence of interchromosomal 
recombinations and deletions associated with DNA double-strand breaks rather 
than to mitotic recombination, break-induced replication, or gene conversion. The 
specific genetic defects that underlie these LOH events still remain unidentified. 
1.1.2.6 Chromosomal Instability Pathway 
Coupled with the typical karyotypic abnormalities observed in CIN tumours is the 
accumulation of a set of mutations in specific tumour suppressor genes and 
oncogenes. These mutations activate oncogenic pathways that are critical for CRC 
pathogenesis. It is not clear whether CIN creates the appropriate environment for 
the accumulation of these mutations or vice versa, although a role for APC in the 
establishment of the CIN phenotype has been recently proposed. Nevertheless, 
the combination of these mutations in CRC in the setting of CIN has been 
historically designated as the “chromosomal instability pathway.” 
APC/β-Catenin 
The earliest genetic event in colorectal tumorigenesis is the activation of Wnt 
signalling through the genetic disruption of APC on 5q21.[77] Germline mutations 
in APC are responsible for familial adenomatous polyposis.[78] Somatic APC 
mutations are observed in 5% of dysplastic aberrant crypt foci, 30%–70% of 
sporadic adenomas, and in as many as 72% of sporadic tumours, indicating that 
functional loss of APC is an early event in tumour initiation. [79,80,81] Although 
germline-inactivating mutations are distributed throughout the entire gene, somatic 
mutations are clustered in the mutation cluster region between codons 1286 and 
1513. [82] Hypermethylation of the APC promoter has been also reported in 18% of 
primary CRC and colonic adenomas, representing an alternative mechanism for 
APC gene inactivation.  [83]  
The APC gene product is a large protein with multiple functional domains that 
regulates complex cellular processes including differentiation, adhesion, polarity, 
migration, development, apoptosis, and even chromosomal segregation. A critical 
function is the interaction between APC and glycogen synthase kinase-3β (GSK-
3β) and β-catenin, each an essential component of the Wingless/Wnt signalling 
pathway. APC binds to β-catenin, GSK-3β, and casein kinase 1α/ε on an axin-
conductin scaffold; the subsequent phosphorylation of β-catenin by GSK-3β leads 
to proteasome-dependent degradation and suppression of the Wnt signal. [84] 
Mutant APC disrupts the complex formation, and the increased cytoplasmic levels 
of β-catenin can translocate to the nucleus, where it drives the transcription of 
multiple genes implicated in tumour growth and invasion through its interaction with 
the T-cell factor/lymphoid enhancer factor family. [85]  
Gain-of-function mutations in β-catenin (CTNNB1) have been identified in as many 
as 50% of CRC with intact APC, reflecting the importance of the Wnt pathway. [86] 
Samowitz et al found a significantly higher frequency of CTNNB1 mutations in a 
sub-groups of small adenomas (12.5%) versus large adenomas (2.4%) and 
invasive cancers (1.4%), suggesting that adenomas with alterations in β-catenin 
are less likely to progress to malignancy and that APC and CTNNB1 mutations are 
not functionally equivalent.[87] Mutations in the AXIN and AXIN2/conductin genes 
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have also been reported, but only in CRCs with defects in the mismatch repair 
system.[88,89] 
K-RAS 
KRAS is mutated in 30%–50% of CRCs.[90] Single nucleotide point mutations that 
occur in codons 12 and 13 of exon 2, and to a lesser extent in codon 61 of exon 3, 
lock the enzyme in the guanosine triphosphate–bound, activated form, leading to 
constitutive activation of RAS downstream signalling. KRAS mutations have been 
observed in 60%–95% of nondysplastic or hyperplastic aberrant crypt foci, 
indicating that these microscopic lesions are unlikely to be precursors of adenomas 
and cancer. [91,92]  
Activated RAS regulates multiple cellular functions through well-described effectors 
The best characterized effector is the Raf–mitogen-activated protein kinase kinase 
(MEK)–extracellular signal-regulated kinase (ERK) pathway. The Raf family 
includes 3 serine/threonine kinases (ARAF, BRAF, and RAF1) that activate MEK1 
and MEK2, which in turn phosphorylate ERK1 and ERK2. ERK then 
phosphorylates cytosolic and nuclear substrates, including JUN and ELK1, which 
regulate enzymes such as cyclin D1, which is involved in the control of cell cycle 
progression.[93] The significance of ERK activation in CRC pathogenesis still 
remains unexplained. Whereas MEK is frequently activated in human CRC, recent 
studies have indicated that inhibitors of MEK are ineffective therapeutics.  
RAS–guanosine triphosphate also binds the catalytic subunit of type I 
phosphatidylinositol 3 kinases, which translocate to the plasma membrane to 
generate phosphoinositol lipids. Of note, PIK3CA is mutated in almost 20% of 
CRC; mutations that occur in the hotspots located on exons 9 (E542K, E545K) and 
20 (H1047R) are oncogenic in cellular models of CRC. [94] AKT/PKB is a critical 
downstream target of phosphatidylinositol 3 kinase that regulates a cascade of 
responses including cell growth, proliferation, and survival by inactivating several 
proapoptotic proteins such as BAD and Forkhead (FKHR) transcription factors.[95, 
96] Phosphatidylinositol 3 kinase also activates Rac, a Rho family guanosine 
triphosphatase, which is important for RAS-mediated transformation in some 
cellular contexts.[97]  
TP53 
TP53 is located on the short arm of chromosome 17; it encodes a 393 aminoacid 
transcription factor that is a tumour suppressor and a central coordinator of cellular 
responses to stress, including DNA damage, aberrant proliferative signals, and 
oxidative stress.[101] TP53 is induced by several oncogenic proteins, such as c-
Myc, RAS, and the adenovirus E1A. [102] Under normal conditions, p53 is 
negatively regulated by MDM2, E3-ubiquitin ligase, and the related protein MDM4 
(also known as MDMX), which bind to the transactivation domain of p53 and target 
it for degradation by ubiquitination. In cells with a high level of stress, the 
interactions between MDM2, MDM4, and p53 are disrupted, allowing activated p53 
to exert its transcriptional activity. Defined as the “guardian of the genome” p53 is a 
master regulator that controls the transcription of hundreds of genes involved in 
DNA metabolism, apoptosis, cell cycle regulation, senescence, angiogenesis, 
immune response, cell differentiation, motility, and migration. Some of the best-
studied targets of p53 are CIP1/WAF1, the p21 cell cycle inhibitor, GADD45 and 
14-3-3, which contribute to G2 arrest, and BAX, FAS (APO1), PIG3, and KILLER 
(DR5), which regulate caspase activation and apoptosis. [103,104]  
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p53 dysfunction is the commonest hallmark of human tumours and its loss of 
function has been reported in 4%–26% of colon adenomas, 50% of adenomas with 
invasive foci, and in 50%–75% of CRC, suggesting its key-role in the transition 
from an adenoma to carcinoma.[105] The majority (~80%) of TP53 mutations are 
missense: GC to AT transitions that occur principally in 5 hotspot codons (175, 
245, 248, 273, and 282).[106] These mutations lead to the synthesis of an inactive 
protein with an abnormally long half-life that can be recognized by 
immunohistochemistry. p63 and p73 proteins are functionally and structurally 
related to p53, and they may play a role in tumor suppression. Although loss of p63 
and p73 has been recently found in many tumour types, their involvement in CRC 
pathogenesis has not yet been determined.[107]  
18q Loss 
Allelic loss at chromosome 18q has been identified in as many as 70% of primary 
CRC, particularly in advanced stages. The major tumour suppressor genes 
localized on 18q are SMAD2 and SMAD4, which are intracellular mediators of the 
transforming growth factor-β (TGF-β) pathway that are involved in the regulation of 
cell growth, differentiation, and apoptosis. However, SMAD4 and SMAD2 
mutations have been found in <20% and 10% of colon cancers, 
respectively.[108,109]  
Cyclooxygenase-2 
Aberrant overexpression of cyclooxygenase-2 (COX-2) is thought to have an 
important role in development of CRC. COX-2, an early-response gene induced by 
growth factors, cytokines, inflammatory mediators, and tumour promoters, is 
overexpressed in as many as 43% of adenomas and 86% of carcinomas.[116] 
Oshima et al first highlighted the role of COX-2 in CRC.91 They showev that in 
APC716 knockout mice, the number of intestinal polyps was reduced by 34% when 
one allele of COX-2 was knocked out and by 86% when both alleles were deleted. 
The tumorigenic effects of COX-2 has been mainly attributed to the production of 
prostaglandin E2. Increased levels of prostaglandin E2 have been reported in 
colorectal adenomas as well as carcinomas.[118,119] It has been demonstrated 
that COX-2 and prostaglandin E2 regulate proliferation, survival, migration, and 
invasion in CRC.[120] It is also known that COX-2 is a regulator of the angiogenic 
process: overexpression of COX-2 induces the production of proangiogenic factors 
including the vascular endothelial growth factor (VEGF) and basic fibroblast growth 
factor (bFGF).[121] In vivo studies have shown that homozygous deletion of COX-2 
not only impairs the growth of tumour xenografts but also reduces tumour 
vascularity.[122]  
1.1.2.7 Timing of CIN: The Chicken or the Egg? 
The question of whether CIN is a cause or a consequence of the malignant 
process remains unanswered. The stage of tumorigenesis at which the CIN 
phenotype arises is controversial Some Authors suggest that CIN initiates 
tumorigenesis, while others contended that CIN is acquired and has a role in 
maintaining the tumorigenic process. 
Several studies have demonstrated that CIN, measured as allelic imbalance in 
specific chromosomal regions, occurs at very early stages of 
tumorigenesis.[123,124,125] Shih et al analyzed 32 sporadic colorectal adenomas 
(with an average diameter of 2 mm) for allelic imbalances using digital single 
nucleotide polymorphism polymerase chain reaction.[125] A relatively high 
frequency of allelic imbalances on chromosomes 5q (55%), 1p (10%), 8p (19%), 
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15q (28%), and 18q (28%) was identified, with >90% of the adenomas exhibiting 
allelic imbalance of at least one chromosomal arm. Cardoso et al investigated the 
CIN status of polyps from patients with germline mutations in APC or MYH.[126] As 
many as 60% and 80% of the polyps exhibited aneuploid changes, respectively, 
with gains of chromosome 7 and 13, and losses of chromosomes 17p, 19q, and 
22q, being the most prevalent aberrations. These findings support the view that 
chromosomal abnormalities can occur during very early stages of tumorigenesis. 
Whether these abnormalities truly constitute an underlying CIN and whether they 
occur before or after APC inactivation are questions difficult to answer. Nowak et al 
developed a stochastic mathematical model to define under what conditions CIN 
would likely be the initial event in colorectal carcinogenesis or the second event 
following mutation of the first copy of the APC gene [127]. Their model has shown 
that for a  wide range of realistic parameter values, CIN mutations have a potential 
role in the initiation of CRC.  
1.1.3 MSI as a Unique Mechanism in Tumour Development 
After the seminal proposal of the multistep genetic model of colorectal 
carcinogenesis, a number of investigators began searching the genome for novel 
tumor suppressor genes using even more powerful techniques. In 1992, Manuel 
Perucho used an arbitrarily primed polymerase chain reaction (PCR), extracting 
DNA from colonic tissues and amplifying thousands of sequences using a small 
number of randomly chosen PCR primers. This technique yielded unique but 
reproducible electrophoretic signatures from each sample[128]. Perucho et al used 
arbitrarily primed PCR to amplify matched samples of DNA from CRC and adjacent 
normal colonic tissue, subsequently they separated the PCR products 
electrophoretically, and compared the results to identify differences in PCR 
amplicons between normal and tumour tissues-DNA missing from the tumour 
would presumably represent somatic cell deletions that were candidate regions for 
new tumour suppressor genes. 
Deleted DNA bands were found in most CRC samples.[129] However, upon careful 
analysis of the comparative autoradiograms, the Authors noted that 12% of ~130 
tumours had bands that were not actually deleted, but were shorter in length and 
migrated slightly further down the gel. Therefore, they analyzed the sequences in 
these bands and discovered that they contained simple repetitive sequences (i.e, 
microsatellites), principally in polyadenine (An) tracts associated with Alu 
sequences. The DNA obtained from these tumours had undergone somatic 
deletion of ≥1 of the adenine residues. The method was unbiased and quantitative, 
permitting the estimate that each tumour contained ~105 such mutations. The 
tumours with these “ubiquitous somatic mutations at simple repeated sequences” 
had unique clinical and pathological characteristics. First, the tumours with these 
deletion mutations were: a) significantly more likely to arise in the proximal colon, 
b) less likely to be invasive, c) less likely to have mutations in KRAS or p53, d) 
more likely to appear poorly differentiated, and e) came from younger patients. 
Based upon these findings, the Authors concluded that these deletions 
represented a unique pathway to tumour development and predicted that the 
“catastrophic loss of fidelity in the replication machinery of normal cells” that 
caused them might be hereditary, although they had no evidence for this 
[129].Simultaneously, Thibodeau et al analyzed dinucleotide repeat sequences (a 
type of microsatellite), and search novel tumour suppressor genes on 
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chromosomes 5q, 15q, 17p, and 18q in CRC. They observed deletion mutations in 
the [CA]n sequences (called “C A repeats”) in these regions and coined the term 
microsatellite instability (which they indicated as MIN). They detected MIN in 25 of 
90 (28%) CRCs, and noted that these aberrations were heterogeneous in different 
tumours. They referred to a large deletion or expansion within the [CA]n tract as a 
“type I mutation,” and called a single 2-base-pair repeat change a minor or “type II 
mutation.” The implications of type I versus II mutations have never been 
elucidated, but they might reflect the cumulative nature of mutations in dinucleotide 
repeat sequences as they occur over time[130].Importantly, Thibodeau et al found 
that 89% of tumours with MIN were in the proximal colon and that the patients with 
MIN CRCs had a better prognosis. Both Perucho et al and Thibodeau et al 
recognized that this represented a unique pathway for tumour development that 
“does not involve loss of heterozygosity.”[75]  
Studies from an international consortium led by Bert Vogelstein in the United 
States and Albert de la Chapelle in Finland helped elucidate the clinical 
implications of MSI, using microsatellites (mainly, but not exclusively dinucleotide 
repeats) as tools for genome-wide linkage analysis of hereditary CRC. Aaltonen et 
al found significant linkage at chromosome 2p using the marker D2S123 in two 
large kindred with Lynch syndrome [then called hereditary nonpolyposis colorectal 
cancer (HNPCC)].[131] The authors used D2S123 to look for LOH at that locus in 
the CRC DNA, testing the hypothesis that this was the site of the tumour 
suppressor gene that caused hereditary CRC and that the second hit to the gene 
would be LOH. Instead, they observed MSI with the marker and then noted that 
deletion mutations in microsatellite sequences were widespread in hereditary CRC. 
They referred to this as the replicative error phenotype. More importantly, they 
found MSI in 13% of sporadic CRC and correctly reasoned that the hereditary 
tumours and a subset of sporadic tumours shared a unique but common pathway 
of tumour development.[132]  
It became apparent that a subset of CRC (at least 12% and perhaps as much as 
28%) were characterized by a large number of mutations at microsatellite 
sequences, formed in the proximal colon, had unique clinical features (such as a 
better prognosis than other types of CRC), and were hereditary. MSI was the first 
DNA marker available to identify hereditary CRC, although none of the 
investigators who discovered MSI in CRC understood mechanisms by which it 
developed. 
A series of observations led to the realization that MSI arises from defects in the 
DNA mismatch repair (MMR) system and the identification of the four genes that 
cause Lynch syndrome. Additionally, microbial geneticists predicted that defects in 
the MMR system were probably responsible for MSI. 
1.1.3.1 DNA MMR System 
The “mutator phenotype” was discovered in bacteria in the 1970s and 1980s and 
was well-characterized by the beginning of the 1990s.[133] It is caused by 
mutational inactivation of genes involved in DNA repair. The first human disease 
that was clearly associated with defects in DNA repair was xeroderma pigmentosa, 
a rare autosomal recessive disease caused by biallelic inactivating mutations in 
genes involved in nucleotide excision repair. Many other DNA repair systems had 
been characterized that included MMR, base excision repair, and a variety of 
nucleases and other DNA excision repair enzymes, yet no human diseases were 
associated with these. 
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In prokaryotes, the MMR system consists of a family of enzymes that detect S-
phase DNA replication errors i.e., those that result in mismatches between the 2 
strands of DNA, in which the newly synthesized strand has incorporated the wrong 
nucleotide. DNA polymerase sometimes makes errors incorporating the correct 
number of bases during replication of long repetitive DNA sequences, such as 
microsatellites. Slippage during replication of a repetitive sequence creates a 
temporary insertion-deletion loop (IDL) that can be recognized and repaired by the 
MMR system, along with single base-pair mismatches. If these are not repaired, 
during the second round of replication the original parental strand is copied 
correctly, but the erroneously synthesized daughter strand (with the mismatch or 
IDL) contains a mutation. Single base-pair mismatches result in point mutations, 
whereas IDLs result in frame-shift mutations that usually lead to a downstream 
nonsense mutation; this results in production of a truncated and therefore 
nonfunctional protein.  
1.1.3.2 The basis of MSI 
It is well known that MMR is more complex in yeast than eukaryotes. The yeast 
homologues of the bacterial mutS and mutL genes were cloned and given the 
names Mut S homologue (MSH) and Mut L homologue (MLH). Subsequently, 
additional homologous copies of these genes were cloned from yeast, giving rise to 
the acronyms MSH1 though MSH6, and MLH1 through MLH3. Another MutL 
homologue, called post-meiotic segregation-1 (PMS1), was also identified in yeast. 
Each of these genes had diverged from the initial mutS and mutL sequences and 
has been associated with specific repair functions in nuclear DNA, during meiosis, 
or in mitochondrial DNA. Phylogenetic analysis indicates that MSH1 was the 
founding member of the Mut S family and that the homologues diverged from this 
progenitor gene, but no highly homologous MSH1 gene is present in higher 
organisms.[134]  
More importantly, in the yeast and other eukaryotes, MutS and MutL proteins no 
longer function as homodimers. Instead, MSH2 forms a heterodimer with MSH6 or 
MSH3, giving rise to MutSα or MutSβ, respectively. [135] These heterodimers have 
different abilities to bind to DNA mismatches and, as a result, yeast and other 
eukaryotes have a broader ability to recognize and repair different types of DNA 
misincorporation. For example, MutSα has a higher affinity for recognizing single 
base-pair mismatches. In fact, MSH6 was initially called the “GT-binding 
protein.”[136,137] It was later discovered that the MSH3 gene encoded another 
MutS homologue that dimerized with MSH2 to create a complex with increased 
ability to bind to larger IDLs.[138] The evolution of diverse homologues of mutS 
increased the cell's ability to recognize and repair synthetic errors in DNA and 
increased replication fidelity in higher organisms.  
Mammals have four homologues of the prokaryotic Mut L gene: MLH1, MLH3, 
PMS1, and PMS2. PMS1 was the first mutL homologue cloned in yeast; it was 
given a unique name because of its functional role in meiosis. Tracing the genes 
phylogenetically is complicated because the yeast PMS1, MLH1, MLH2, and MLH3 
genes correspond to human PMS2, MLH1, PMS1, and MLH3 genes, respectively. 
The function of the products of the MutL homologues are not as clear as those of 
the MutS homologues, but the encoded proteins function as heterodimers. MLH1 
and PMS2 form MutLα, which mediates the interaction between the MutS proteins 
and enzymes involved in long-patch excision in postreplication mismatch repair. 
However, MLH1 (the major MutL homologue in humans) encodes a product that 
 14 
can dimerize with PMS1 to form MutLβ, which suppresses mutagenesis in yeast 
but has an uncertain function in humans. Moreover, the dimer of MLH1 and MLH3 
(MutLγ) helps suppress IDL mutations and functions during meiosis in yeast, but its 
function in humans is unknown. Loss of MLH1 results in total loss of MMR activity, 
but loss of PMS2 can be partially compensated by MLH3. It is not known how 
PMS1 fits into this model, but the MLH1-PMS1 heterodimer is not part of the 
canonical human MMR system. Figure 1.2 shows this model system. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 The DNA MMR system functions through a series of steps. (A) MSH2–
MSH6 (MutSα) recognizes single base-pair mismatches, in which the DNA 
polymerase has matched the wrong base (G) with the T on the template (shown on 
left), and creates a sliding clamp around the DNA. This step that requires the 
exchange of adenosine triphoshpate (ATP) for adenosine diphosphate (ADP) (by 
MSH2, but not MSH6 or MSH3). The complex diffuses away from the mismatch 
site, which is then bound by the MLH1-PMS2 (MutLα) complex (right). This 
“matchmaker” complex moves along the new DNA chain until it encounters the 
DNA polymerase complex. (B) The DNA MMR protein sliding clamp interacts with 
exonuclease-1, proliferating cell nuclear antigen (PCNA), and DNA polymerase. 
This complex excises the daughter strand back to the site of the mismatch (shown 
on left). Eventually, the complex falls off the DNA and resynthesis occurs, 
correcting the error. (C) Variations on the DNA MMR theme. Whereas MSH2–
MSH6 recognizes single pair mismatches and small IDLs, MSH2–MSH3 (MutSβ) 
complements this by also recognizing larger IDLs (shown on left). The right side 
shows the possible interactions with different MutL dimers,as MLH1 can dimerize 
with PMS2, PMS1, or MLH3. The preferred interaction with MSH2–MSH3 is 
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MLH1–MLH3 (MutLγ, but the precise roles of the other MutL heterodimers in this 
reaction are not entirely understood. 
 
1.1.3.3 MSI  is Caused by Deficiencies in MMR  
By 1993, it was recognized that about 15% of colorectal tumors have a unique 
mechanism of pathogenesis; they might have been first solid tumors with 
subclasses that had features so distinct they could be considered as separate 
diseases. To identify the different pathogenic mechanisms, researchers analyzed 
the PCR products of colorectal tumors with MSI. 
Microsatellite sequences are abundant throughout the genome; they are 
polymorphic among individuals but are unique and uniform in length in every tissue 
in each person. The heterogeneity of dinucleotide repeats made them valuable for 
forensic, gene mapping, and allele discrimination analyses. Figure 1.3 illustrates 
amplification of dinucleotide and mononucleotide repeats in colonic tissues using 
autoradiography and gel electrophoresis. 
The initial published examples of MSI were autoradiograms of radiolabeled PCR 
products; findings in yeast indicated that defects in genes that encode MMR factors 
might be responsible for the MSI observed, although no human MMR genes had 
been cloned. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Figure 1.3 MSI was initially discovered by autoradiography analyses of the PCR 
products after separation by gel electrophoresis (upper panel). N refers to DNA 
from the normal colon, and T from the tumor. The DNA polymerase used in PCR 
also has difficulty with the accurate amplification of templates, which is thought to 
be the explanation for the “ladder” of DNA bands that can be seen in the lanes for 
normal and tumor DNA. The upper panel illustrates the use of the 5 markers 
recommended by the National Cancer Institute consensus group; these consist of 3 
dinucleotide repeats and 2 mononucleotide repeats (BAT25 and BAT26). In each 
instance, the DNA in the tumor has undergone somatic mutations (frequently, but 
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not always, deletions), and the PCR product migrates to a different position on the 
gel, as indicated by the arrowheads. The lower panel shows the PCR products as 
they are analyzed by most laboratories using automated DNA sequencing with 
fluorescent primers. In this instance, 5 mononucleotide repeats have been 
analyzed, and in each instance, the mutations consist of deletions with different 
electrophoretic mobility (mutant alleles indicated by the arrows). 
 
1.1.3.4 MMR Genes, HNPCC, and Lynch Syndrome 
As much of the attention was focused on MSI in hereditary CRC, several 
investigators set out to determine whether germline mutations in MMR genes were 
responsible for Lynch syndrome. Fishel et al cloned the human MSH2 gene based 
on its homology to the yeast sequence, mapped it to human chromosome 2p22–21 
(close to the locus implicated earlier in the year[132]), and found a sequence 
variation in patients with familial CRC[143] at the -6 position of intron 13 of MSH2. 
It was proposed that this variant altered splicing, inactivated the gene product, and 
was a germline mutation that mediated CRC pathogenesis. In fact, this is a 
common intronic polymorphism, but it was linked (in cis) to a true inactivating 
mutation that was found shortly thereafter. The association between MSH2 and 
hereditary CRC explained the MSI phenotype observed in CRC; MSH2 is located 
near the locus described in the first reported linkage study. 
Leach et al confirmed the role of MSH2 mutations in hereditary CRC, identifying 
germline mutations in three kindreds with familial CRC: one leucine to proline 
missense mutation, one large in-frame deletion, and one nonsense mutation.[144] 
These were found in multiple affected members of the family but not in individuals 
without cancer. Parsons et al showed that the CRC cell line HCT116 which had 
MSI at [CA]n sequences, was deficient in MMR activity.[145] Seven months after 
the discovery of MSI in CRC, MMR activity was linked to a class of genes that had 
not previously been of interest to cancer biologists. It was recognized that CRC 
might develop through loss of a DNA repair mechanism and that germline 
mutations in at least one of these genes mediated HNPCC.[146]  
MLH1, PMS2, PMS1, and MSH6 
Briefly, after the 2p locus was linked with familial CRC, CRC in three Swedish 
families was linked to chromosome 3p21-23.[147] The association between MSH2 
and Lynch syndrome suggested that other genes that encode MMR factors might 
be located on 3p, which would represent a second familial CRC locus. Two groups 
found MLH1 on 3p21.[148] Bronner et al identified the human homologue of yeast 
MLH1 and found germline mutations in multiple members of a CRC family with 
significant linkage to the 3p locus.[149]  
In the same time, Vogelstein et al and de la Chapelle et al scanned a DNA 
database for sequences homologous to the yeast MLH1, mapped one to 
chromosome 3p, and cloned the gene. Papadopoulos et al identified germline 
mutations in seven members of a large Finnish CRC kindred that had been linked 
to 3p, found mutations in three more CRC families, and reported a mutation in this 
gene in a CRC cell line.[150] Using the same strategy of searching databases for 
homologous sequences, the human PMS1 and PMS2 genes were implicated in 
familial CRC shortly thereafter.[151] The association between PMS2 and CRC has 
been established, but the role of PMS1 in sporadic or familial CRC remains 
unidentified. From December 1993 to September 1994, three more genes were 
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linked to familial CRC; it took another several years to identify the relationship 
between the MSH6 gene[137] and Lynch syndrome.[152] MSH6 is associated with 
somewhat atypical CRC kindreds with delayed onset of the cancer, which obscured 
the initial efforts at discovery. Once it was realized that MSH5 families did not fit the 
classical expectations of the Lynch Syndrome phenotype, the case for its 
involvement was secured.[153]  
Lynch Syndrome 
The focus of MSI in CRC was immediately aimed at Lynch syndrome because of 
its inherited and unique features.[154] These patients develop tumours at early 
ages, often between 20 and 30 years old. They frequently have multiple tumours, 
including colon, rectum, endometrium, stomach, ovary, urinary tract, small 
intestine, and other sites, but no increase in the frequency of cancers of the breast, 
lung, or prostate.[155]  
Families with clusters of CRC were therefore evaluated in linkage studies to 
identify loci of putative hereditary CRC genes. The Amsterdam Criteria were 
developed in 1991 so that research groups would have a uniform collection of 
families to study.[156] These criteria called for three CRC cases in a family in 
which one individual was a first-degree relative of the other two, CRC occurred in 
at least two generations (in which familial polyposis was excluded), and one 
affected family member was younger than 50 years of age. The Amsterdam II 
Criteria were introduced in 1999 to acknowledge the involvement of noncolonic 
tumors in the phenotype.[156]  
Studies of these families facilitated the identification of genes responsible for this 
disease. Lynch syndrome is the hereditary disease caused by inactivating germline 
mutations in genes that encode MMR factors.[157] There are four definite genes 
involving in the Lynch syndrome: MSH2, MLH1, MSH6, and PMS2.[158] Other two 
genes (MLH3[158] and Exo1[159]) that are candidates for Lynch syndrome, have 
been only rarely associated with familial CRC or the reported associations were 
unexpected. There has been no independent confirmation of a role for MLH3 in 
CRC and there has been a contradictory report on the role of Exo1 in this 
disease.[160] However, both genes are an integral part of the MMR system, so 
there is rationale for considering these genes. 
It is indubitable that the Amsterdam Criteria are rigorous; However, Although, it 
was surprising that 40%–60% of families that met the Amsterdam Criteria did not 
have a germline mutation in an MMR gene and the tumours did not have 
MSI.[161,162]. Families with non-Lynch syndrome CRC have been termed familial 
colorectal cancer, type X by one large collaborative study.[161] These families are 
characterized by microsatellite-stable tumours, a lower relative risk for CRC, the 
absence of excess tumours outside of the colon, and later onset of CRC. The 
genetic basis of this group is not known. 
1.1.3.5 MMR Gene Mutations in Lynch Syndrome 
To diagnose Lynch syndrome, MMR genes are analyzed, preferably using exon-
by-exon sequencing with PCR primers that include relevant portions of the intron–
exon boundaries; these detect point mutations and small insertion-deletion 
mutations that involve DNA sequences between the primers but not larger 
deletions or rearrangements, such as DNA sequence that are rejoined after a 
break, because the breakpoints are usually located deep within introns or 
completely outside of the coding regions. When DNA sequencing is performed, the 
tracing is examined for a double signal, i.e., the simultaneous presence of a wild-
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type and mutant nucleotide in the same sequence position. When there is a 
deletion of an entire exon in which the breakpoints are outside of the primers for 
that exon, the analysis gives normal results because only one strand is sequenced, 
and conventional techniques cannot determine whether one or two alleles are 
detected. Large deletions can be detected by multiplex ligation-dependent probe 
amplification, which quantifies the number of alleles at each exon.[163] Large 
deletions account for >33% of all MSH2 mutations associated with HNPCC[164] 
MSH2 is located within a dense cluster of Alu sequences, which are prone to 
internal recombination followed by excision of the DNA loop. Large rearrangements 
also occur with MLH1 and MSH6.[165]  
Analysis for mutations in DNA MMR genes does not end when a sequence 
variation is found; interpretation is another issue. Most deletions and nonsense 
mutations have pathologic consequences, but missense mutations are not always 
interpretable. It is important to determine how well the sequence has been 
preserved (indicating its functional significance) and if it is located in a region 
where the MMR proteins interact. Disruption of regions of protein-protein 
interaction by a nonconservative amino acid change could disrupt complex 
formation and function. The mutant allele might need to be cloned and its product 
tested in a functional assay.[166] A proportion of mutations identified in genetic 
testing are reported as “variants of uncertain significance,” until the better ability to 
predict protein function based on its structure. It is interesting that there is a 
missense mutation in MLH1 (c415G→C; D132H) that affects adenosine 
triphosphate binding of the mutant gene product, increases risk for CRC, but does 
not always cause MSI in CRC cells.  
1.1.4 MSI in Sporadic CRC 
Two of the three initial descriptions of MSI were made in specimens from sporadic 
CRC, rather than tumours from patients with familial CRC. Much of the subsequent 
attention to MSI was directed to familial CRC, but only about 3% of all CRC come 
from Lynch syndrome families. Approximately 12%-17% of all CRC have MSI, 
depending upon the methods used to detect it;[167,168] most CRC with MSI are 
sporadic. 
The majority of CRC with MSI have lost expression of MLH1 and PMS2 protein. In 
1997, Kane et al have shown that MLH1 was silenced by methylation in most of 
these tumors.[169] The characteristic features of sporadic CRC with MSI include 
the absence of significant familial clustering, biallelic methylation of the MLH1 
promoter[170]; absence of MLH1 and PMS2 proteins; and frequent mutation 
(usually V600E) in BRAF[171]. The tumours are frequently diploid (74%) and 
patients with sporadic CRC with MSI have a better prognosis than those with non-
MSI tumors.[172] Whereas patients with Lynch syndrome are younger than those 
with sporadic CRC, those with sporadic CRCs with MSI are older. It is known that 
loss of MLH1 expression increases with age. Moreover, the gene is lost in ~50% of 
CRC patients older than 90 years of age. 
1.1.4.1 Sporadic MSI and CpG Island Methylator Phenotype 
MSI-associated sporadic CRCs arise through a process that involves the CpG 
island methylator phenotype (CIMP).[174] About half of the genes in the human 
genome have promoters that are embedded in clusters of cytosine-guanosine 
residues called CpG islands.[175] Cytosines in these regions can be methylated by 
DNA methyltransferases. Methylation is an epigenetic phenomenon by which a cell 
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permanently silences genes, and it remains in the progeny of each cell. In vitro, it is 
possible to demethylate at least some promoters using the DNA methyltransferase 
inhibitor 5-azacytidine; however, upon removal of this agent, remethylation occurs. 
Histone modifications indicate which CpG sites are marked for permanent 
methylation[176]. 
A subset of CRC has been identified as characterized by CIMP.[179,180] These 
tumours progress by methylating tumour suppressor genes and have distinctive 
clinical features compared to non-CIMP CRC.[180] Some of the commonly 
methylated promoters have no apparent role in tumour development and have 
been labelled “methylated in tumor” or MINT genes, but methylation also occurs in 
promoters of known tumour suppressor genes, including p16 and insulin-like 
growth factor 2, and DNA repair genes such as methylguanine methyltransferase 
and MLH1. 
The region of the MLH1 promoter in which methylation mediates gene silencing is 
the 3′ end, close to the start codon. The 5′ end of the promoter is also prone to 
methylation, but this is not of functional importance unless the methylation extends 
to the critical 3′ region.[181] Therefore, specific CpG residues are more important 
than others in mediating gene silencing. Importantly, most of the CRCs with 
sporadic MSI come from a CIMP background, which creates an important 
distinction from Lynch syndrome tumours.[182,183] Consequently, it is essential to 
know more about CRC than whether there is MSI or not. It is remarkable that 
Lynch syndrome tumours are associated with germline mutations in DNA MMR 
genes, occur in younger individuals, can have KRAS mutations (but never BRAF 
mutations), and are associated with a better prognosis than non-MSI tumors.[184] 
Conversely, most sporadic CRC with MSI occur in older individuals, have BRAF 
mutations in about half of the cases (V600E), are associated with a background of 
CIMP and a reduced mortality. 
1.1.4.2 Germline Epimutations 
To aide in the diagnosis of Lynch syndrome, several investigators have searched 
for germline mutations in a coding regions, splice sites, or promoter regions of 
MMR genes. However, instead of a genetic mutation, some cases of Lynch 
syndrome are caused by epigenetic inactivation of genes by promoter methylation. 
These events, originally described as germline epimutations, are better referred to 
as constitutional epimutations, to reflect the aberrant silencing of a gene that is 
normally active in somatic cells in the absence of a sequence mutation. 
Constitutional epimutations of MLH1 [185,186,187]and MSH2[188,189] have been 
identified in families with Lynch syndrome who have no apparent MMR gene 
sequence mutations. MSH2 methylation can arise from a deletion in the 3′ end of 
the gene just upstream of MSH2 (TACSTD1). The loss of the stop codon somehow 
results in methylation of the CpG island downstream, which leads to constitutional 
silencing of MSH2. Similar to germline mutations, constitutional epimutations in 
MSH2 demonstrate classic autosomal dominant inheritance and are associated 
with a 50% risk of transmission to the offspring.[189,190]  
1.1.5 Pathophysiology of Colorectal Carcinogenesis with MSI 
CRCs with MSI were discovered, in part, because they were different from most 
other CRCs; the tumoural cells had a tendency to be diploid and had less LOH. 
The mutational patterns were of interest because of the unique clinical features of 
 20 
these tumours. In 1995, Markowitz et al provided an important insight into the 
colorectal carcinogenetic pathway.[17]  
It has been showed that TGF-β signalling inhibits proliferation in the colonic 
epithelium. Markowitz et al showed that the TGF-β type II receptor (TGFβR2) was 
not expressed in colorectal cell lines with MSI, but not without MSI, or in xenografts 
of these cells grown in nude mice.  
TGFβR2 includes two microsatellite sequences: from nucleotides 1931 to 1936, 
there is a 6-base pair [GT]3 sequence (the inverse of a C–A repeat) and from 
nucleotides 709 to 718 there are 10 consecutive adenines (A10). Deletion mutations 
in these microsatellite sequences create frame-shifts that inactivate the gene 
product. These were found predominantly in the colorectal MSI cell lines. Cells with 
mutant forms of TGFβR2 did not slow proliferation in response to TGF-β. The most 
frequent mutation was a single base-pair deletion in the A10 sequence. Markowitz 
et al reported that this mutation made the protein nonfunctional.[191] Furthermore, 
they identified mutations in the A10 tract of 90% of 111 CRC found to have MSI, 
proving that this was a relevant site of this form of genomic instability.[192] In a 
new paradigm, repetitive DNA sequences were proposed to be particularly 
sensitive to the loss of DNA MMR activity, resulting in frame-shift mutations that led 
to premature stop codons and gene inactivation. 
A number of other genes affected by MSI have been identified that encoded 
regulators of cell proliferation, including GRB1, TCF-4, WISP3, activin receptor-2, 
insulin-like growth factor-2 receptor, axin-2, and CDX, the cell cycle or apoptosis 
such as BAX, caspase-5, RIZ, BCL-10, PTEN, hG4-1, and FAS, and DNA repair 
comprising MBD-4, BLM, CHK1, MLH3, RAD50, MSH3, and MSH6 [193]. 
Remarkably, every human MMR gene except MLH1 includes a mononucleotide 
repeat of at least A7,[194] so the process of MMR could become increasingly 
defective with cumulative losses of components on the system.[195] However, it is 
not clear how many of the mutations at these loci are of functional significance 
(which has been determined for TGFβR2), or whether some are simply markers of 
MSI, because biallelic inactivation of these genes has not been documented in all 
the tumours. 
The identification of the proximate targets of carcinogenesis in the setting of 
defective MMR activity indicates that MSI-associated colorectal tumorigensis 
occurs through a different biological pathway compared to sporadic tumours. CRC 
cells with MSI can activate or inactivate the same signalling pathways as those 
without MSI, but different proteins within these pathways are involved. Genes are 
altered by different mechanisms in CRC cells with MSI compared to those without 
MSI. For example, sporadic CRC arise from a combination of mutations and LOH, 
resulting in biallelic inactivation of APC. CRC with MSI have mainly an increase in 
the number of point mutations compared to cancer cells without MSI, are more 
likely to be diploid, and do not have experienced widespread allelic imbalance or 
LOH. A substantial portion of CRC with MSI have normal expression of APC, but 
have mutations in β-catenin that make it unable to interact with APC protein and 
undergo degradation,[196,197] the biological equivalent of having no APC protein. 
Moreover, some colorectal tumours with MSI that have neither inactivated APC nor 
mutated β-catenin could have frame-shift mutations in factors further downstream 
in the WNT pathway, such as in the A9 sequence of TCF-4. 
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Of equal importance are the differences in the pathogenesis of CRC with MSI that 
come from patients with Lynch syndrome compared with sporadic CRC cells with 
CIMP.  
1.1.6 Models of MSI 
Studies of MMR expanded from Escherichia coli and Saccharomyces cerevisiae to 
human cells and diseases in the mid-1990s. Parsons et al discovered that HCT116 
cells had defects in MMR activity and MSI25 that were associated with biallelic 
mutations in MLH1. Stable transfer of human chromosome 3 into HCT116 
(HCT116-ch3 cells) restored MLH1 and created a model to study the role of MMR 
in the response to DNA damage and regulation of the cell cycle.[206] MMR activity 
was restored in HCT116 -ch3 cells, which had reduced tolerance to DNA alkylation 
by N-methyl-N=-nitro-N-nitrosoguanidine. The model also demonstrated that MMR 
regulates passage through the G2/M cell cycle checkpoint and the response to 6-
thioguanine, which is incorporated into DNA as guanine but acts like a mismatch in 
newly synthesized DNA.92 MMR activity is required to restrain clonal expansion of 
cells exposed to N-methyl-N=-nitro- N-nitrosoguanidine and prevent proliferation of 
cells with damaged DNA.[208] Cultured CRC cells with intact MMR activity were 
significantly more sensitive to therapeutic concentrations of 5-fluorouracil (5-FU; 5–
10 _M) than DNA MMR–deficient cells,[209] as well as other chemotherapeutics. 
[210,211] This provided the theoretical basis for later observations that patients 
with MSI CRCs mightnot respond to traditional 5-FU–based chemotherapy. Cell 
models were subsequently developed to study other genes in the DNA MMR 
family. Although stable transfer of human chromosome 3 corrected some DNA 
MMR activity, HCT116-ch3 cells were still devoid of MSH3 activity. Therefore, the 
HCT116 -3 - 5 cell line was created by stable transfer of human chromosome 5 into 
HCT116 -ch3 cells, permitting an exploration of the effects of MSH3 on MMR.[212] 
The CRC cell line HCT15 does not express MSH6 and the endometrial cancer cell 
line HEC59 does not express MSH2 or MSH6. Stable transfer of human 
chromosome 2 (which contains MSH2 and MSH6) into these cells created cell lines 
that permitted analysis of the role of the MutS system in human cells.[213] In the 
modified HCT15 and HEC59 cell lines, MSH2 and MSH6 were re-expressed, MSI 
and the hypermutable phenotype were corrected (reducing mutations at the HPRT 
locus by 96% in HCT15), and the cells became more sensitive to cell death after 
exposure to mutagens. Similarly, in LoVo cells, which have defects at the MSH2 
locus, MMR activity and sensitivity to mutagenic agents were restored following 
transfer of a fragment of chromosome 2.[214] Lynch syndrome is an autosomal 
dominant disease, associated with the inheritance of a single mutated gene. 
However, in cultured cells, defects in MMR are recessive; a single copy of the gene 
restores DNA MMR activity. MMR activity is lost in cells that lack MSH2 or MLH1, 
but only partially disrupted in cells without MSH6 or MSH3. 
1.1.7 Diagnosis of MSI 
Patients with colorectal tumors with MSI have longer survival times than patients 
with tumors without MSI.[75] A study of 175 patients with Lynch syndrome (120 of 
whom had Lynch syndrome-MLH1 type), compared to more than 14,000 
population-based patients with CRC, showed that the 5-year cumulative relative 
survival for patients with Lynch syndrome was 65%, compared to 44% of patients 
with sporadic CRC who were older than 65 years of age.[231] A pooled analysis of 
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MSI that included 32 studies and 7642 CRC cases found an overall hazard ratio of 
0.65 for patients with tumors that have MSI. Patients with Lynch syndrome have 
lower-stage disease when they are identified compared to patients with other types 
of CRC, and it is less common for patients with Lynch syndrome to present with 
metastatic disease[232-234]. Gryfe et al reported that 17% of 607 CRC patients 
who were younger than 50 years old had MSI; the hazard ratio for patients with 
MSI-associated tumors was 0.42, compared with patients in the same cohort with 
non- MSI tumors. Patients with tumors with MSI had lower mortality rates when 
patients were stratified by tumor stage, including patients with stage IV 
cancer.[235] 
Tumors with MSI have greater numbers of tumor-infiltrating lymphocytes that are 
activated and cytotoxic;[236] the lymphocytic reaction is independently associated 
with longer survival.[237] Studies report that colorectal tumors with lymphocytic 
infiltrates are associated with longer survival times; in fact, lymphocyte infiltration 
may be a better prognostic factor than routine pathology staging. [238] Abnormal 
results from immunohistochemical analyses of MSH2 and MLH1 independently 
predict better outcomes in patients with stage II–T3 colorectal tumors. [239] 
Therefore, detection of MSI in a patient with CRC is a positive prognostic factor, 
particularly among young patients. However, not all studies have confirmed the 
value of MSI detection in prognosis.[240,241] This might be because there are 
technical challenges in identifying tumors with MSI. Some studies could have 
included CRC cases that were falsely reported to have MSI-positive tumors, which 
might have altered the modest differences in predicted patient outcomes.[241,242] 
Second, MSI analyses include 2 groups of patients: those with Lynch syndrome 
(who tend to be younger) and those with acquired methylation of the MLH1 gene 
(who are older). If Lynch syndrome patients are excluded from a cohort, the 
average age of patients with MSI is older—older patients have shorter overall 
survival times regardless of whether or not they have CRC. Most evidence, 
however, indicates that MSI predicts positive outcomes in patients with CRC. The 
principal use of MSI testing in the clinic is to identify patients with Lynch syndrome. 
Approximately 15% of all colorectal tumors have MSI, and 75%–80% of this group 
have acquired methylation of MLH1; only 2%–3% of all CRCs have germline 
mutations in one of the MMR genes.49 Although MSI analysis is the first approach 
to identifying patients with Lynch syndrome, immunohistochemical analysis is 
equivalent in levels of sensitivity and specificity and is accessible to most pathology 
laboratories. 
Several panels of microsatellites have been used to diagnose MSI. The first 
consensus meeting recommended a panel of 3 dinucleotide repeats and 2 
mononucleotide repeats that had been validated by a German consortium. This 
panel required that normal tissue be compared with tumor tissue, so many groups 
use a panel of 5 mononucleotide repeats that can be amplified and analyzed in a 
single assay. The location and nature of each of the microsatellite targets used for 
diagnostic purposes are listed in Table 2. The Pentaplex panel is as sensitive and 
specific as the initial panel proposed by the National Cancer Institute, but has some 
advantages that improve specificity. The T25 repeat in the 3'-untranslated region of 
caspase-2 is useful in detecting loss of MSH6. 
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1.1.8 Clinical Implications of CIN and MSI 
The insights into the genetic basis of CRC have allowed the identification of new 
prognostic and predictive molecular biomarkers as well as novel therapeutic 
strategies. Many Authors have attempted to determine whether KRAS, TP53, or 
18q alterations could serve as prognostic markers. Some data have indicated an 
increased risk of relapse and death among patients with a codon 12 mutation in 
KRAS, but other studies have failed to confirm this association.[231,232,233,234] 
Similarly, some studies suggested that a TP53 mutation is associated with a higher 
risk of death, but this appears to be confined to those who already have the worst 
prognosis (Dukes' stage D).[243,235] A number of compelling studies associated 
allelic deletion of chromosome 18q with poor outcomes.[236,237] However, recent 
studies have failed to validate these earlier observations.[238,239]] Consequently, 
none of proposed individual markers are actually used as molecular prognostic 
factors.[240] However, data indicate that the overall CIN phenotype is associated 
with a less favourable outcome in patients compared with those with tumours that 
exhibit MSI. Patients with CIN consistently exhibited low rates of overall and 
progression-free survival, irrespective of ethnicity, anatomic location, or treatment 
with 5-fluorouracil, compared to patients with MSI tumours. Additionally, prognosis 
is not influenced by adjuvant therapy in patients with stage II–III CRC.[241]  
Therapeutic targeting of pathways that directly initiate and perpetuate CIN has now 
reached the clinical practice. Small-molecule inhibitors of Aurora kinases, Plks, the 
spindle motor protein Eg5, and CENP-E have shown anti-tumour activity in 
preclinical models and are currently being evaluated in phase I and II clinical trials 
for the treatment of solid tumours. Of particular interest, is the observation by 
Swanton et al that CIN-positive tumours are intrinsically resistant to taxanes due to 
the similarity between pathways that regulate the separation of chromosomes at 
mitosis and those implicated in the response to taxanes.[242] This serves as the 
basis for the Chromosomal Instability and Anti-Tubulin Response Assessment 
(CINATRA) trial to assess whether patients with near diploid MSI-positive CRC 
derive benefit from EPO906, a new microtubule stabilizer, relative to patients with 
CIN-positive cancers. 
The time course of progression from adenoma to cancer provides a window of 
opportunity for chemoprevention. COX-2 inhibitors successfully prevent polyp 
recurrence. Three prospective, randomized, placebo-controlled, multicenter trials of 
secondary prevention of colorectal adenomas [Adenomatous Polyp Prevention on 
Vioxx (APPROVe), Adenoma Prevention with Celecoxib (APC), and Prevention of 
Sporadic Adenomatous Polyps (PreSAP) trials] demonstrated that selective COX-2 
inhibitors reduced polyp recurrence, with a greater effect on formation of advanced 
adenomas.[242,243]  
In the future, attempts to better define the mechanisms that initiate CIN, the 
relationship between CIN and tumour progression, and the feasibility of targeting 
chromosomally unstable cells will be critical to advance our understanding of the 
most common form of genetic instability in CRC. 
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1.2 EPITHELIAL TO MESENCHYMAL TRANSITION 
1.2.1 What is epithelial-mesenchymal transition? 
Epithelial-to-mesenchymal transition (EMT) refers to a biologic dynamical process 
that allows a polarized epithelial cell, which normally interacts with basement 
membrane via its basal surface, to undergo multiple biochemical changes that 
enable it to assume a mesenchymal cell phenotype, which includes enhanced 
migratory capacity, invasiveness, elevated resistance to apoptosis, and greatly 
increased production of extra-cellular matrix (ECM) components [246]. The 
completion of an EMT is signalled by the degradation of underlying basement 
membrane and the formation of a mesenchymal cell that can migrate away from 
the epithelial layer in which it originated. A number of distinct molecular pathways 
are engaged to initiate the EMT and enable it to reach completion. These include 
activation of transcription factors, expression of specific cell-surface proteins, 
reorganization and expression of cytoskeletal proteins, production of ECM-
degrading enzymes, and changes in the expression of specific microRNAs. In 
many cases, the involved factors are used as biomarkers to demonstrate the 
dynamics of EMT (Figure 1.4). 
The pioneering study of Elizabeth Hay first described an “epithelial-mesenchymal 
transformation” using a model of chick primitive streak formation [247]. 
Subsequently, the term “transformation” has been replaced with “transition,” 
reflecting in part the reversibility of the process and the fact that it is distinct from 
neoplastic transformation [246]. The phenotypic plasticity afforded by an EMT is 
revealed by the occurrence of the reverse process, called mesenchymal-to-
epithelial transition (MET), which involves the reversal of a mesenchymal cell to its 
originating epithelial cell.. Today, a few data are still available about this process. 
The most-studied example is the MET associated with kidney formation, which is 
driven by genes including paired box 2 (Pax2), bone morphogenetic protein 7 
(Bmp7), and Wilms tumor 1 (Wt1) (248-250). 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 EMT involves a functional transition of polarized epithelial cells into 
mobile and ECM component–secreting mesenchymal cells. The epithelial and 
mesenchymal cell markers commonly used by EMT researchers are listed. 
Colocalization of these two sets of distinct markers defines an intermediate 
phenotype of EMT, indicating cells that have passed only partly through an EMT. 
Detection of cells expressing both sets of markers makes it impossible to identify 
all mesenchymal cells that originate from the epithelia via EMT, as many 
mesenchymal cells likely shed all epithelial markers once a transition is completed. 
For this reason, most studies in mice use irreversible epithelial cell–lineage tagging 
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to address the full range of EMT-induced changes. ZO-1, zona occludens 1; 
MUC1, mucin 1, cell surface associated; miR200, microRNA 200; SIP1, survival of 
motor neuron protein interacting protein 1; FOXC2, forkhead box C2. 
 
1.2.2 Why does EMT occurs? 
The concept of cell division as a way to generate more cells and expand tissue size 
emerged about 150 years ago [250]. Central to this concept was an understanding 
that all cells in a body derive from other cells and the resulting deduction that 
ultimately all are derived from a single cell, the fertilized egg. An additional level of 
complexity came from the realization that cells can assume various phenotypic 
states during their development. In other words, they can undergo the process of 
differentiation. As was learned more recently, during specific steps of 
embryogenesis, the cells within certain epithelia appear to be plastic and thus able 
to move back and forth between epithelial and mesenchymal states via the 
processes of EMT or MET [251]. Upon completion of the development of human 
organs, the epithelial cells typically exert tissue-specific functions, while the 
mesenchymal cells play a supporting role. This notion implies that a state of 
terminal differentiation is necessary to carry out such specialized functions and that 
cells are maintained in a permanent state of differentiation once development is 
complete. 
This concept has been challenged by several observations that the cells within a 
terminally differentiated epithelium can indeed change their phenotype through 
activation of an EMT program, which enables transdifferentiation, resulting in the 
conversion of epithelial cells to mesenchymal derivatives during development and 
adulthood. These programs can also be activated in association with tissue repair 
and pathological stresses, including those involving various types of inflammation 
and high-grade carcinomas. 
The above considerations make it possible to,state that EMT is the main 
mechanism involved to disperse cells in embryos, generate mesenchymal cells in 
injured tissues, and promote the invasive and metastatic behaviour of epithelial 
cancers. 
1.2.3 Classification of EMT into three different subtypes 
EMTs are encountered in three distinct biological settings that carry very different 
functional consequences (Figure 1.5). While the specific signals that delineate the 
EMT in the three discrete settings are not yet clear, it is now well accepted that 
functional distinctions are apparent. A proposal to classify EMT into three different 
biological subtypes based on the biological context in which they occur was 
discussed at a 2007 Meeting on EMT in Poland and a subsequent Meeting in 
March 2008 at Cold Spring Harbor Laboratories.  
The EMTs that are associated with implantation, embryo formation, and organ 
development are organized to generate diverse cell types that share common 
mesenchymal phenotypes.This class of EMT termed as “type 1,” neither causes 
fibrosis nor induces an invasive phenotype resulting in systemic spread via the 
circulation. Among other outcomes, type 1 EMT can generate mesenchymal cells 
(primary mesenchyme) that have the potential to subsequently undergo a MET to 
generate secondary epithelia. 
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The EMT associated with wound healing, tissue regeneration, and organ fibrosis is 
defined as ”type 2”. In type 2 EMT, the program begins as part of a repair-
associated event that normally generates fibroblasts and other related cells to 
reconstruct tissues following trauma and inflammatory injury. However, in contrast 
to type 1 EMT, type 2 EMT is associated with inflammation and cease once 
inflammation is attenuated, as is seen during wound healing and tissue 
regeneration. In the setting of organ fibrosis, type 2 EMT can continue to respond 
to ongoing inflammation, leading eventually to organ destruction. Tissue fibrosis is 
in essence an unabated form of wound healing due to persistent inflammation. 
Type 3 EMT occurs in neoplastic cells that have previously undergone genetic and 
epigenetic changes, specifically in genes that favour clonal outgrowth and the 
development of localized tumours. These changes, notably affecting oncogenes 
and tumour suppressor genes, conspire with the EMT regulatory circuitry to 
produce outcomes far different from those observed in the other two types of EMT. 
Cancerous cells undergoing a type 3 EMT may invade and metastasize and 
thereby generate the final, life-threatening manifestations of cancer progression. 
Importantly, cancer cells may pass through EMTs to differing extents, with some 
cells retaining many epithelial traits while acquiring some mesenchymal ones and 
other cells shedding all vestiges of their epithelial origin and becoming fully 
mesenchymal. It still remains unclear what specific signals induce type 3 EMT in 
carcinoma cells. It is known that such signals may originate in the tumour stroma 
that is associated with many primary carcinomas. 
While these three classes of EMT represent distinct biological processes, a 
common set of genetic and biochemical elements appears to underlie and thus 
enable these outwardly diverse phenotypic programs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5 Different types of EMT. (A) Type 1 EMT is associated with implantation 
and embryonic gastrulation and gives rise to the mesoderm and endoderm and to 
mobile neural crest cells. The primitive epithelium, specifically the epiblast, gives 
rise to primary mesenchyme via an EMT. This primary mesenchyme can be re-
induced to form secondary epithelia by a MET. It is speculated that such secondary 
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epithelia may further differentiate to form other types of epithelial tissues and 
undergo subsequent EMT to generate the cells of connective tissue, including 
astrocytes, adipocytes, chondrocytes, osteoblasts, and muscle cells. (B) EMTs are 
re-engaged in the context of inflammation and fibrosis and represent the type 2 
EMTs. Unlike the type 1 EMT, the type 2 EMT is expressed over extended periods 
of time and can eventually destroy an affected organ if the primary inflammatory 
insult is not removed or attenuated. (C) Finally, the secondary epithelia associated 
with many organs can transform into cancer cells that later undergo the EMTs that 
enable invasion and metastasis, thereby representing type 3 EMTs. 
 
1.2.3.1 Type 1 EMT: EMT during implantation, embryogenesis, and organ 
development 
Following the earliest stages of embryogenesis, the implantation of the embryo and 
the initiation of placenta formation are both associated with an EMT that involves 
the parietal endoderm [253]. In particular, the trophoectoderm cells, which are 
precursors of the cytotrophoblast, undergo an EMT to facilitate invasion of the 
endometrium and the subsequent proper anchoring of the placenta, enabling its 
function in nutrient and gas exchange [254,255]. As described briefly below, this is 
only the first of many type 1 EMT that accompany and underlie embryonic 
morphogenesis; details regarding some of the EMT that occur during development 
are discussed elsewhere [256]. 
A fertilized egg undergoes gastrulation, generating three germ layers. Initially, a 
primitive streak is generated in the epiblast layer [257]. The epithelial cells in this 
tissue express E-cadherin and exhibit apical-basal polarity. Formation of the 
primitive streak is considered to be the first sign of gastrulation, which leads in turn 
to the formation of the three germ layers that generate all tissue types of the body. 
The primitive streak is formed from a furrowed invagination in the midline of the 
epiblast layer that forms initially at the lower extremity of the embryo and, later on, 
extends in the direction of the future head. The epithelial-like cells of the epiblast 
undergo programmed changes dictated by specific expression of proteins 
associated with cell migration and differentiation [258]. 
Once formed, the primitive streak, acting via invagination or ingression, generates 
the mesendoderm, which subsequently separates to form the mesoderm and the 
endoderm via an EMT (also known as epiblast-mesoderm transition) [247] by 
replacing the hypoblast cells, which presumably either undergo apoptosis or 
contribute to the mesoderm layer via an EMT. The embryonic mesoderm that forms 
between the epiblast and hypoblast eventually gives rise to primary mesenchyme 
associated with the axial, paraxial, intermediate, and lateral plate mesodermal 
layers [259]. Cells of the primary mesenchyme exhibit enhanced migratory 
properties when compared with those of the epiblast and the hypoblast. 
At the biochemical level, the EMT associated with gastrulation is dependent on and 
orchestrated by canonical Wnt signaling, and embryos deficient in Wnt3 cannot 
undergo the EMT associated with gastrulation [260,261] The subsequent formation 
of the primitive streak is associated with expression of Wnt8c, and ectopic 
expression of Wnt8c in embryos leads to multiple primitive streaks [262,263]. TGF-
β superfamily proteins, notably Nodal and Vg1, mediate the action of Wnts, and 
their deficiencies can lead to mesodermal defects due to the absence of functional 
EMTs [264,265,266,267,268]. Wnts also cooperate with FGF receptors to help 
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regulate an EMT associated with gastrulation [269-272]. The Snail, Eomes, and 
Mesps transcription factors orchestrate the EMT associated with gastrulation (273-
275]. It has been shown that Snail represses E-cadherin and induces EMT 
mediated by cell adhesion molecules, such as occludins and claudins, and by 
polarity genes, including Discs large (Dlg) and Crumbs homolog 3 (Crb3) [276-
278]. 
During embryonic development, an EMT involving the epithelial cells of the 
neuroectoderm gives rise to migratory neural crest cells [279]. Initially, the 
premigratory neural crest cells express genes such as Sox, Snail, Slug, and 
forkhead box D3 (FoxD3), and these cells subsequently undergo an EMT 
[280,281]. As a consequence, they then dissociate from the neural folds, become 
motile, and disperse to the different parts of the embryo, where they undergo 
further differentiation into, among other cell types, the melanocytes that provide 
pigment to the skin. 
This EMT occurring in the neural crest is triggered by signalling pathways similar to 
those orchestrating the EMT associated with gastrulation. Thus, signalling 
pathways mediated by Wnts, FGFs, BMPs, c-Myb, and msh homeobox 1 (Msx-1) 
conspire to induce EMT [282-283]. Among them, BMP most prominently induces 
the 
migratory property of neural crest cells. Noggin, an inhibitor of BMP, is essential in 
negatively regulating this activity, and its expression places a hold on EMT 
[284,285]. Additionally, E-cadherin and N-cadherin need to be repressed in order 
for neural crest EMT to occur [287]. By some estimates, EMT programs are 
deployed during several subsequent phases of embryogenesis, indicating the 
continued involvement of these programs later in development, such as the 
endothelial-mesenchymal transition (EndMT) that takes place during heart valve 
formation. 
1.2.3.2 Type 2 EMT: EMT associated with tissue regeneration and organ 
fibrosis 
Organ fibrosis, which occurs in a number of epithelial tissues, is mainly mediated 
by inflammatory cells and fibroblasts that release a variety of inflammatory signals 
as well as components of a complex ECM that includes collagens, laminins, 
elastin, and tenacins. More specifically, such EMT are found to be associated with 
fibrosis occurring in kidney, liver, lung, and intestine [288-291].  
Some of the earliest proof of this came from the study of transgenic mice bearing 
germ-line reporter genes whose expression was driven by epithelial cell-specific 
promoters. The behaviour of these reporters provided direct evidence for epithelial 
cells serving, via EMTs, as important precursors of the fibroblasts that arise during 
the course of organ fibrosis [292-294]. 
Fibroblast-specific protein 1 (FSP1; also known as S100A4 and MTS-1), an S100 
class of cytoskeletal protein, alpha-smooth muscle antigen (α-SMA), and collagen I 
have provided reliable markers to characterize the mesenchymal products 
generated by the EMT that occur during the development of fibrosis in various 
organs [292-293]. These markers, along with discoidin domain receptor tyrosine 
kinase 2 (DDR2), vimentin, and desmin, have been largely used to identify 
epithelial cells of the kidney, liver, lung, and intestine that are in the midst of 
undergoing an EMT associated with chronic inflammation. Such cells continued to 
exhibit epithelial-specific morphology and molecular markers, such as cytokeratin 
and E-cadherin, but showed concomitant expression of the FSP1 mesenchymal 
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marker and α-SMA. Such cells are likely to represent the intermediate stages of 
EMT, when epithelial markers continue to be expressed but new mesenchymal 
markers have already been acquired. The behaviour of these cells provided one of 
the first indications that epithelial cells under inflammatory stresses can advance to 
various extents through an EMT, creating the notion of “partial EMTs” (Figure 1.6). 
It has been shown that these cells leave the epithelial layer, negotiate their way 
through the underlying basement membrane, and accumulate in the interstitium of 
the tissue [296], where they ultimately shed all of their epithelial markers and gain a 
fully fibroblastic phenotype. 
Recent data in mice have demonstrated that endothelial cells associated with the 
microvasculature can also contribute to the formation of mesenchymal cells during 
the course of fibrosis, doing so via an analogous process like EndMT. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6 EMT and fibrosis. The EMTs associated with fibrosis are associated 
with inflammation and the generation of numerous types of molecules by 
inflammatory cells and resident activated fibroblasts (myofibroblasts). These 
molecules cause disruption of the epithelial layers via degradation of the basement 
membrane. The epithelial cells lose polarity and either undergo apoptosis (the 
majority of cells) or EMT (the minority of cells). MCP1, monocyte chemoattractant 
protein 1 
 
This pathologic process echoes a similar normal process occurring during 
development [288]. Thus, during embryogenesis, an EndMT occurs during the 
organization of the endocardial cushion and the heart valves. In cardiac fibrosis 
associated with post-ischemic injury of the heart, EndMT, which involves both the 
endocardium (the inner endothelial layer of the heart) and the microvascular 
endothelium of the heart, has been demonstrated to play a key role in contributing 
to the emergence of newly formed fibroblasts [289] (Figure 1.6). In tissue culture 
models of EndMT, TGF-β1 induces EndMT of capillary endothelial cells and the 
loss of endothelial markers, such CD31 and integrin αVβ3, as well as the 
acquisition of fibroblast- and myofibroblast-specific markers such as FSP1, α-SMA, 
DDR2, collagen I, and vimentin. While not yet documented, it is plausible that many 
of the molecular regulators of EMT also play critical roles in orchestrating EndMTs. 
In one analysis [246], lineage-tagging experiments and bone marrow transplant 
studies demonstrated that during the course of kidney fibrosis in mice, about 12% 
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of fibroblasts are derived from the bone marrow and about 30% are derived via 
EMT from the tubular epithelial cells of the kidney. In addition, it has been shown 
more recently that in kidney fibrosis about 35% of fibroblasts are derived via 
EndMT from the endothelial cells normally residing within the kidney. The 
remaining portions are speculated to arise via activation of resident fibroblasts or 
other mesenchymal cells, such as perivascular smooth muscle cells/pericytes and 
fibrocytes [297] in the circulation. It is likely that these proportions may vary 
dramatically, depending on the stage of fibrosis, the organ, and the particular 
experimental model being studied. 
Inflammatory injury can result in the recruitment of a diverse array of cells that can 
trigger an EMT through their release of growth factors, such as TGF-β, PDGF, 
EGF, and FGF-2 [301]. In kidney, most prominent among these cells are 
macrophages and activated resident fibroblasts that accumulate at the site of injury 
and release these growth factors. In addition, these cells release chemokines and 
MMPs, notably MMP-2, MMP-3, and MMP-9. Epithelial cells come under the 
influence of these signalling molecules and, acting together with the inflammatory 
cells, induce basement membrane damage and focal degradation of type IV 
collagen and laminin [301]. Delaminated epithelial cells may then migrate toward 
the interstitial area (the space between epithelial layers) under the influence of 
gradients of growth factors and other chemoattractants [301]. This initial 
recruitment of epithelial cells into an EMT can be inhibited by blocking the 
expression of MMP-9 through the disruption of tissue plasminogen activator (tPA) 
[302]. 
Other studies have also demonstrated that Hepatocyte-growth factor (HGF) can 
decrease levels of TGF-β, restore TGF-β–mediated loss of E-cadherin, and 
potentially decrease amounts of active MMP-9 [303]. β1 integrin and integrin-linked 
kinase (ILK) are also identified as important mediators of the TGF-β-induced EMT 
associated with tubular epithelial cells [304]. TGF-β induces EMT via both a 
Smad2/3-dependent pathway and a MAPK-dependent pathway. Recently it has 
been also demonstrated a key role for the E-cadherin/β-catenin signaling axis for 
EMT involving epithelial cells [305,306]. 
The significance of TGF-β-induced EMT for progression of organ fibrosis has been 
showed using BMP-7, an antagonist of TGF-β signalling, in mouse models of 
kidney, liver, billiard tract, lung, and intestinal fibrosis [307]. BMP-7 functions as an 
endogenous inhibitor of TGF-β-induced EMT [307]. Among other effects, it 
reverses the TGF-β-induced loss of the key epithelial protein, E-cadherin [307]. 
Restoration of E-cadherin levels by BMP-7 is mediated via its cognate receptors, 
activinlike kinase-2/3/6 (ALK-2/3/6), and the Smad4/5 downstream transcription 
factors. Systemic administration of recombinant BMP-7 to mice with severe fibrosis 
resulted in reversal of EMT and repair of damaged epithelial structures, with 
repopulation of healthy epithelial cells, all presumably mediated via a MET. This 
reversal was also associated with restoration of organ function, a substantial 
decrease in FSP1+ and α-SMA+ interstitial fibroblasts, and the de novo activation of 
BMP-7 signalling [307]. 
In a study of 133 patients with kidney fibrosis, an EMT was demonstrated in a 
substantial number of the specimens, as evaluated using double labelling of the 
tubular epithelial cells with cytokeratin, vimentin, α-SMA, or zona occludens 1 (ZO-
1). Similarly, in patients with Crohn disease, an EMT was demonstrated in areas of 
fibrosis in the colon [308]. The above studies suggest the necessary confidence to 
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develop novel therapeutic interventions to suppress EMTs and potentially reverse 
organ fibrosis. 
1.2.3.3 Type 3 EMT: EMT associated with cancer progression and metastasis 
Excessive epithelial cell proliferation and angiogenesis represent the hallmark of 
the initiation and early growth of primary epithelial cancers [309]. The subsequent 
acquisition of invasiveness, initially manifested by invasion through the basement 
membrane, is thought to herald the onset of the last stages of the multi-step 
process that leads eventually to metastatic dissemination, with life-threatening 
consequences. The genetic and biochemical mechanisms underlying the 
acquisition of the invasive phenotype and the subsequent systemic spread of the 
cancer cell have been areas of intensive research. In many of these studies, 
activation of an EMT program has been proposed as a critical mechanism for the 
acquisition of malignant phenotypes by epithelial cancer cells [310]. 
Many studies conducted in mouse models as well as in vitro have shown that 
cancer cells can acquire a mesenchymal phenotype and express mesenchymal 
markers such as α-SMA, FSP1, vimentin, and desmin [311]. These cells are mainly 
located at the invasive front of the tumour, and are considered to be the cells that 
might enter in the subsequent steps of the invasion-metastasis cascade, that 
involves intravasation, transport through the circulation, extravasation, colonization 
of distant organs, formation of micrometastases and growth of small colonies into 
macroscopic metastases [310,311,312]. 
An apparent paradox comes from the observation that the EMT-derived migratory 
cancer cells typically establish secondary colonies at distant sites that 
morphologically resemble the primary tumour; accordingly, they no longer exhibit 
the mesenchymal phenotypes ascribed to metastasizing carcinoma cells. 
Reconciling this behaviour with the proposed role of EMT as a facilitator of 
metastatic dissemination requires the additional notion that metastasizing cancer 
cells must shed their mesenchymal phenotype via a MET during the course of 
secondary tumour formation [313]. The tendency of disseminated cancer cells to 
undergo MET likely reflects the local microenvironments that they encounter after 
extravasation into the parenchyma of a distant organ, quite possibly the absence of 
the heterotypic signals they experienced in the primary tumour that were 
responsible for inducing the EMT in the first site [314,315]. These considerations 
indicate that induction of an EMT is likely to be a centrally important mechanism for 
the progression of carcinomas to a metastatic stage and implicates MET during the 
subsequent colonization process (Figure 1.7). However, many steps of this 
mechanistic model still require direct experimental validation. Moreover, it remains 
unclear whether these phenomena and molecular mechanisms relate to and 
explain the metastatic dissemination of non-epithelial cancer cells and the full 
spectrum of signalling agents that contribute to EMT.. One suggestion is that the 
genetic and epigenetic alterations undergone by cancer cells during the course of 
primary tumour development render them especially responsive to EMT-inducing 
heterotypic signals originating in the tumour-surrounding stroma.  
In the case of many carcinomas, EMT-inducing signals emanating from the tumor-
associated stroma, notably HGF, EGF, PDGF, and TGF-β, appear to be 
responsible for the induction or functional activation in cancer cells of a series of 
EMT-inducing transcription factors, notably Snail, Slug, zinc finger E-box binding 
homeobox 1 (ZEB1), Twist, Goosecoid, and FOXC2 [319,322]. Once expressed 
and activated, each of these transcription factors can act pleiotropically to 
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choreograph the complex EMT program, more often than not with the help of other 
members of this cohort of transcription factors. The actual implementation by these 
cells of their EMT program depends on a series of intracellular signalling networks 
involving, among other signal transducing proteins, ERK, MAPK, PI3K, Akt, 
Smads, RhoB, β-catenin, lymphoid enhancer binding factor (LEF), Ras, and c-Fos 
as well as cell surface proteins such as β4 integrins, α5β1 integrin, and αVβ6 
integrin [323]. Activation of EMT programs is also facilitated by the disruption of 
cell-cell adherens junctions and the cell-ECM adhesions mediated by integrins 
[324-329]. 
 
 
 
 
 
 
 
 
Figure 1.7 Contribution of EMT to cancer progression. Progression from normal 
epithelium to invasive carcinoma goes through several stages. The invasive 
carcinoma stage involves epithelial cells losing their polarity and detaching from the 
basement membrane. The composition of the basement membrane also changes, 
altering cell-ECM interactions and signaling networks. The next step involves EMT 
and an angiogenic switch, facilitating the malignant phase of tumor growth. 
Progression from this stage to metastatic cancer also involves EMTs, enabling 
cancer cells to enter the circulation and exit the blood stream at a remote site, 
where they may form micro- and macro-metastases, which may involve METs and 
thus a reversion to an epithelial phenotype. 
1.2.4 TGF-β inducers of EMT 
TGF-β is an important suppressor of epithelial cell proliferation and thus primary 
tumorigenesis. However, it is now clear that in certain contexts it can also serve as 
a positive regulator of tumour progression and metastasis [330-331]. Thus, in vitro 
studies have demonstrated that TGF-β can induce an EMT in certain types of 
cancer cells [333]. Two possible signalling pathways have been identified as 
mediators of TGF-β-induced EMT. The first of these involves Smad proteins, which 
mediate TGF-β action to induce EMTs via the ALK-5 receptor [334-338]. Smad-
mediated signalling induced by TGF-β facilitates motility. Inhibitory Smads 
modulate differential effects of relevant transcription factors and cytoplasmic 
kinases and induce the autocrine production of TGF-β, which can further reinforce 
and amplify the EMT program [339,340]]. Signalling pathways that mediate the 
action of β-catenin and LEF also cooperate with Smads [341] in inducing an EMT 
[342-343]. In this regard, the involvement of LEF and β-catenin in PDGF-induced 
EMT was recently described [341]. These studies collectively demonstrate that the 
TGF-β/Smad/LEF/PDGF axis is an important inducer of an EMT phenotype in 
cancer. 
Evidence for the involvement of a second TGF-β-induced pathway in EMT is also 
compelling. More specifically, some data indicate that p38 MAPK and RhoA 
mediate an autocrine TGF-β-induced EMT in NMuMG mouse mammary epithelial 
cells [339]. This process also requires integrin β1-mediated signalling and the 
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activation of latent TGF-β by αVβ6 integrin. Fibulin-5, an ECM molecule, augments 
TGF-β-induced EMT in a MAPK-dependent mechanism [340]. TGF-β can induce 
an EMT in Ras-transformed hepatocytes, mammary epithelial cells (via MAPK), 
and MDCK cells; at the same time, Ras-activated PI3K inhibits TGF-β-induced 
apoptosis to facilitate this transition [341-344]. 
Evidence for these connections comes from observations that ERK/MAPK and 
PI3K/Akt pathways mediate Ras mutant-induced EMT, and that such an EMT is 
reversed by either wild-type Ras or MAPK kinase 1 (MEK1) inhibitors [344]. In this 
regard, Raf also mediates TGF-β-induced EMT and promotes invasiveness of 
cancer cells. In mouse models of skin carcinoma and human CRC, the absence of 
TGF-β receptor expression actually confer better prognosis [345,346]. The 
connection between inflammation and EMT has been demonstrated by the fact that 
COX-2 inactivate Smad signaling and enhance EMT stimulated by TGF-β through 
a PGE2-dependent mechanism [. Changes in the expression of certain cell polarity 
proteins may also play an important role in TGF-β–induced EMT, since evidence of 
a role for partitioning detective protein 6 (Par6) in this process is emerging [353]. 
The connection between loss of E-cadherin expression by cancer cells and 
passage through an EMT has been established by many studies [354-355]. For 
example, induction of the c-Fos oncogene in normal mouse mammary epithelial 
cell lines induces an EMT and is associated with a decrease in E-cadherin 
expression [342]. Moreover, epithelial cell adhesion complexes reorganize and cell 
proliferation is suppressed when the full-length or the cytoplasmic portion of E-
cadherin (containing the β-catenin binding site) is ectopically expressed in cells 
that have passed through an EMT, causing such cells to lose their mesenchymal 
phenotype [356]. Sequestration of β-catenin in the cytoplasm is important for the 
preservation of epithelial features of cancer cells, and acquisition of the 
mesenchymal phenotype correlates with the movement of β-catenin to the nucleus, 
where it becomes part of Tcf/LEF complexes [357]. Such β-catenin accumulation in 
the nucleus, which is often associated with loss of E-cadherin expression, 
correlates with susceptibility to enter into an EMT and acquisition of an invasive 
phenotype. Thus, cells that lose E-cadherin become more responsive to induction 
of an EMT by various growth factors. 
Several Authors have demonstrated that the epigenetic control of E-cadherin and 
β-catenin/LEF activity is important in establishing the metastatic potential of cancer 
cells [358-360]. In addition, it has also been shown that cell lines that lack E-
cadherin show increased tumorigenicity and metastasis when transferred into 
immunodeficient mice [361]. E-cadherin expression levels vary dramatically in 
different human tumours, and an inverse relationship between levels of E-cadherin 
and patient survival has been documented [360]. In this regard, mutations in the E-
cadherin gene have been identified in cancer cells, making them more susceptible 
to EMT and metastasis. A more thorough analysis of such mutations and their 
correlation to metastatic progression is still required. 
The central role played by E-cadherin loss in the EMT program is further suggested 
by the actions of several EMT-inducing transcription factors that facilitate 
acquisition of a mesenchymal phenotype, such as Snail and Slug, as well as those 
encoding two key zinc finger-containing basic helix-loop-helix transcription factors, 
survival of motor neuron protein interacting protein 1 (SIP1) and E12 (also 
indicated as E47-E2A). These transcription factors are induced by TGF-β exposure 
and, once expressed, repress E-cadherin expression. Snail also facilitates an 
 34 
invasive phenotype in mice [275]. Loss of E-cadherin promotes Wnt signaling and 
is associated with high levels of Snail in the nucleus [362]. SIP1 represses E-
cadherin expression and binds, along with Snail, to the E-cadherin promoter in an 
overlapping fashion [363]. The expression of Snail and E-cadherin correlates 
inversely with the prognosis of patients suffering from breast cancer or oral 
squamous cell carcinoma [365]. The use of gene expression analyses to compare 
expression of genes in metastatic and non-metastatic mouse breast cancer cell 
lines has led to the identification of Twist and Goosecoid as important genes that 
facilitate EMT and induce metastasis[325] . It has been reported that matrix-
degrading enzymes such as MMP-3 facilitate EMT by inducing genomic instability 
via Rac1b and ROS [366]. 
Noncoding microRNAs are also components of the cellular signalling circuitry that 
regulates the EMT program. microRNA 200 (miR200) and miR205 inhibit the 
repressors of E-cadherin expression, ZEB1 and ZEB2, and thereby help in 
maintaining the epithelial cell phenotype [367-372]. In breast carcinoma, a loss of 
miR200 correlates with increased expression of vimentin and a decrease in the 
levels of E-cadherin in cancer cells. Acting in the opposite direction, miR21 is up-
regulated in many cancers and facilitates TGF-β-induced EMT [372]. Interestingly, 
CD44hiCD20lo cells purified from normal and malignant breast cancer tissue 
exhibit features of an EMT, and human cancer cells induced to undergo EMT 
exhibit stem cell-like properties and increased metastatic potential [327]. Therefore, 
EMT may play a role in the generation of high-grade invasive cells with stem cell-
like features, and the latter phenotype, which includes self-renewal potential, may 
facilitate the formation of secondary tumours by disseminating cancer cells, a 
notion that still requires direct demonstration. 
1.2.5 EMT Biomarkers 
Table Ib shows the commonest markers, some of which are acquired and other 
are attenuated or repressed during the EMT. All of the available biomarkers applied 
to investigate the subtypes of EMT can be grouped in four classes: a) cell-surface 
markers, b) Cytoskeletal markers, and c) extra-cellular proteins and d) transcription 
factors. 
Cell-surface markers of EMT. E-cadherin is the prototypical epithelial cell marker. It 
is expressed in epithelial cells, and its expression is decreased during EMT in 
embryonic development, tissue fibrosis, and cancer. Moreover, loss of E-cadherin 
function promotes EMT [381]. In recent years, changes in the level of expression of 
different cadherins, so-called “cadherin switches”, have been increasingly used to 
monitor EMT. Indeed, the cadherin switch from E-cadherin to N-cadherin, which is 
expressed in mesenchymal cells, fibroblasts, cancer cells, and neural tissue, has 
often been used to monitor the progression of EMT during embryonic development 
and the advancement of cancer. In addition, because OB-cadherin is a more 
definitive marker for activated fibroblasts, an E-cadherin-OB-cadherin switch is of 
interest for type 2 EMT associated with fibrogenesis. 
EMT is associated classically with a relocation of cells from a basement membrane 
microenvironment into a fibrillar ECM. A change in the level of expression of 
different integrins i.e. an integrin switch often reflects alterations in cell-ECM 
interactions. In addition, integrin signalling facilitates EMT [383], and various 
integrins are expressed on both epithelial and mesenchymal cells. 
 35 
Usually, integrins have limited utility as biomarkers for EMT. There are, however, 
examples where integrins can be used as EMT markers in a context-dependent 
manner. 
In CRC, only cancer cells that have undergone type 3 EMT to a metastatic 
phenotype express high levels of β6 integrin (normal epithelial cells and non-
invasive cancer cells have low-level expression) [384]. During gastrulation, type 1 
EMT is associated with de novo expression of α5β1, which is a receptor for 
fibronectin [385]. Similarly, type 2 EMT in experimental kidney fibrosis is associated 
with increased α5 integrin expression [386]. Increased expression of α5 integrin 
also correlates with the metastatic potential of B16F10 melanoma cells and EMT 
[387], suggesting that α5 integrin plays a role in each subtype of EMT. 
Another marker that reflects adaptation to the altered ECM microenvironment 
associated with EMT is the collagen-specific receptor tyrosine kinase (DDR2, 
discoidin domain receptor tyrosine kinase 2) [388]. Upon binding to type I or type X 
collagen, DDR2 mediates up-regulation of MMP1 and cell motility [389]. In adult 
tissues, expression of DDR2 is confined to subsets of fibroblasts and vascular 
smooth muscle cells, whereas de novo expression of DDR2 in endothelial cells is 
associated with type 2 EMT [390]. 
DDR2 expression in cancer cells correlates with increased invasiveness, 
demonstrating its utility in identifying type 3 EMT [391]. 
Cytoskeletal markers of EMT. FSP1 is a member of the family of Ca2+-binding 
S100 proteins. It is a prototypical fibroblast marker for detecting EMT in cancer and 
fibrogenesis [373,377]. Most epithelial cells undergoing type 2 EMT express FSP1 
early in transition to fibroblasts, and lineage tagging in transgenic reporter mice 
reveals that more than one-third of all FSP1+ fibroblasts in fibrotic kidneys and 
livers are EMT derived [377,378]. In addition, in models of cancer, metastatic cells 
often express FSP1 as a part of the molecular program of type 3 EMT. Ectopic 
expression of FSP1 itself facilitates EMT in adult epithelial cells and cancer cells 
[379]. In embryonic development, FSP1 is expressed from E8.5 in the mouse, well 
after mesenchymal cells first appear. Because FSP1 is mainly confined to 
transitioning epithelial cells and fibroblasts as opposed to primitive mesenchymal 
cells, it has limited utility for detection of type 1 EMT. 
A controversial marker of EMT is the intermediate filament vimentin, which is 
expressed in various cells, including fibroblasts, endothelial, hematopoietic and 
glial cells [392-393]. During the mouse embryonic development, vimentin is first 
expressed at E6.5–E7.0, and it is used as a marker for type 1 EMT during the 
gastrulation phase [394,395]. However, because adult epithelial cells transiently 
express vimentin in response to various insults [396], vimentin should not be 
considered a marker of type 2 EMT in the setting of fibrosis. By contrast, vimentin 
is commonly used to identify cells undergoing type 3 EMT in cancers [397]. 
This is based on a positive correlation of vimentin expression with increased 
invasiveness and metastasis [398]. 
α-SMA is one of six actin family members. In the adult, prominent α-SMA 
expression can be found in vascular smooth muscle cells and myoepithelial cells 
[399]. During embryonic development, the EMT that gives rise to the endocardial 
cushion is characterized eventually by de novo α-SMA expression [400]. Type 2 
EMT is also sometimes associated with cells that eventually express α-SMA as 
myofibroblasts. Although some of these cells that express both α-SMA and FSP1 
are known as myofibroblasts, most α-SMA+ cells express only α-SMA and are 
 36 
distinct from EMT-derived fibroblasts. In cancer, evidence that type 3 EMT is 
associated with α-SMA is mostly confined to breast cancer [401]here α-SMA 
largely is detected in breast tumours of the “basal phenotype” [402] 
β-Catenin is a cytoplasmic plaque protein that plays a dual role in EMT: it links 
cadherins to the cytoskeleton and serves as a co-transcriptional activator together 
with T cell factor (TCF)/LEF [403]atenin activity is mainly regulated by mechanisms 
controlling the level of β-catenin in the cytoplasm, through either its recruitment to 
cadherin-binding partners or ubiquitination and subsequent degradation [404] β-
catenin/TCF/LEF complex directly controls gene expression associated with EMT, 
particularly Snail1 [405]Catenin has been used as a marker of EMT in embryonic 
development, cancer, and fibrosis [406]. Although β-catenin is localized to cell 
membranes in normal epithelial cells and non invasive tumoural cells, it is located 
either in the cytoplasm (as reflective of dissociation from E-cadherin) or in the 
nucleus (as reflective of its role as a transcriptional activator) in cells that undergo 
EMT [374]. 
Extracellular proteins. Fibronectin is a high-molecular weight glycoprotein that 
serves as a scaffold for fibrillar ECM [407]. Because it is one of the first molecules 
to 
appear when the fibrillar ECM is formed, it has been used as an indicator of type 1 
EMT associated with gastrulation, palate fusion, and neurulation. Even though 
fibronectin is an integral constituent of the fibrotic ECM associated with fibrosis and 
the desmoplastic stroma in tumours, the utility of fibronectin as a type 2 and type 3 
EMT biomarker is limited, in part, because it is produced by various cell types, 
including fibroblasts, mononuclear cells, and epithelial cells [408, 409]. Both type 2 
and type 3 EMT, however, are associated with increased fibronectin expression in 
vitro [410]. 
Type IV collagen, laminin, nidogen, and sulphated proteoglycans are the principal 
basement membrane constituents that during EMT are downregulated.  
Among these laminin is the better established biomarker of the EMT. Laminins are 
heterotrimeric glycoproteins composed of one α chain, one β chain, and one γ 
chain [411]. Currently, 15 different heterotrimers are known [411]. With regard to 
EMT, most studies focused on laminin1 (α1β1γ1), which is present in the embryo 
from the peri-implantation period forward [412]. Type 1 EMT during gastrulation 
and palate fusion is marked by loss of laminin 1 [413]. Both type 1 and type 2 EMT 
are associated with downregulation of laminin 1 in vitro and disruption and loss of 
laminin 1 in vivo [414]. By contrast, up-regulation of laminin 5 (α3β3γ2) is 
associated with type 3 EMT in cancer and type 2 EMT. Laminin 5 is detected in the 
discontinuous laminin patterns associated with invasive cancers, and its expression 
is linked to type 3 EMT in breast carcinomas of the ductal type [415], hepatocellular 
carcinoma [416], and oral squamous carcinoma [417]. 
Similarly, laminin 5 is part of the fibrotic ECM associated with idiopathic pulmonary 
fibrosis [418]. A correlation between laminin 5 and EMT in the embryo has not yet 
been reported. 
Transcription factors. Fibroblast transcription site-1 (FTS-1) is a cis-acting 
regulatory element present in the promoter region of various EMT-associated 
genes, including those that encode FSP1, Twist, Snail1, high mobility group AT-
hook 2 (HMGA2), LEF1, Ets-1, E-cadherin, β-catenin, ZO-1, α-SMA, and vimentin. 
CBF-A and KRAB-associated protein 1 (KAP-1) form a complex with FTS-1 to 
modulate gene activity. Formation of the CBF-A/KAP-1/FTS-1 complex induces 
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type 2 EMT in kidney tubular epithelial cells. De novo expression of CBF-A, a 
member of the heterogeneous nuclear ribonucleoprotein A/B (hnRNP A/B) family, 
can be observed in type 2 and type 3 EMT associated with onset of fibrosis and 
metastatic tumour formation. However, its expression is not confined to EMT, and it 
is involved in various other processes, including stimulation of Ig transcription 
[419]. KAP-1 is also a ubiquitously expressed transcriptional co-repressor or 
activator that is well known to bind KRAB domains on zinc finger proteins [419]. In 
EMT, under the limited circumstances where it has been studied, KAP-1 seems to 
be an activator and, in the CBF-A/KAP-1/FTS-1 complex, a proximal master 
activator of EMT-associated genes. 
An increasing number of environmental factors are now known to induce EMT, 
including growth factors, ECM constituents, proteases, and hypoxia. Despite the 
different nature of known stimulants, the EMT response is relatively uniform. This 
raises interest in potential key regulators of EMT that are at the intersection of 
various signalling pathways and control the EMT response. Snail transcription 
factors are one prominent example of a common downstream target of various 
signalling pathways that regulates EMT [428]. Of the three vertebrate Snail family 
members of zinc finger proteins (Snail1, Snail2, and Snail3), the functionally 
equivalent Snail1 and Snail2 (which was formerly known as Slug) mediate EMT 
[428]. In fact, all known EMT events during development, cancer, and fibrosis 
appear to be associated with Snail activation [428]. 
Snail is most widely recognized as a suppressor of E-cadherin expression, 
although it regulates various other aspects of the EMT phenotype, including the 
increased expression of mesenchymal cell/fibroblast markers i.e. fibronectin and 
vitronectin, decreased expression of epithelial markers i.e. claudins, occludins, and 
cytokeratins, inhibition of proliferation through suppression of cyclin D proteins and 
cyclin-dependent kinase 4 (CDK4), increased MMP expression, and protection 
from cell death (through suppression of expression of caspases, DNA 
fragmentation factor, and Bcl-interacting death agonist). Snail transcriptional 
activity is regulated by control of its subcellular localization. Phosphorylation of 
Snail causes its export from the nucleus into the cytoplasm, resulting in its 
inactivation as a transcription factor. In human renal biopsies, fibrosis is associated 
with increased Snail1 expression [420], and Snail activation in tamoxifen-inducible 
Snail1-transgenic mice results in type 2 EMT and renal fibrosis. 
Twist is a basic helix-loop-helix protein that is transcriptionally active during lineage 
determination and cell differentiation. It is up-regulated during early embryonic 
morphogenesis [421,422], fibrosis [423], and cancer metastasis [424]. In the 
development of metastatic cancer cells by type 3 EMT, Twist can act independently 
of Snail to repress E-cadherin [6] and to up-regulate fibronectin and N-cadherin 
[410]. 
Another transcription factor is called Forkhead box C2 (FOXC2). It acts as a 
pleiotropic inducer of EMT. During embryonic development, FOXC2 is widely 
expressed and is required for angiogenesis, musculogenesis, and organogenesis 
of the kidney, heart, and urinary tract [425]. Postnatally, expression of FOXC2 is 
normally restricted to adipocytes [426]. However, FOXC2 is also expressed in 
ductal breast cancers and metastatic breast cancer cell lines [427]. Over-
expression of any one of the EMT inducers TGF-β1, Snail, Twist, or Goosecoid 
increases FOXC2 expression, and over-expression of FOXC2 itself induces EMT, 
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suggesting an important role for FOXC2 in type 3 EMT [427]. A role for FOXC2 in 
EMT associated with embryogenesis or fibrosis has not been established yet. 
 
 
 
Table Ib EMT Biomarkers 
 
   Acquired    Attenuated 
Name    EMT type   Name   EMT type 
Cell-surface proteins 
N-cadherin   1, 2    E-cadherin  1, 2, 3 
OB-cadherin   3    ZO-1   1, 2, 3 
α5β1 integrin   1, 3 
αVβ6 integrin   1, 3 
Syndecan-1   1, 3 
Cytoskeletal markers 
FSP1    1, 2, 3    Cytokeratin  1, 2, 3 
α-SMA    2, 3 
Vimentin   1, 2 
β-Catenin   1, 2, 3 
ECM proteins 
α1(I) collagen   1, 3    α1(IV) collagen  1, 2, 3 
α1(III) collagen   1, 3    Laminin 1  1, 2, 3 
Fibronectin   1, 2 
Laminin 5   1, 2 
Transcription factors 
Snail1 (Snail)   1, 2, 3 
Snail2 (Slug)   1, 2, 3 
ZEB1    1, 2, 3 
CBF-A/KAP-1 complex  2, 3 
Twist    1, 2, 3 
LEF-1    1, 2, 3 
Ets-1    1, 2, 3 
FOXC2   1, 2 
Goosecoid   1, 2 
MicroRNAs 
miR10b   2    Mir-200 family  2 
miR-21   2, 3 
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1.3 TWIST 1: A HOMOLOG OF DROSOPHILA TWIST 
TWIST1 belongs to the basic helix-loop-helix (bHLH) class of transcriptional 
regulators that recognize a consensus DNA element called the E box. 
1.3.1 Cloning 
By PCR of a placenta cDNA library using primers based on mouse Twist, 
Bourgeois et al. in 1996 [429] first cloned human TWIST. The deduced 206-amino 
acid protein contains a central DNA-binding basic region followed by a helix-loop-
helix domain. Mouse and human TWIST share 96.6% amino acid identity. In vitro-
translated TWIST had an apparent molecular mass of 25 kD.  
The protein contains 201 amino acids and has a calculated molecular mass of 20.9 
kD. It has a hydrophilic N terminus, followed by a bHLH DNA-binding and 
dimerization motif. It also contains several potential phosphorylation sites, including 
two in the loop region of the dimerization domain that are conserved among all 
species examined. TWIST orthologs were detected in all mammalian species 
examined, and within mammals, the DNA-binding region showed 100% sequence 
conservation. A possible ortholog was also detected in chicken, but not in yeast. 
Northern blot analysis detected a 1.6-kb transcript that was highly expressed in 
placenta. Lower expression was detected in adult heart and skeletal muscle, and 
weak expression was found in kidney and pancreas, but not in brain. Twist 1 
expression was also detected in endometrial fibroblasts, peritoneal mesothelial 
cells, and fetal lung fibroblasts, but not in other cell lines examined.  
1.3.2 Gene Function  
Studies in Drosophila by Shishido et al (1993) [435] indicated that Twist may affect 
the transcription of fibroblast growth factor receptors (FGFRs), a gene family 
implicated in craniosynostosis. The emerging cascade of molecular components 
involved in craniofacial and limb development included TWIST, which may function 
as an upstream regulator of FGFRs.  
Histone acetyltransferases (HATs) play a critical role in transcriptional control by 
relieving repressive effects of chromatin. Hamamori et al (1999) showed that Twist 
directly binds two independent HAT domains of acetyltransferases, p300 and 
p300/CBP-associated factor (PCAF), and directly regulates their HAT activities 
[436]. The N terminus of Twist is a primary domain interacting with both 
acetyltransferases, and the same domain is required for inhibition of p300-
dependent transcription by Twist. Adenovirus E1A protein mimicked the effects of 
Twist by inhibiting the HAT activities of p300 and PCAF.  
Using electrophoretic mobility shift assays, El Ghouzzi et al (2001) demonstrated 
that the TWIST-E12 (TCF3; 147141) dimer specifically recognizes the CATATG 
motif [431]. 
Using a murine breast tumour model, Yang et al (2004) determined that Twist plays 
an essential role in metastasis [6]. Suppression of Twist expression in highly 
metastatic mammary carcinoma cells specifically inhibited their ability to 
metastasize from the mammary gland to the lung. Ectopic expression of Twist 
resulted in loss of E-cadherin mediated cell-cell adhesion, activation of 
mesenchymal markers, and induction of cell motility, suggesting that Twist 
contributes to metastasis by promoting an epithelial-mesenchymal transition. In 
human breast cancers, high Twist expression correlated with invasive lobular 
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carcinoma, a highly infiltrating tumour type associated with loss of E-cadherin 
expression.  
1.3.4 Mapping 
Bourgeois et al (1996)[429] used isotopic in situ hybridization to map the TWIST1 
gene to chromosome 7p21. The murine gene had been mapped to bands B-C1 of 
chromosome 12 by Mattei et al (1993)[433]. 
1.3.5 Molecular Genetics 
Twist is required in head mesenchyme for cranial neural tube morphogenesis in 
mice. While homozygous Twist-null murine embryos exhibit failure of neural tube 
closure, heterozygosity for Twist-null mutations results in a moderate phenotype 
including minor skull and limb anomalies consistent with those of the Saethre-
Chotzen syndrome (SCS). Furthermore, the clinical phenotype of SCS was 
mapped to 7p22-p21 by linkage analysis; Bourgeois et al (1996) and Howard et al 
(1997) mapped the human TWIST gene to the same region of 7p. This prompted 
Howard et al (1997) and El Ghouzzi et al (1997) to seek mutations in the TWIST 
gene in SCS[429,432]. Both groups found a number of mutations occurring within 
the basic DNA binding, helix I, and loop domains resulting in substitutions or 
premature termination of the protein.  
1.3.6 Animal Model 
Heterozygous-null Twist mice have variable expression of craniofacial and limb 
defects consistent with the phenotype and variability seen in SCS (Bourgeois et al, 
1998)[437]. 
Mice heterozygous for the ethylmethanesulfonate (EMS)-induced polydactyly ems 
(pde) mutation show preaxial polydactyly of the hindlimbs. Browning et al (2001) 
determined that the pde mutation maps to chromosome 12 and is an allele of Twist 
[430]. However, sequencing the Twist protein-coding region and several hundred 
basepairs upstream of the coding region failed to reveal a disease-associated 
mutation. Browning et al (2001) concluded that the lesion may be in a regulatory 
element of the gene.  
Pan et al (2009) found that homozygous Twist1 knockout in mice was embryonic 
lethal [434].  
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2. SCIENTIFIC ISSUES and AIMS  
The main reasons for poor prognosis in CRC are delayed diagnosis, at a 
metastatic stage (International Union Against Cancer, stage IV) and disease 
spreading to regional lymph-nodes (stage III). Of locally advanced disease (stage 
II, T3 and T4,) a considerable fraction (up to 30%) can eventually undergo 
metastatic evolution after surgery.  Very few molecular markers have been proved 
to correlate with colon cancer prognosis. Among these, the presence of 
microsatellite instability (MSI) and thus of mismatch repair defects (10%-15% of all 
colon cancers) is the most frequently cited and has even been proposed for clinical 
purposes. The main determinant of the prognostic advantage of MSI cancers is 
their lower metastatic potential, as compared to MS-stable (MSS) ones. Yet, the 
molecular understanding of the favourable prognostic implications of MSI remains 
largely a matter of speculation.  
As to functional models explaining for the metastatic behaviour of cancer, in 
epithelial malignancies in which the MSI phenotype does not occur, it has recently 
been suggested that epithelial to mesenchymal transition (EMT) is one of the 
determinants of cancer-cell invasion and metastasis. Although EMT cannot be 
thought to be the only determinant of metastatic spread, nor a mandatory signature 
of cancers, it provides a model to approach mechanistic studies on metastasis 
development. In a breast cancer, syngenic animal model (BALB/c), the 
mesenchymal development driving gene Twist1 has been shown to correlate with 
the invasive and metastic properties of an orthotopic mice breast cancer tumor 
according to an EMT model. In human breast cancer, Twist1 expression correlates 
with the degree of chromosomal abnormalities (chromosomal instability), 
invasiveness and angiogenesis. Twist1 expression has also been reported in other 
invasive/metastatic human cancers. Among the gastrointestinal cancers, Twist1 
expression seems to occur in gastric and liver tumors, but data on CRC are scarce. 
Colon cancer provides the chance to test Twist1 expression in relation to the 
presence/absence of the molecular phenotype of MSI, and in the light of the classic 
genetic model of cancer progression through the accumulation of genetic damage. 
Relying upon the breast cancer published data we propose to investigate Twist1 
expression in CRC according their MS-status. Accordingly, we plan not only to 
verify whether Twist1 constitutive expression will ultimately result in the transition to 
mesenchymal features, coupled to invasive properties in CRC cells, but also to test 
whether specificTwist1 inducers can induce EMT in CRC cell-lines, with and 
without MSI. Moreover we aim to explore EMT driven by Twist1 in a mouse model 
of CRC.  
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3. MATERIALS AND METHODS 
3.1 Cell culture 
Human Colon Cancer cell lines: CoLo115, GP5D, HCT116, SW48, DLD1, LoVo, 
CoLo741, HT29, CoLo205, SW403, CaCo2, CX-1, LS174T, SW480, SW620, 
SW837, LS180, LS411, CT26 were purchased from  American Type Colture 
Collection were cultured in RPMI with 10% fetal bovine serum (FBS),100mg/ml of 
penicyllin G, 50mg/ml of Streptomicin and Ultraglutamine 2mM and  growth at 
37°C, 5% CO 2  incubator. 
3.2 Gene expression profile microarray 
Microarray analysis 
The transcriptional profile of the CoLo115, GP5D, HCT116, SW48, DLD1, LoVo, 
CoLo741, HT29, CoLo205, SW403, CaCo2, CX-1, LS174T, SW480, SW620, 
SW837, LS180, LS411 colorectal cancer cell lines: as affymetrix raw data files [cell 
intensity (Cell) files] was kindly given by Giancarlo Marra (University of Zurich).  
Each preparation derived from a different single donor using the Human Genome 
U133 Plus 2.0 Array (Affymetrix, Santa Clara, CA, USA), containing a total of 
~55,000 transcripts. Cell files were processed using a Robust Multi-Array Analysis 
(RMA) procedure, an algorithm that is freely available at 
http://www.bioconductor.org. The RMA method was used to convert the intensities 
from the multiple probes of a probe set in a single expression value with greater 
precision and reduced background noise (relying on perfect the perfect match 
probes only and thus ignoring the mismatch probes) and then to normalize by 
sketch quintile normalization. Significance analysis of Microarray (SAM), Principal 
Component Analysis (PCA) of variance and Hierarchical Clustering (HCL), after 
mean scaling and log2 transformation, were performed using a software tool of The 
Institute for Genomic Research (TIGR) MeV: 
http://www.tigr.org/software/th4/mev.html. 
For the analysis of pathways was used Ingenuity System Pathways Analysis 
software (IPA). 
3.3 RNA extraction 
3.3.1 Mammalian Cell lines 
Cells were detached with trypsin 1%, washed with physiologic water, then 
centrifuged at 1550 rpm for 10 min, disrupted in 600 ml of Buffer RLT and finally 
homogenized. The same volume of Ethanol is then added to the lysate, creating 
conditions that promote selective binding of RNA to the RNeasy membrane. The 
sample is then applied to the RNeasy Mini spin column. Total RNA binds to the 
membrane, contaminants are efficiently washed away, and RNA is eluted in 50 ml 
of RNase-free water. All bind, wash, and elution steps are performed by 
centrifugation in a microcentrifuge. 
 43 
3.3.2 Tissues 
78 CRC tissues and their normal mucosa counterpart were used to study Twist1 
mRNA expression. RNA from was purified using Trizol reagent (Applied 
Biosystem). 
100 mg of tissue samples were homogenized in 1 ml of Trizol reagent using Tissue 
ruptor (Qiagen). 
Samples were incubated for 5 min at 15 to 30°C to p ermit the complete 
dissociation of nucleoprotein complexes. 0.2 ml of chloroform was added per 1 ml 
of TRIZOL® and tubes were shacked vigorously by hand for 15 sec and incubated 
at 15 to 30°C for 2 to 3 min. Then samples were cen trifuged at 12,000g for 15 min 
at 4°C. Following centrifugation, the aqueous phase  was transferred to a fresh 
tube. RNA was precipitated from the aqueous phase by mixing with 600 ml of 
isopropyl alcohol and tubes incubated at room temperature for 10 min and 
centrifuged at 12,000g for 30 min. 
The supernatant removed and the RNA pellet washed two times with1 ml of 75% 
ethanol. After a centrifugation at 12,000 x g the RNA pellet was suspended with 
100 ml of nuclease free water. 
3.4 DNase treatment 
To remove genomic DNA contamination, all samples were treated with TURBO 
DNA free kit (Applera). 
Each sample was incubated for 1h at 37 C after the addition of 0.1 Volume of 10x 
Turbo DNase free buffer and 2 ml of DNase enzyme. 
Dnase was then neutralized using DNase Inactivation Reagent.   
3.5 Reverse-Trascription Polymerase Chain Reaction (RT-PCR)  
Total RNA derived from cell lines or tissue specimens was reverse-transcripted to 
single-stranded cDNA using High Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems). Reaction mixture was prepared addicting to 2 mg of total 
RNA 5ml of 10x RT Buffer, 5ml of 10x RT Random Primers, 2 of dNTP Mix 
(100mM), 2,5 ml of MultiScribe™ Reverse Transcriptase and 1ml  RNase Inhibitor. 
Thermal cycler () was programmed following these optimized conditions: 
Step 1: 25°C for 10 min 
Step 2: 37°C for 120 min 
Step 3: 85°C for 5 min 
3.6 Quantitative Real-time Polymerase Chain Reaction (qRT-
PCR) 
Quantitative Real-Time PCR was performed using the HT 7900 Fast system 
Instrument (Applied Biosystem, California, USA) and SYBR Green (Applied 
Biosystem, California, USA) as intercalating fluorescent dye.  
All primer sequences were designed with Primer 3 program (Rozen and Skaletsky). 
One µl of sample cDNA (40 ng) was added to the PCR reaction mixture containing 
2X Power SYBR Green Master Mix and forward and reverse primers (5 µM) in a 
final volume of 25 µl. All analyses were performed in triplicate. The PCR 
amplification profile has been employed as follows: initial denaturation at 95°C for 
10min, followed by 40 cycles of denaturation at 95°C for 15 s, annealing for 40 s at 
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60°C and extension at 72°C for 20 s. Detection of t he fluorescent product was 
carried out during the annealing period. Data analysis was performed using the 
comparative Delta Delta Ct (∆∆Ct) method (Livak and Schmittgen) The relative 
gene copy number was calculated using the expression 2-∆∆Ct, in order to 
establish the range of values for each group. The standard deviations (SD) from 
the mean values were also calculated. 
3.7 Cell lines treatment 
3.7.1 Cytokines & Hypoxia 
To induce Twist1 expression the human colon cancer Cell lines HT29, SW480 and 
Colo741 were plated into six well-plates at the density of 70-80% of confluence and 
the subsequent day treated with TGF-β, IL-6, TNF-α, IFN-γ and IL-1β at a final 
concentration of 20 ng/ml for 6 h. Another plate was also incubated in hypoxia 
condition for 6 h using an incubator with controlled atmosphere 1% O2, 5% CO2 
and 94% N. 
3.7.2 2'-deoxy-5-azacytidine (DAC) 
Colorectal cell lines HCT116 and CoLo741 were treated with 4µM of the de-
methylator agent 2'-deoxy-5-azacytidine (DAC) for 4 days. During the treatment 
every 24 h the medium was changed with fresh one added with 4µM of DAC, this 
procedure was necessary due to the toxicity of DAC. 
3.7.3 Emetine and Actionomycin D 
HCT116 and CoLo741 cell lines once reached the 70% of confluence in a six-plate 
dish were treated with Emetine and Actinomicycin D at final concentration of 100 
µg/ml and 2 µg/ml from 1 to 3 h. 
3.8 Twist1 sequencing 
The coding region of TWIST gene was amplified and sequenced (see Table IIIb for 
primer sequences). 
PCRs were performed in 40µl volumes that contained 200 ng genomic DNA, 4 µl 
High Fidelity PCR buffer, 0.2 mM each dATP, dCTP and dTTP, 0.15 mM 7-deaza-
dGTP, 0.05 mM dGTP, 0.25 µM each primer, 2mM MgSO4, and 1U Platinum Taq 
High Fidelity (Invitrogen). PCR parameters were: 94°C for 6 min; 38 cycles of 94°C 
for 1 min, 66°C for 15 sec, and 68°C for 45 sec; fo llowed by 68°C for 7 min. 
PCR products were purified with Qiagen PCR purification kit (Qiagen, Milan, Italy). 
To perform the cycle sequencing reaction, 2 µl of purified DNA fragment was 
blended with each primer (0.8 mmol/l) in a Terminator Ready Reaction Mix 
containing Big Dye Terminators (Applied Biosystems, Foster City, California, USA), 
denatured for 5 min at 95°C and submitted to 30 cyc les at 95°C for 30 s, 50°C for 
10 s, and 60°C for 4 min. A second purification wit h DyeEx 2.0 Spin Kit (Qiagen) 
was performed for Big Dye removal. Five µl of marked and purified DNA were 
submitted to sequencing analysis on an ABI PRISM 310 Genetic Analyser (Applied 
Biosystems). 
 45 
3.9 Twist1 transfection in SW480 cell line 
Twist1 stable transfection in SW480 cell line was performed using a full length 
cDNA cloned in pCMV6-AC vector (Origene) (see Figure 2.1 for plasmid scheme). 
Before transfection in mammalian cells, the plasmidic DNA was propagated in 
Top10 E. Coli chemically competent cells. 
3.9.1 DNA Plasmid amplification in Top10 E.Coli 
10 µL of chemically competent cells (Top10, E. Coli) was thawed on ice and then 5 
µL (5ng) of expression plasmid was added and incubated on ice for 30 min.  
The heat shock procedure was performed by incubating the mixture of DNA and 
cells at 42oC for 30 sec, and then they were removed to ice immediately. 
After heat-shock, 250 uL of recovery medium (SOC) was added to the cells, and 
incubated at 37oC for 1 h with agitation. Two different dilutions of the 
transformation mixture were plated in separate LB-amp agar plates (10% and 50% 
of the transformation reaction on separate plates, each diluted up to 100 uL in 
SOC). The plates were incubated overnight at 37o C. The following day, 5 single 
bacterial colonies from each transformation were inoculated into individual sterile 
culture tubes containing 50 mL of liquid medium with 100 ug/mL ampicillin (LB-
amp) and incubated overnight at 37o C with agitation. 
3.9.3 Plasmid purification 
Cells were pelleted using centrifugation at 5,000 × g for 10 min and the 
supernatant discarded. 
Pellets were resuspended in 3 mL of cell re-suspension solution and lysed in 3 mL 
of cell lysis solution, after 3 min of incubation at room temperature was added 3 ml 
of Neutralization Solution to the lysed cells, the tubes capped and mixed by gently 
inverting 10 times. 
The lysate were centrifuged at room temperature, 15,000 × g for 15 min. This 
centrifugation pelleted the bulk of the cellular debris. Remaining debris was 
removed using the PureYield™ Clearing Columns. 
The cleared lysate was decanted into the PureYield™ Clearing Column and 
applying vacuum the lysate passed through the clearing membrane in the 
PureYield™ Clearing Column, and the DNA remained bound to the binding 
membrane in the PureYield™ Binding Column. 
Columns were washed with 5 mL of Endotoxin Removal Wash and 20ml of Column 
Wash Solution. Membranes were dried for 30 sec by applying a vacuum. After 
drying, the columns were placed into a new 50 ml disposable plastic tube tip of the 
column on a paper towel to remove excess ethanol. Place the column into a new 
50ml disposable plastic tube (e.g., Corning or Falcon™). 
Elution was done by vacuum using the Eluator™ Vacuum Elution Device and 600µl 
of Nuclease-Free Water applying maximum vacuum for 1 min. DNA was then 
quantified using the nanodrop. 
3.9.3 Plasmid sequencing 
DNA sequencing from the 5` end of the cDNA insert was performed with VP1.5 (5`-
GGACTTTCCAAAATGTCG-3`) whose priming site is located ~120 bp upstream of 
the polylinker. DNA sequencing from the 3` end of the cDNA insert was performed 
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with XL39 (5`-ATTAGGACAAGGCTGGTGGG-3`) whose priming site is located 
~70 bp downstream of the polylinker. 
 
 
 
 
 
 
 
 
 
Figure 3.1 Schematic of pCMV6-AC plasmid and its multiple cloning sites  
3.9.4 Mammalian cells transfection 
The day before transfection, 1x106 SW480 cells were plated into each vessel of a 6 
well plate. Cells were grown overnight at 37oC in a 5% CO2 incubator. The 
following day was prepared the transfection mixture as follow: 4 ng of plasmidic 
DNA was diluted  into 250 ml  serum-free medium OptiMEM without antibiotics 
same was done with 4 ml of the transfection reagent Lipofectamine 2000 
(invitrogen) . After 5 minutes of incubation the diluted DNA and Lipofectamine were 
combined and incubated for 20 minutes at room temperature .Then 500 ml of the 
complexes were added to each well containing cells and medium. Cells were 
incubated at 37°C 5% CO2 incubator for 48h then pas sed 1:10 and for 2 weeks 
treated with selective medium containing 0.5mg/ml of Neomicyn. 
3.10 Twist1 silencing 
Twist1 knockdown in Colo741 cell line was performed using a lentiviral based 
ShRNA vector.  5 different shRNA were tested. 
The ShRNA vectors were purchased as twist homolog 1 (acrocephalosyndactyly 3; 
Saethre-Chotzen syndrome) (Drosophila) MISSION® shRNA Bacterial Glycerol 
Stock from Sigma. 
The ShRNA was provided as frozen bacterial glycerol stocks (Luria Broth, 
carbenicillin at 100 µg/ml and 10% glycerol) in Escherichia coli for propagation and 
downstream purification of the shRNA clones (pLKO.1) which contains the 
puromycin selection marker for stable transfection. 
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Five different shRNA were tested, below the sequences:  
 
 
 
shRNA 1 Region: 3UTR  
Sequence: CCGGGCATTCTGATAGAAGTCTGAACTCGAGTTCAGACTTCTATCAGAATGCTTTTT  
shRNA 2 Region: codifing sequence  
Sequence::  CCGGCCTGAGCAACAGCGAGGAAGACTCGAGTCTTCCTCGCTGTTGCTCAGGTTTTT  
shRNA 3 Region: codifing sequen 
Sequence:   CCGGCGCCTTCTCGGTCTGGAGGATCTCGAGATCCTCCAGACCGAGAAGGCGTTTTT  
shRNA 4 Region: codifing sequen 
Sequence:  CCGGTCCGCAGTCTTACGAGGAGCTCTCGAGAGCTCCTCGTAAGACTGCGGATTTTT  
shRNA 5 Regione: codifing sequen 
Sequence: CCGGGCTGGACTCCAAGATGGCAAGCTCGAGCTTGCCATCTTGGAGTCCAGCTTTTT  
 
Bacteria were first amplified (as described before) and to reach a good quantity of 
ShRNA, plasmidic DNA was purified using MIDI prep protocol (as described 
before). 
3.10.1 Lentiviral supernatant production 
To produce lentiviral surnatant  HEK293T cells were used as packaging cells. 
HEK293T cells originally derived from a continuous human embryonic kidney cell 
line. 293T were seeded the first day at 40% of confluence in complete medium 
(RPMI), when they reached the 70% of confluence were transfected with 3 lentiviral 
vectors (packaging plasmid, envelope plasmid, transfer vector) as follow: 
MIX 1:    
o VSV G-expressing plasmid: 5 ug, 
o pCMVdeltaR8.74: 5 ug  
o Transfer vector: 15 ug 
o Optimem: 1.5 ml 
 
MIX 2:     
o Lipofectamine: 60 ul 
o Optimem 1.5 ml 
 
MIX 2 was incubated for 5 minutes and then was added to MIX 1 for 20 minutes at 
RT and added to 293T. 
After 18 hours, transfection medium was removed and added complete medium, 
for viral harvest. 
Cells were incubated for 24 hours then the viral supernatant recovered and 
harvested and meium was replaced with fresh complete medium and the 
procedure repeated after 24 hours. The viral harvests were then pooled and 
spinned at 4000 rpm 2 minutes to pellet packaging cells that were collected during 
harvesting. The supernatant  was stored to a sterile polypropylene tube, till the 
infection of Colo741.  
Packaging plasmid (pCMV-R8.74): second generation vector, it contains gag, pol 
and rev gene. 
Envelope plasmid: contains VSV-G gene (it’s a vector pseudotyped with the 
vesicular stomatitis virus glycoprotein, to allow entry in a broad spectrum of cell 
types). 
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3.10.2 Infection 
The infection was checked after 48 and72 hours with qRT-PCR and western 
blotting. After infection, cells should be kept in P3 room for at least 2 passages and 
supernatant produced should be checked on independent cells for absence of viral 
activity. 
All the procedures were be carried out in accordance with biosafety requirements 
of the host institution. 
3.11 Immunofluorescence 
Glass slides coated with poly-L-lisine were used as bulk to grow the cells. 
Cells were plated at density of 4x104 in 500 ml of culture medium. The following 
day medium was aspirated and cells were washed with physiologic and fixed with 
PFA 4% in PBS for 15 min at room temperature. The glasses were washed two 
times with PBS BSA 2% and incubated in PBS and BSA 2% for 30 min to block the 
aspecific sites. 
After blocking, cells were permeabilized with triton 0.3% in PBS, and than 
saturated with PBS BSA 2%, Glycin 0.1% and normal goat Serum 5% for 1h at 
room temperature. 
Staining was than performed by treating the cells with the primary antibody (see 
Table IIIa for Antibodies dilutions). 
The following day after 2 washes with PBS, glasses were incubated with the 
secondary antibody Alexa Fluor® 647 or 488 goat anti-mouse or anti-rabbit IgG 
(H+L) 2 mg⁄mL (Invitrogen) (dilution 1:2000) for 1h at room temperature. Nuclei 
were couterstaining with DAPI (Invitrogen). Glasses were than mounted on slides 
using Fluor Save Iinvitrogen. 
All the images were acquired using a confocal microscopy (Olympus) and a CellR 
microscopy (Olympus) 
3.12 Western blotting 
Colorectal cancer cell lines were lysed in chilled lysis buffer supplemented with a 
complete protease inhibitor cocktail (Roche). Whole cell protein extracts were used 
for protein determination using a Coomassie Bradford assay kit (BioRad). Equal 
amounts of proteins (30µg) for each sample were loaded onto 10% polyacrilamide 
gels. Proteins were then separated by SDS gel electrophoresis and transferred 
onto nitrocellulose membrane (BioRad). The membranes were incubated 1 h with 
PBS 5% skimmed milk and then were incubated  with primary antibodies diluted in 
PBS 3% skimmed milk.  
Membranes were then incubated 1 h with anti-mouse or anti-rabbit secondary 
antibody conjugated to horseradish peroxidase (Amersham) diluted with PBS 3% 
skimmed milk. Antibody binding was visualized by enhanced chemiluminescence 
ECL (Amersham) immunoblotting detection system and chemiluminescence was 
detected by autoradiography. 
3.13 Wound Healing assay 
Cells were seeded in multi-well plates and cultured until reach the confluence. 
Using a pipette tip it was made a straight scratch, simulating a wound.  After 18 h, 
32 h and 44 h the wound enclosure was photographed in phase contrast using Cell 
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R Olympus microscope. The enclosure dimension was measured using Cell R 
software and expressed as percentage of enclosure. The experiment was done in 
triplicate, and for each wound 3 images were captured.     
3.14 Invasion assay 
To assess the invasive properties of cells in vitro BioCoat GFR Matrigel Invasion 
Chambers were used. The BioCoat GFR Matrigel Invasion Chamber consists of 
Falcon Cell Culture Inserts with 8 micron pore size PET membrane. Each 
membrane has a thin layer of GFR Matrigel Basement Membrane Matrix that 
serves to reconstitute the basement membrane in vitro. The layer occludes the 
pores of the membrane, blocking non-invasive cells from migrating through the 
membrane. However, cells that migrate are able to detach from the insert and 
invade through the GFR Matrigel matrix and the 8 micron membrane pores.  
To rehydrate the membrane 0.5 ml of warm (37°C) cul ture medium were added to 
the interior of the inserts. 
After rehydration were prepared cell suspensions in culture medium containing 
0.1% FBS at 5 x 104 cells/ml and 0.5 ml were added to the inside of the inserts 
while in the lower chamber were added 0.5 ml of culture medium containing 10% 
FBS. 
All incubated for 24 h in a humidified tissue culture incubator at 37°C, 5% CO 2 
atmosphere. 
After incubation, the non-invading cells were removed from the upper surface of 
the membrane by "scrubbing" with cotton tipped swab. The cells on the lower 
surface of the membrane were stained with Diff-Quick stain. The Diff-Quick kit 
contains a fixative and two stain solutions. The cell nucleus stained purple and the 
cytoplasm stained pink. Cells were counted by photographing the central fields 
(triplicate) of the membrane.  Data were expressed as mean of the number of cells 
that invaded the GFR Matrigel™ Matrix. 
3.15 Patient and Samples 
3.15.1 Study population and retrieval of clinico-pathological data 
The study included 201 unselected Caucasian patients undergwent to resective 
surgery for colorectal cancer at our Institution between 1997 and 2006. Patients 
were excluded from the study if (a) pathologic examination did not confirm a 
tumour invading at least the sub-mucosa (pT1 or higher); (b) the tumour was a local 
recurrence of previously resected colorectal cancer. The study was approved by 
the Ethical Committee of the Istituto Clinico Humanitas, and the informed consent 
of the patient to the treatment of their personal data was obtained by the referring 
physician or by other clinicians involved in the study.  
A clinical database was prepared by investigators blind to the results of cancer 
genetic testing. Pathologic tissue specimens were reviewed by a single pathologist 
who was also unaware of molecular data. Tumour pathologic staging, 
histopathological typing, tumour grade, and presence or absence of extramural 
vein invasion were assessed. Tumour clinico-pathologic staging was finally 
assessed by combining histopathologic findings, surgical records (including 
intraoperative liver ultrasonography), and perioperative imaging (abdominal 
computerized tomography and chest X-rays in all patients). Demographics and 
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complete clinical data at diagnosis were made available at hospital Intranet 
resources. 
3.15.2 Assesment of MSI 
Coded sections of paraffin-embedded colorectal cancer tissue were sent from the 
pathologist to the Research Laboratory. MSI assignment was based on the 
analysis of repeats in mononucleotides. Using dinucleotide markers BAT25-BAT26. 
After DNA extraction by proteinase-K digestion and phenol-chloroform purification, 
amplification of the BAT25 and BAT26 loci with fluoresceinated primers (see Table 
IIIb for primer sequences) was followed by capillary-gel electrophoresis (ABI 
PRISM 310 DNA Sequencer, Perkin-Elmer). 
3.16 Immunohistochemistry 
201 CRC specimens of 2 µm thick sections were cut and processed for 
immunohistochemistry for Twist1. After deparaffining and rehydration, the sections 
were immersed in an antigen retrieval bath, incubated with 3% H2O2 for 15 min to 
quench endogenous peroxidase activity, and then treated for two h at room 
temperature with primary antibodies raised against TWIST1 or with mouse IgG 
(Dako, Milan, Italy) as a negative control, followed by 30 min’ incubation with the 
DAKO Envision system (Dako). 3,3-diaminobenzidine tetrahydrochloride (Dako) 
was used as a chromogen to yield brown reaction products. The nuclei were lightly 
counterstained with hematoxylin solution (DAKO). Twist1 staining extent was rated 
according to the percentage of positive cells. Samples with no stained cells were 
rated as 0, those with <10% stained cells were rated as 1, those with 10-50% of 
stained cells were rated as 2, those with > 50% were rated as 3. 
In order to verify whether TWIST1 was co-expressed with epithelial, mesenchymal 
markers and CD antigens (see Table IIIa) 2 µm thick sections were processed for 
double-immunohistochemical assay. After deparaffining and rehydration, the 
sections were incubated with 3% H2O2 for 15 min to quench endogenous 
peroxidase activity and then treated for two h at room temperature with primary 
antibodies raised against TWIST1, followed by 30 min’ incubation with the DAKO 
Envision system (Dako). 3,3-diaminobenzidine tetrahydrochloride (Dako) was used 
as a chromogen to yield brown reaction products. The slides were then incubated 
for 60 min with primary monoclonal/policlonal antibodies (see Table IIIa for 
Antibody used and dilutions), followed by 30 min’ incubation with secondary 
antibody (Envision, Dako, and Mach4 Biocare) with BAJORAN PURPLE (BioCare 
Medical) or AEC (Dako) used as a chromogens to yield a purple or red reaction 
products. The nuclei were lightly counterstained with hematoxylin solution (DAKO). 
3.17 iFish-IHC  
To perform FISH on paraffin embedded tissues, was used the Zymed Hotspot-light 
kit (Invitrogen). 
Paraffin embedded (FFPE) sections of  4-5 µm were stained as previous described 
for Twist1 (see immunohystochemistry paragraph), without perform Hematoxilin 
staining. After wash with BioClear solution, slides were immersed in 100% Ethanol 
solution three times for three min and then air dryed. Slides were placed on slides 
rack and boiled at 98°C for 20 min in Heat pre-trea tment Solution (Reagent 
A,Invitrogen). After the heat pre-treatment slides were placed immediantly in dH2O 
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at RT (15-30°C) and washed three times. Tissues wer e then subjected to 
Enzymatic digestion (Reagent B, Invitrogent) for 14 min at 37°C. After digestion 
slides were washed three times in  dH2O for 2 min and dehydratated in graded 
ethanol series: 70% EtOH 2 min, 85% EtOH 2 min., 95 % EtOH 2 min., 100% 
EtOH 2 min., 100% EtOH 2 min. After Air-drying 6 µl of CEP7 spectrum green 
probe (Vysis) was added to the center of the tissue section, than the Coverslip was 
placed and sealed using rubber cement. Probe denaturation for 5 min at 85°C and 
incubation for 20 h at 37°C was performed using Hib ridizer (Dako). The following 
day were prepared two Coplin jars containing SSC buffer and 0.07% of NP-40 
where the slides were placed and washed for 5 min at 73°C two times (stringent 
was). After stringent wash slides were placed in dH2O and than 100% Ethanol. 
After air-drying , slides were mounted using 5 ml of DAPI (Vectastain) and 
preserved at -20°C. FISH stainig were observed at F ish station microscope 
(Olympus). Images were acquired using Cytovision software (Olympus). 
3.18 Animal  model 
3.18.1 Retroviral GFP transfection of CT26 
Retroviral transfection of CT26 was performed as mentioned before .. using as 
lentiviral transfection vector pRRL-sin-PPT-hCMV-GFP-WPRE. 
3.18.2 Mice, Transanal injection, necropsy and tissue preparation 
Male Balb/c mouse were purchased from Charles River. The mice were housed 
and maintained in specific pathogen-free conditions. 
The mice were used in accordance with institutional guidelines when they were 8-
12 weeks old. 
Murine colon cancer CT26-GFP was harvested from near-confluent culture by a 
brief exposure to 0.5% trypsin and 0.02% ethylenediaminetetraacetic acid (EDTA) 
(Lonza). 
Cells were concentrated and re-suspended in DMEM containing 10% FBS. 
Five Balb/c mice were anesthetized with 100 mg/Kg Ketamine and 50mg/Kg 
xylazine. The mice the received gentle anal dilatation using blunt-tipped forceps at 
the anal opening. Using a 29-gauge syringe, murine colon cancer CT26-GFP 
transfected were injected sub-mucosal into the distal-posterior rectum at 
concentrations of 1x103 in a volume of 100 µl. 
The mice were killed by CO2 on day 28. After dissection and removal of tumor 
(rectum), mesenteric lymphnodes, liver and kidneys, tissue samples were prepared 
for histological analysis. For Hematoxylin and Eosin staining and 
immunohystochemistry analysis the tissue samples were fixed in formalin and 
embedded in paraffin. 
3.18.3 Immunohistochemistry on mouse tissues  
Immunohystochemistry on mouse tissues was performed as previous described 
(section 3.16). 
When was used a primary antibody of Mouse origin to prevent a-specific signals, 
the primary antibody was prior biotinylate by using Mouse on Mouse Biotinylation 
System (BioCare Medicals). 
5 to 10 µl of antibody is mixed with a biotinylation reagent for 30 min. 
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The biotinylated primary antibody complex can be immediately applied to the tissue 
specimen. The tissue is then incubated with streptavidin-peroxidase, and the 
reaction is developed by a diaminobenzidine/hydrogen peroxide chromogen-
substrate (DAB).  
 
 
Table IIIa: List of Antibodies used for Immunohistochemistry (IHC-P), 
Immunofluorescence (IF) and Western Blotting (WB) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Antibody Species Application Dilution Producer
IHC-P 1:30
IF 1:30
WB 1:100
IHC-P 1:100
IF 1:100
WB 1:500
IF 1:400
WB 1:1000
IHC-P 1:100
IF 1:100
WB 1:1000
CD54 mouse IHC-P 1:100 DAKO
α-SMA mouse IHC-P 1:100 DAKO
CD45RO mouse IHC-P 1:100 DAKO
CD138 mouse IHC-P 1:100 DAKO
CD68 mouse IHC-P 1:100 DAKO
CD20 mouse IHC-P 1:200 DAKO
FSP-1 rabbit IHC-P 1:50 DAKO
ACTIN mouse WB 1:10000 ABCAM
CD133 mouse IF 1:1 Miylteni
GFP rabbit IHC-P 1:200 INVITROGEN
mouseTWIST1 ABCAM
mouse DAKOE-CADHERIN
ABCAMrabbitN-CADHERIN
VIMENTIN mouse DAKO
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Table IIIb: Primer sequences used for quantitative Real-Time PCR (qRT-PCR) and 
for fragment analysis and sequencing (sequencing)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene Species Assay Sequence
Forward CGC CGC TAG AGG TGA AAT TCT
Reverse CTT TCG CTC TGG TCC GTC TT
Forward  AGC AAG ATT CAG ACC CTC AAG CT
Reverse  CCT GGT AGA GGA AGT CGA TGT ACC T
Forward GCT ACA CGT TTT GCC TAC CGC
Reverse CGA TTA CCT GCT CCT TTG GGT T
Forward CTT CCA GCA GCC CTA CGA C
Reverse CGG TGG GGT TGA GGA TCT
Forward TGT TTG CAA GAT CTG CGG C
Reverse TGC AGT CAG GGC AAG AAA AA
Forward GAA AGT CAT CCA GCC AAA TGG
Reverse ACT TGG TTC TCA GCT TGG GGA ATC A
Forward GGA ACT ATG AAA AGT GGG CTT G
Reverse AAA TTG CCA GGC TCA ATG AC
Forward GGT GGA GGA GAA GAA GAC CAG
Reverse GGC ATC AGG CTC CAC AGT
Forward TGG TCC TAC CCA CGC AGA TT
Reverse GGC CAA CCC AGA AGT TGG AA
Forward TAC CTC CAC CAT GCC AAG TG
Reverse ATG ATT CTG CCC TCC TCC TTC
Forward TTA AGG GGT TAC CTG GGT TGC CAA GC 
Reverse ACT TGG TTC TCA GCT TGG GGC ATC A
Forward ACA AGC CAG AAA CTG TAA TCT TAGG  
Reverse AGG CAT CAG AAT AAT AAA CAG CAG
Forward TCA CAC TCT GCA TTC TGA TAG AAG
Reverse CAC GAC CTC TTG AGA ATG CATG
Forward GAG GCG CCC CGC TCT TCT CC  
Reverse AAT CGA GGT GGA CTG GGA ACC G
Forward AGG ACT GCC CAT CCA CTG AGA CAC  
Reverse GGA GCT TGG GGT CAT GGC AAA CT
Forward TCG CCT CCA AGA ATG TAA GTG  
Reverse TCT GCA TTT TAA CTA TGG CTC
Forward TGA CTA CTT TTG ACT TCA GCC  
Reverse AAC CAT TCA ACA TTT TTA ACC C
Forward CGC CGC TAG AGG TGA AAT TCT
Reverse CTT TCG CTC TGG TCC GTC TT
Forward  AGC GGG TCA TGG CAT GGC TAA CG
Reverse  CAG CGT GGG GAT GAT CTT G
Forward AGA GTG TTG TGG AGC ACA G
Reverse TGC ATC ATA ATC TTC CTT CAT
Forward CTT CCA GCA GCC CTA CGA C
Reverse CGG TGG GGT TGA GGA TCT
Forward TGT TTG CAA GAT CTG CGG C
Reverse TGC AGT CAG GGC AAG AAA AA
Forward AAA ATG AAA AGG GCG AAT TT
Reverse GTA GAA AAC CTT TGT TTC TTT GTC
Forward GGT GGA GGA GAA GAA GAC CAG
Reverse GGC ATC AGG CTC CAC AGT
Forward AAC CTG GCC GAG GAC ATC
Reverse CTT TCG GCT TCC TCT CTC TCT G
18s
TWIST1
E-cadherin
TGFBRII
qRT-PCR
qRT-PCR
qRT-PCR
qRT-PCRN-cadherin
SIP1/ZEB2 qRT-PCR
Vimentin Human qRT-PCR
ZEB1 qRT-PCR
SNAI1 qRT-PCR
SNAI2/SLUG qRT-PCR
Human
Human
Human
Human
Human
Human
Human
Human
VEGFA Human qRT-PCR
IL-10 Human qRT-PCR
CD133 Human qRT-PCR
18s Mouse qRT-PCR
Twist1 Mouse qRT-PCR
SIP1 Mouse qRT-PCR
SNAI1 Mouse qRT-PCR
SLUG Mouse qRT-PCR
E-cadherin Mouse qRT-PCR
N-cadherin Mouse qRT-PCR
Vimentin Mouse qRT-PCR
TWIST1-20T Human Sequencing
BAT26 Human Sequencing
Human Sequencing
TWIST1 codifing seq Human Sequencing
BAT25 Human Sequencing
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4. RESULTS 
4.1 Identification of Colon Cancer cells in EMT status 
expressing Twist1  
The main feature of neoplastic epithelial cells going through a mesenchymal 
transition is the switch from a round-shape to an elongated fibroblast-like 
morphology. Accordingly, to identify CRC cell-lines in EMT-status we moved from a 
simple morphological observation. Out of 17 human CRC cell lines [9 MSS ones, 
Colo741, HT29, Colo205, SW403, CaCo2, CX-1, SW480, SW620, SW837, and 8 
MSI ones, GP5D, HCT116, SW48, DLD1, LoVo, LS174T, LS180 and LS411], the 
CoLo741 cells, derived from a peritoneal metastasis, qualified for their fibroblast-
like appearance(as shown in Figure 4.1).   
 
 
 
 
 
 
 
 
 
Figure 4.1: A, B. Colo741 CRC cells  showing the typical elongated mesenchymal 
morphology (20x objective and 40x objective, respectively) 
 
In parallel, the molecular phenotype was explored by gene-expression microarray. 
The analysis focused on the expression of Twist1 the EMT master regulator, plus 
the other transcription factors involved in the transition: SNAI1, SIP-1, Zeb1, and 
SLUG. Microarray results indicated that Twist1 expression was a rare phenomenon 
in cultured immortal CRC cells, as only two cell lines (12% of tested ones) 
expressed  significant Twist1 mRNA levels (as shown in Table IVa). Besides the 
MSS/CIN CoLo741 cells with a morphology consistent with the EMT status, the 
other was the MSI cell-line HCT116.  
Specifically, the Colo741 cells were the only ones to simultaneously express 4 out 
of 5 EMT regulators: Twist1, Zeb1, Slug and SIP1, while all the other cell lines, 
expressed no EMT player (LS180), only one (ZEB1, in HT29, DLD1, LS174T, 
SW480 and CX-1, or SNAI1 in LOVO, SW403 and LS411), two (SNAI1 and ZEB1 
in CO115, GP5D, SW48, CaCo2 and SW837, or Twist1 and ZEB1 in HCT116) or 
at most three (SNAI1, SLUG, and ZEB1 in SW620) (see Table IVa). Consistently, 
only Colo741 cells showed the simultaneous absence of E-cadherin coupled with 
the over-expression of N-cadherin (for all the genes up/down expressed by 
CoLo741 see Appendix I-II). 
 
 
A B 
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Table IVa. mRNA expression of EMT-associated transcription 
factors in CRC cell lines (by microarray analysis) 
 
      
 Transcription factors  
CRC Cell-Line ZEB1 SNAI1 SNAI2/SLUG SIP1/ZEB2 Twist1 
 
     LS180* - - - - - 
HT29 + - - - - 
DLD1* + - - - - 
LS174T* + - - - - 
SW480 + - - - - 
CX-1 + - - - - 
LOVO* - + - - - 
SW403 - + - - - 
LS411* - + - - - 
CO115 + + - - - 
GP5D* + + - - - 
SW48* + + - - - 
CaCo2 + + - - - 
SW837 + + - - - 
HCT116* + - - - + 
SW620 + + + - - 
CoLo741 + - + + + 
      
*MSI CRC cell-lines, as opposed to MSS/CIN ones  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 56 
4.2 Genes exclusively up- and down-regulated in CoLo741 cells 
By analysis of the microarray data, a total of 345 genes were found to be differently 
expressed with respect to the other cells. Of these genes, 323 were expressed only 
by Colo741, while 22 were not expressed (see Appendix I-II). 
Analysis with IPA software revealed that these genes mediate several  biological 
functions as summarized below and reported in the detailed table below.  
 
 
 
Diseases and Disorders             p-value    # Molecules 
Genetic Disorder      3,34E-18 - 6,95E-03    198 
Cardiovascular Disease     3,10E-16 - 7,91E-03    102 
Neurological Disease      9,15E-16 - 7,81E-03    137 
Skeletal/Muscular Disorders      1,69E-13 - 7,81E-03    112 
Immunological Disease     7,31E-11 - 7,81E-03      91 
 
Molecular and Cellular Functions       p-value    # Molecules 
Cellular Development      2,79E-11 - 7,95E-03      99 
Cellular Movement      1,58E-10 - 7,81E-03      69 
Cellular Growth/Proliferation     2,64E-09 - 7,63E-03      95 
Cell Death       2,77E-08 - 7,88E-03      91 
Cell Morphology      8,24E-07 - 7,88E-03      59 
 
System Development /Function         p-value                # Molecules 
Tissue Development      4,89E-11 - 7,95E-03      75 
Nervous Development    1,59E-05 - 7,81E-03      66 
Hematological Development     4,73E-05 - 6,41E-03      42 
Cardiovascular Development     5,91E-05 - 7,53E-03      34 
Organismal Development     5,91E-05 - 6,17E-03      37  
 
Canonical Pathway              p-value    Ratio 
IL-8 Signaling       2,8E-05    12/186 (0,065) 
Hepatic Fibrosis      3,51E-04      9/135 (0,067) 
Huntington's Disease Signaling    1,01E-03    11/239 (0,046) 
Thrombin Signaling      1,48E-03    10/205 (0,049) 
CRC Metastasis Signaling    1,82E-03    11/249 (0,044) 
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Figure 4.2 Schematic representation by IPA software of CRC mestatasis signalling 
activated in CoLo741 cells. Green balloons indicate genes exclusively down-
regulated while Red balloons indicate gene exclusively up-regulated. 
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4.3 Spheroid pattern of growth of CRC cell-lines is restricted to 
epithelial cells, independently from the presence of CD133+ 
(stem) cells 
In line with their phenotype and adhesive molecular pattern, epithelial cell-lines are 
able to grow in low adhesive plates to form three dimensional structures mimicking 
the structure of a primary glandular tumor. The spheroid formation allows to 
summarize cell-lines’ adhesiveness and cohesive status, plus eventually their 
stem-cell like features.  
After 15 days of culture all the cell-lines with an epithelial phenotype (HT29, 
HCT116 and SW480) formed tumor spheroids of different dimension, as shown in 
Figure 4.3, while CoLo741 cells remained attached to the plate in a monolayer, the 
same behavior displayed by fibroblasts cultured in these condition.     
With respect to other CRC cell-lines, the lack of the capability to form spheroids 
further supports the unique mesenchymal phenotype of these cells, which lost the 
ability to adhere each other, rather tending to disseminate into the culture plate. 
This feature indicates that a stable EMT status confers to the Colo741 cells the 
capability to detach from other tumor cells, coupled to a pronounced tendency to 
spread.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3  Example of Spheroids derived from HT29 (A, upper-left panel), 
HCT116 (B,upper-right panel) and SW480 cells (C,down-left panel). Mesenchymal 
CoLo741 cells (D) remain attached to the plate. 
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Additionally, in HT29 and SW480 cells forming  spheroids we analyzed (by qRT 
PCR and by immunofluorescence) the expression of the CD133 stem-cell marker, 
thought to be related to the formation of colon-spheres. From qRT PCR analysis 
performed from mRNA extracted from the monolayer cultured cells resulted that 
CD133 gene was expressed only by HT29 (AQ 1,77E-05). As both HT19 CD133+ 
cells and SW480 CD133- cells were able to form spheroids, our results revealed 
that immortalized cells can growth into spheroids independently from CD133 
expression (Figure 4.4). Finally, CD133 immunopositivity in HT29 cells was 
restricted to the spheroid core.  
These results support the notion that within an epithelial cell population sharing a 
clonal origin, CD133 expression is dynamically modulated by factors which act 
differently depending upon cell location. 
 
 
 
 
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4 Three-dimensional re-building with Imaris software of 
immunofluorescence staining for CD133. Examples of spheroids derived from 
HT29 CD133+ cells and SW480 CD133- cells (upper-left and down-left merge 
DAPI and CD133, upper-right and down-right CD133 staining)  
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4.4 Aneuplody of chromosome 7 in CIN CoLo741 cells 
expressing Twist1  
Considering the known MSS/CIN status of Colo741cells, we decide to approach 
their karyotyping by classical cytogenetic analysis. The purpose of these 
experiments was to identify a genetic hallmark of these Twist1 positive cells, to be 
later used for the FISH analysis of stromal Twst1 positive cells in human CRC 
specimens.  
Chromosome count revealed that Colo741 cells comprise heterogeneous 
populations with different chromosomal number anomalies, ranging from 46 to 67 
chromosomes (as shown in Figure 4.5). 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5 Classical Cytogenetic analysis of CoLo741 cells; A,B CoLo741 clone 
with 46 chromosomes of which one is derived from rearrangements of 
chromosome 7. C,D CoLo741 clone with  chromosomal anapleudy, 67 
chromosomes with 4 copies  of chromosome 7 of which 1 normal, 3 inverted and 1 
derivative.    
 
Several chromosomes as shown in Figure 4.5 were affected by translocation and 
different derivatives chromosome were seen. We identified by Q banding a 
different number of chromosome 7, from 2 to 4. 
When thereafter was performed a FISH by staining for Twist1, position 7p21.1, and 
for CEP7 probes an abnormal number of Chr. 7 was confirmed. Additionally, by 
FISH we also identified a derivative chromosome 7 containing only Twist1 but not 
its centromere, and moreover a chromosome 7 with the inversion of a large part of 
 Clone with 46 Chr. Clone with 67 Chr. 
A 
B 
C 
D 
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the p arm containing Twist1 (as shown in Figure 4.6). Of great interest, 
chromosome 7 derivative and inversion were common to all the nuclei studied, 
independently from their chromosomal content, confirming the same clonal 
derivation of the different cell populations.   
The fact that the more hyperploid population can derive from the almost-diploid one 
is reinforced, besides the shared anomalies of the chromosome 7, by the fact the 
second showed a heterozygous BRAF mutation, while we detected a hemyzygous 
mutation in the hyperploid cells (data not shown).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6  In Situ Hybridization for CEP7 (green) and Twist1 (red) of CoLo741 
chromosomes (left panel). Magnification and details of Chromosome 7 anomalies: 
a normal copy, an inversion of the p-arm containing Twist1 and a derivative of 
Chromosome 7 which lost the centromere and contained Twist1 signals (right 
panel). 
4.5 CIN CRC cells (CoLo741) but not MSI CRC cells (HCT116) 
express Twist1 protein and show a full mesenchymal phenotype 
Once identified a cell-line with morphology and an expression pattern 
demonstrating its stabilized transition in a mesenchymal state, we focused on 
Twist1 as the master regulator of the epithelial to mesenchymal transition. As 
previously described Microarray analysis identified two cell lines expressing Twist1: 
CoLo741 and HCT116. 
The two cell lines differ for the type of genetic instability: Colo741 are colon cancer 
cells with chromosomal instability (CIN/MSS), while HCT116 are CRC cells with 
microsatellite instability (MSI). 
Twist1 expression microarray data were confirmed by qRT-PCR, western blot and 
immunofluorescence. As well as Twist1, a panel of other genes implicated in the 
transition (N-cadherin, Vimentin and E-cadherin) was studied to evaluate the 
activation of EMT according to the morphology.    
Interestingly, despite the presence of Twist1 transcript in HCT116, although less 
than in the Colo741 cells, they  did not express any other marker of EMT (Vimentin, 
N-cadherin, as shown in Figure 4.7), retaining E-cadherin expression and 
maintaining a visible epithelioid morphology. In contrast CoLo741, the MSS 
counterpart, manifested all the features of the transition: a spindle-like morphology 
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and the mRNA expression of the mesenchymal markers proper to the EMT, such 
as N-cadherin, Vimentin (as shown in Figure 4.7), Fibronectin (see Appendix I), 
and three of the other transcription factor related to the phenomenon: SIP1, Slug 
and Zeb1 and contemporary absence of the epithelial marker E-cadherin.   
To better understand the discrepancy between Twist1 mRNA expression and the 
absence of other EMT hallmarks in HCT116, we decided to investigate its protein 
status compared to Colo741 and to HT29 cell line as epithelial control.  
Despite Twist1 mRNA expression in HCT116 the protein was undetectable (as 
shown in Figures 4.7-4.8). As to the expression of the epithelial marker E-cadherin 
(), we found that there was an overlapping pattern of both epithelial and 
mesenchymal protein markers, between the epithelial cells HT29 and the Twist1-
expressing HCT116 cells. The absence of expression of N-cadherin and Vimentin 
and the expression of E-cadherin were common to the two cell-lines (as shown in 
Figure 4.7-4.8) while an opposite situation was seen in CoLo741, where according 
to the literature the presence of Twist1 protein come together with the repression of 
E-cadherin and an enhanced activation of N-cadherin and Vimentin.  
These results sustained the possibility that Twist1 impaired expression in HCT116 
is mainly due to its MSI type of genetic instabilty.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7 mRNA expression as Absolute Quantification (AQ, 2-dCT method) and 
protein expression of mesenchymal markers: Twist1, N-Cadherin and Vimentin, 
and Epithelial marker E-cadherin in HT29, HCT116 and CoLo741 CRC cells,, by 
qRT-PCR and Western Blot. 
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Figure 4.8 Different protein expression of mesenchymal and epithelial markers  in 
HT29, HCT116 and CoLo74 cells, by immunofluorescence (40x objective) 
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4.6 DNA methylation affects Twist1 mRNA but does not account 
for the lack of protein in MSI CRC cells 
A plausible explanation of the lack of Twist1 protein in  HCT116 might be related to 
the epigenetic phenomen of methylation. For this reason, we performed an 
analysis of Twist1 expression in HCT116 and Colo741 after treatment with the de-
methylator agent 2'-deoxy-5-azacytidine (DAC). 
In HCT 116 treated with 4µM of DAC for 78 h, a 3-fold increase of Twist1 transcript 
was detected as compared to the untreated cells (Figure 4.9). Differently, the 
levels of Twist1 mRNA in Colo741 were no different before and after treatment.  
Following DNA de-methylation in HCT116, coupled with Twist1 mRNA increase, 
we also observed the appearance of the Twist1 protein expression, as shown in 
Figure 4.9. Noticeably, while the amount of Twist1 transcript in de-methylated 
HCT116 was identical to that found in Colo741 cells in basal condition (HCT116 
AQ mean±SD 1.06 E-06 ± 7.28 E-08, AQ mean±SD CoLo741 1.65 E-06 ± 7.71 E-
08) the protein levels remained lower by 2-fold than in Colo741 cells (Figure 4.9). 
Moreover, in HCT-116 N-cadherin mRNA and protein was not affected by the 
restoration of a minimal quote of Twist1 protein, and the concomitant stimulation 
with TGF-β for 6h did not further affect Twist1 expression. 
Our results suggest that methylation of Twist1 promoter in HCT116 partially 
determines the low  transcript levels (as compared to Colo741). In meantime when 
similar levels were reached, using DAC, protein level remained low, and N-
cadherin expression absent.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9 A Twist1 mRNA  expression in HCT116 cells after 78h of treatment with 
DAC, TGF-β or DAC+TGF-β; B Twist1 and N-Cadherin protein expression in 
HCT116 cells, pre- and post- DAC/TGF-β treatment compared to CoLo741 cells 
(by Western Blot) 
 
 
 
 
 
 
Twist1 expression in HCT 116
C DAC TGF-β DAC + TGF-β
0
1
2
3
4
A B
 
Twist1 
N-Cadherin 
 
β-Actin 
 65 
4.7 Analysis of Twist1 sequence in CRC cell-lines and tissues 
specimens according to MS- status. 
To explain for the differential expression of Twist1 protein among the MSS and MSI 
CRC cell lines, we looked for the presence of frameshift mutations in  Twist1 
coding sequence (cds).  
Twist1 cds was first entirely sequenced and compared in HCT116 and  CoLo741. 
Although the codifying sequence contained a non perfect tri-nucleotide repeats 
(CGG)11, we did not found any genetic damage in MSI CRC specimens. However, 
exploring the 3’-UTR mRNA, we found a (T)20 tract which was affected by 
shortening in MSI cell line HCT116. Moving from this finding we explored the 
presence of this shorted untranslated-region in other 5 MSI cell lines, of which one 
derived from a primary prostate cancer (DU145), compared to 5 MSS cell lines and 
in 61 mRNA derived  from  thirty MSI CRC and thirty-one MSS CRC tissues. None 
of the transcripts of the 5  MSS cell lines (0/5) showed a shortening of T20 tract, 
while five of the six MSI cell lines, including HCT116, had the (T)20 tract in the 3-
UTR reduced from 5 to 6 bases (5/6; 84%, p= 0.002), and only DU-145 did not 
show 3’-UTR shortening (as shown in Figure 4.10). 
The same behaviour was seen in CRC tissues: 27 of 30 (90%)  MSI CRC 
displayed the reduction of  the 3-UTR region,  but none of the MSS tissues (0/31; p 
p<0.0001) did (examples given in Figure 4.10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10 A. Chromatograms of  cancer cell lines analyzed for the 3'-UTR status 
(COLO320 and HeLa MSS cell lines with wild type 3'-UTR, DU145 MSI cell line 
with wild type 3'-UTR and HCT116, LOVO MSI cell lines with shortned 3'-UTR; B. 
Chromatograms of 4 CRC specimens analyzed for their 3'-UTR status according to 
the MS-status (MSI CRC with a shortened 3'-UTR while MSS CRC with wild-type 
3'-UTR) 
 Cell lines CRC specimens A B 
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4.8 Frameshifts shortening Twist1 3-UTR as cause of mRNA 
instabilty in MSI cancer cells   
The presence of a mutated 3'-UTR tract in mRNA is a well documented 
mechanism inducing instability of the transcript and impaired protein expression.  
To study Twist1 mRNA stability according to the 3-UTR shorted tract, HCT116 and 
CoLo741 cells were treated in a time course experiment from 1h to 3h with Emetin 
and Actinomicin D, the first stabilizing the mutant transcript through the inhibition of 
the non sense mediated decay complex (NMD), implicated in the degradation of 
unstatble mRNA, and the second inhibits RNA transcription by binding DNA. 
As internal control was used TGFBRII, a gene mutated in MSI [17] and degraded 
by NMD complex. 
After 3h of treatment with Actinomicin D and Emetin, we saw an increase of ~35 
fold of TGFBRII mRNA in HCT116, not in CoLo741. By analyzing Twist1 behaviour 
in the same conditions, we found that the transcript increased of ~3 fold in HCT116 
respect to the untreated cells and CoLo741 (as shown in Figure 4.11), indicating 
an instability of Twist1 transcript.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.11 A. mRNA expression of TGFBRII after 3h of treatment with 
Actinomicin D and Emetin in Colo741 CIN/MSS cells and HCT116 MSI TGFBRII 
mutated cells; B. Twist1 mRNA expression in CoLo741 and HCT116 cells  after 1,2 
and 3 h of treatment with Actinomycin-D and Emetin. A significant increase after 3h 
of Twist1 mRNA in HCT116 MSI cell line with shortened 3-UTR region respect to 
CoLo741 cells  is shown.    
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4.9 Twist1 expression allows to complete EMT by enhancing 
migration and invasiveness in CRC cells 
Twist1, as transcription factor, plays a pivotal role in the modulation of the gene set 
which prime EMT. In breast cancer models, Twist1 is directly involved in the 
repression of E-cadherin, and in the transcriptional activation of N-cadherin[6]. 
However, its role in EMT gene activation or silencing in CRC remains unexplored. 
To unravel the functions that Twist1 specifically exerts during invasion and 
migration of cancer cells in the colon, we analyzed the major target genes 
downstream Twist1 in CRC cellular models selected and modified on the basis of 
our microarray-based exploratory analysis of EMT gene expression in CRC cell-
lines. 
In a first model, ZEB1 expressing SW480 cells, the transfection of Twist1 (SW480 
pCMV6.0-Twist1) resulted in its ectopic, constitutive expression at both mRNA and 
protein level (as shown in Figure 4.13). In SW480-pCMV6.0-Twist1 the two 
mesenchymal markers N-cadherin and Vimentin were up-regulated, respectively 3 
and 6 fold, but the mRNA levels of E-cadherin, the epithelial gene selectively 
repressed by Twist1, did not differ with respect to control cells (SW480-pCMV6.0-
empty vector).  
In line with the partial mesenchymal switch documented by the mRNA pattern of 
SW480-Twist1 transfected, the analysis of the migration rate by wound-healing 
assay, showed an increase of the migration capability, as percentage of wound 
closure after 18h, 30h and 42h, of SW480-pCMV6.0-Twist1 compared to the 
SW480-pCMV6.0. At 30h, we recorded the largest difference in migration capability 
(Figure 4.14), when the closure of the wound break accomplished by SW480-
Twist1 transfected cells was 22% ahead of the repair reached by the control. 
Results were similar when an invasion assay was perfomed on a matrigel coated 
chamber: the index of invasion, calculated based on the number of cells that 
invaded the matrigel membrane, was about two fold higher in SW480-Twist1 cells 
than in the control cells (mean±SD of SW480 pCMV6.0 invading cells after 24h, 
33±3.6 versus 58±12.1 of SW480 pCMV6.0-Twist1 invading cells, p<0.03).  
As a second explorative model of Twist1 role in CRC cells, we performed the 
stable knock-down of Twist1 gene in our CRC cell line model of EMT. By silencing 
Twist1 with a short hairpin RNA in Colo741 (Colo741pLK0.1-shRNA-Twist1) we 
observed a change from dispersed cell growth to tightly packed colonies, coupled 
with a cell morphology close to an epithelial one (Figure 4.12).  
 
 
 
 
 
 
 
 
 
 
 
The partial loss of the spindle like shape was associated with the de novo 
expression of the E-cadherin, at the mRNA and protein level, with unmodified 
Figure 4.12 A CoLo741-pLK0.1 
showing a mesenchymal morphology, 
B CoLo741-pLK0.1-shRNA Twist1 
with a more pronunciated epithelial 
morphology and a cobble –stone 
growth. 
A B 
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mRNA levels of N-cadherin (Figure 4.13).  In keeping with the partial reversion 
from a mesenchymal to an epithelial-like phenotype (MET), a 47% decrease of the 
number of cells invading the matrigel membrane was seen in an invasion assay 
(mean±SD of Colo741-pKL0.1 invading cells after 24h was 102.3±24 versus 55±16 
of Colo741-pLK0.1-shRNATwist1 invading cells, p<0.05).  
Results suggest that Twist1 expression by itself is not sufficient per se for the 
switch from the expression of epithelial (E-cadh) to mesenchymal (N-cadh) 
markers (EMT), nor for the reverse process (MET). Differently, Twist1 expression 
confers enhanced motility, coupled with fibroblastoid-like shape and growth 
changes which lead to EMT completation in the background of N-Cadherin 
expression.  
Twist1 alone can induce a partial switch to the mesenchymal phenotype and at the 
same time its knocking down a partial reversion to the epithelial morphology, 
Twist1 expression is a necessary condition to the EMT program and in particular its 
expression orchestrate CRC cells migration and invasiveness.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.13 Panel I First model: ectopic expression of Twist1 in SW480 CRC cells 
induces mRNA up-regulation of N-cadherin and Vimentin (A), not affects E-
cadherin mRNA and protein expression (B) but increases cells invasion (C) (by 
Matrigel invasion assay). 
Panel II Second model: Twist1 knock-down in CoLo741 CRC cells induces the 
expression of E-Cadherin at both mRNA (D) and protein level (E) and 
contemporary inhibits cell invasiveness (F).  
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Figure 4.14 SW480 migration assay: A wound enclosure of SW480-pCMV6.0 after 
30h from the stretch; B wound enclosure of SW480-pCMV6.0-Twist1 after 30h 
from the stretch; C Graph indicating the percentage of wound enclosure of SW480 
and SW480 Twist1 transfected with SD (error bars) measured at 18, 30 and 42 ho. 
Data shown are the result of three independent  experiments (**, P=0.0034; ***, P 
< 0.0001). 
4.10 Effects of microenvironment modulators on Twist1 
expression  
It is known that factors of the tumor microenvironment may induce the perturbation 
of the epithelial state of cancer cells leading to a partial or complete EMT through 
Twist1 up-regulation. The two main micro environmental factors driving the EMT 
are hypoxia [424] and the soluble TGF-β [330]. 
To test whether hypoxia and/or TGF-β can induce de novo Twist1 expression in 
HT29, or up-regulate its expression in HCT116 and/or CoLo741 cell-lines, we 
performed stimulation studies in which the mRNA of the downstream targets of 
HIF-1alfa (VEGF) and TGF-β (IL-10) were also assessed. 
Six hours after the treatment with TGF-β we found that only HT29 and Colo741 
were responsive to the stimulus (IL-10 increase 3.7 and 2 fold respectively, Figure). 
HCT116 were unable to respond as predicted by their MSI status associated with 
the lack of functional TGFBRII due to its frameshifted coding sequence [439].  
Opposite to the un-responsiveness of the other cell lines, only Colo741 cells up-
regulated Twist1 (≈2-fold increase, Figure 4.15). 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.15 Twist1 and IL-10 expression after six 6h of treatment with TGF-β in 
HT29, HCT116 and CoLo741 CRC cells. 
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which consequently increased the expression of VEGF in all of the cell lines (mean 
increase: 5-fold, as shown in Figure 4.16). Even though HIF-1α is a direct 
regulator of Twist1 transcription and all the treated cell lines were sensitive to the 
hypoxic condition, only CoLo741 up-regulated Twist1 mRNA. 
To expand these observations aimed to explore the microenvironmental capability 
to induce and/or sustain EMT in CRC cells, we also performed stimulation with 
other cytokines (namely: IL-6, IL-10, TNF-α and INF-γ) which have not yet directly 
related to the EMT (data not shown). After ten hours of treatment, none of these 
stimuli induced or up-regulated Twist-1 expression in all the cell lines. These 
results indicate that short microenvironment stimuli push EMT through Twist1 
activation only in neoplastic clones which are already in the EMT status. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.16 Twist1 and VEGF expression in HT29, HCT116 and CoLo741 CRC 
cells cultured for  6h in Hypoxic conditions. 
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4.11 TWIST1 mRNA levels are increased in Colorectal Cancer 
and are significantly associated with local invasion, nodal and 
distant metastasis 
To elucidate the involvement of Twist1 in CRC we analyzed the mRNA levels in 78 
CRC specimens compared to their normal colorectal mucosa, using quantitative 
real-time PCR. 18S ribosomal RNA was used as the internal control and the 
analysis of gene expression was performed using the absolute quantification (AQ) 
2-DCt method (normal mucosa AQ and tumour AQ). The AQ expression pattern 
between normal and tumour tissues was found to be significantly different 
(P<0.001, Student’s t-test). The mean value of normal AQ was 3.3 E-07± 8.5 E-07, 
whereas tumour tissues displayed a mean AQ of 2.7E-06±6.9E-06 (Figure 4.17). 
Our results indicates that Twist1 mRNA is up-regulated in CRC tissues compared 
with their normal counterparts. Furthermore, concerning the MS-status of tumoral 
specimens, no differences in Twist1 mRNA levels between MSS (n=65, 83.3%; AQ 
mean: 2.7E-06±7.5E-06) and MSI cancers (n=13, 16.7%; AQ mean: 3.0E-06±3.6E-
06, p=0.5) was found. Considering that the Twist1 transcript is unstable in the MSI 
CRC cell-line HCT116 with impaired EMT, despite the presence of Twist1 mRNA in 
MSI CRC, the analysis of clinico-pathological features was performed only for MSS 
CRC.  
mRNA level of Twist1 was significantly correlated with CRC stage at diagnosis. As 
shown in Figure 4.17, according to TNM staging system, Twist1 expression 
increased with the extension of local invasion (expression in pT3 and pT4 CRC 
versus expression in pT1-pT2 CRC,  p=0.001 and p=0.01, respectively). Moreover, 
Twist1 expression was significantly up-regulated in patients with regional nodal 
invasion (Stage III) and metastasis in distant organs (Stage IV) than in those who 
did not present lymph node or distant organ metastases (AQ mean stage III/IV: 
4±1.4E-6 vs AQ mean stage I/II: 1.1±1.4E-6; p=0.04). These findings suggest that 
Twist1 is involved in the progression of CRC. 
  
 
 
 
 
 
Figure 4.17 A Twist1 mRNA expression in CRC specimens compared to their 
Normal counterpart and according to MS-status; B Twist1 mRNA expression 
according to the Stage at diagnosis. 
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4.12 Immunolocalization and characterization  of Twist 1+ cells 
in CRC tissues 
By using an immunohistochemical approach, the expression of Twist1 was 
evaluated in 201 specimens of surgically resected primary CRC. Only cells with 
nuclear reactivity were considered as Twist1 immunopositive cells. For each CRC 
specimen included in the study, two sections were analyzed. Twist1 was detected 
in 165 of the 201 tumor tissues analysed (82%) but not in normal colonic mucosa. 
Representative stained tissues are shown in Figure 4.18.  
 
 
 
 
 
 
 
 
 
 
 
 
The number of immunopositive cells detected in CRC specimens with Twist1+ 
immunostaining was variable, ranging from few (Score 1), to widely diffuse 
immunopositive Twist1+ cells (Figure 4.19, score 2-3). Nuclear Twist1 expression 
was recognizable in different tumor compartments: in the neoplastic glands and in 
the stromal compartment (Tumor and Stroma pattern), where Twist1+ cells had a 
spindle fibroblast-like morphology (as shown in Figure 4.19). In several cases 
Twist1 was detected only in the stromal, not in tumor, cells (Stromal pattern). In the 
latter cases, immunopositive cells were located close to tumor glands (Figure 
4.19), at the invasive front, in areas where the tumour was losing its glandular 
epithelial structure (Figure 4.19).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.18 Rappresentative staining of 
Twist1 in tumor stroma (upper-left and right, 
10x and 40x objective, respectively),in a 
tumor gland (down-left picture, 100x 
objective) and endhothelial cells (down-right, 
40x objective)  
Figure 4.19 A,B Twist1 positive cells 
(nuclei brown) in CRC glands and in 
the stromal compartment (20x and 40x 
objective, respectively); C,D Twist1 
positive cells with fibroblast-like 
morphology in the stroma, detaching 
from a degenerating gland (20x and 
40x objectives, respectively) 
A B 
C D 
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By double immuhystrochemistry (Twist1 and CD54) we found a high density of 
Twist1 positive cells in proximity of blood vessels (Figure 4.20), even resembling 
intravasation. At the same time, occasionally, endothelial cells were found 
immunopositive (Figure 4.18).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.20 A,B Examples of Twist1 positive cells (Brown) located in proximity of 
blood vessels (Red) (40x objective), (by double immunohistochemestry). 
 
To asses the presence of Twist1+ cells in the metastasis of CRC patients, 
immunohistochemistry was also performed in three metastasis (liver, uterus and 
lymph-node) derived from the same Twist1+  primary CRC. Few Twist1+ cells were 
seen in the liver and in the lymph-node metastasis, while in the uterus metastasis 
Twist1+ cells were abundant in the stromal compartment (Figure 4.21). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.21 A,B Twist1 immunopositive cells in the stromal compartment of a 
uterus CRC metastasis (10x and 40x  objectives, respectively) 
 
To better characterize the phenotype of Twist1 immunopositive cells doubles 
staining were performed. Antibodies against both epithelial (E-cadherin) and 
mesenchymal (Vimentin, α-Smooth Muscle Antigen (α-SMA) antigens were used. 
As shown in Figure 4.21 all the Twist1-immunopositive cells located in the tumor  
gland and those in the stromal compartment, lack the expression of E-cadherin, 
while a number of cells expressed Vimentin or α-SMA. However, in all the sections 
examined, a variable amount of Twist1 immunopositive cells were found 
immunonegative for both epithelial and mesenchymal markers. 
B 
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Moreover, different attempts with antibodies for Cluster of Differentiation (CD), 
proper of sub-population of the immune system were also tried (CD45RO, CD138, 
CD68, CD20), to draw an immunologic profile of Twist1+ cells. As shown in Figure 
X none of the Twist1 immunopositive cells co-expressed these antigens. 
Additionally to exclude the fibroblast origin of Twist1 immunopositive cells a double 
staining with antibodies raised against fibroblast-specific-protein-1 (FSP1) and 
Desmin were performed. All the Twist1 immunopositive cells were immunonegative 
for both. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.21 A,B Double immunohystochemistry for Twist1 and E-cadherin.  
Twist1+ (Brown) cells are located in both tumor glands and stroma and do not 
express epithelial marker E-cadherin (Purple), while Twist1 positive cells (Brown) in 
the stroma are positive for Vimentin (Purple) (C) and Smooth-muscle-antigen 
(Purple) (D). 
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4.13 Twist1 protein expression in CRC specimens and patients’ 
clinical-pathological features 
Resembling Twist1 expression pattern in our series, tissue specimens were 
categorized in three classes, on the basis of the localization of Twist1 
immunopositive cells: a) tissues completely immunonegative for Twist1 (negative 
pattern), b) tissues with immunopositive cells located in both the stroma and in 
tumor glands (stromal and tumor positive pattern), and c) tissues containing 
immunopositive cells located only in the stroma (stromal positive pattern).  
Thirty-six of 201 (18 %) tissues were negative for Twist1 expression. Twist1 
immunoreactivity was mainly observed in the stromal compartment (116/201, 
57.8%, see Table IVb.). In 49 of 201 (24.4%) tissues Twist 1 immunopositive cells 
were recognized in both the stroma and the tumor glands. Considering the MS-
status, stromal-only Twist+ specimens were more frequent in MSS (109/174; 
62.6%) than in MSI (7/27; 25.9%;  p=0.015 by Pearson's test) CRC (Figure 4.22). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table IVb Association of Clinical-pathological features of CRC patients with Twist1 
protein expression (for P-value was used Chi-Square Test or Pearson's Test, when 
appropriated). 
Twist1- Twist1+ T&S Twist1+ S P 
Gender
 M 114 (56.7%) 20 (17.5%) 28 (24.6%) 66 (57.9%)
 F
 87 (43.3%) 16 (18.4%) 21 (24.1%) 50 (57.5%)
Age (mean±STD) 64.8±11.9 65.0±11.9 64.9±11.9 64.9±12 0,98
Microsatellite status
 MSS 174 (86.6%) 29 (16.7%) 36 (20.7%) 109 (62.6%)
 MSI
 27 (13.4%) 7 (25.9%) 13 (48.1%)    7 (25.9%)
Tumor site
 Proximal colon 70 (35,0%) 15 (21,4%) 19 (27,2%) 36 (51,4%)
 Distal colon 89 (44.5%)  12 (12,4%) 22 (24.7%) 56 (62.9%)
 Rectum 41 (20.5%) 10 (24.4%)   8 (19.5%) 23 (56.1%)
Tumor stage
 I 27 (13.4%) 10 (37.0%)  7 (26.0%) 10 (27.0%)
 II 69 (34.3%) 16 (23.2%) 28 (26.1%) 35 (50.7%)
 III 60 (29,9%)
 7 (11.7%) 16 (26.6%) 37 (61.7%)
 IV 45 (22.4%) 3 (6.7%)   8 (17.8%) 34 (75.6%)
Tumor invasion
 pT1
 8 (4.0%)  3 (37.5%)   3 (37.5%)  2 (25.0%)
 pT2
 25 (12.4%)  7 (28.0%)   6 (24.0%) 12 (48.0%)
 pT3
 127 (63.2%) 20 (15.7%) 32 (25.2%) 75 (59,1%)
 pT4
 41 (20.4%)  6 (14.6%)   8 (19.5%) 27 (65.9%)
Tumor grade
 G1
 21 (10.4%)  6 (28.6%)   6 (28.6%) 9 (42.8%)
 G2
 122 (60.7%) 23 (18.9%) 26 (21.3%) 73 (59.8%)
 G3
 58 (28.9%)  7 (12.1%) 17 (29.3%) 34 (58.6%)
Nodal Metastasis
 N0
 99 (49.3%) 27 (27.3%) 25 (25.3%) 47 (47.4%) 0.001
 N+
 102 (50.7%)     9 (  8,8%) 24 (23.5%) 69 (67.7%)
Metacronous Metastasis
 M0
 155 (76.7%) 34 (21.9%) 40 (25.8%) 81 (52.3%)
 M+
 47 (23.3%) 3 (6.4%)   9 (19.1%) 35 (74.5%)
Angioinvasion
 Yes
 151 (75.1%) 30 (21.9%) 40 (25.8%) 81 (52.3%)
 No
 47 (23.4%) 6 (12.8%)   9 (19.1%) 32 (68.1%)
 N.A.
   3 (23.3%) 0 0  3 (100%)
0,21
116 (57.8%)
0.014
0,33
0,98
0,34
0,001
0,008
0,31
All patients 201 (100%) 36 (18%) 49 (24.4%)
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In MSI CRC Twist1 expression was not significant correlated with any clinico-
pathological features.  
 
 
 
 
 
 
 
 
 
 
Expression of Twist1 was also evaluated according to the stage at diagnosis in 
MSS-CRC. Twist1-negative tissues decreased from stage I/II (21/80, 26.2%) to 
stage III (5/51, 9.8%, p=0.07 vs stage I/II) and IV (3/43, 7%; p=0.03 versus stage 
I/II), see Figure 4.23. Conversely, stromal-only TWIST1 immunopositive cancers 
increased from stage I/II (41/80, 51.2%) to III (35/51, 68.6% p=0.07) and IV (33/43, 
76.7%; p=0.007 vs stage I/II). Furthermore, Twist1 stromal expression was 
associated with more locally invasive tumors (pT1/pT2, 13/29, 44.8% vs pT3/pT4, 
96/145, 66.2%, p=0.04, Figure 4.23).  
A correlation between Twist1-expression and lymph-node status was found: the 
rate of stromal positive pattern versus negative pattern significantly increased from 
patients without to those with nodal metastasis (p<0.001, Figure 4.23). Similarly, 
the rate of CRC with stromal positive pattern versus those with a negative one 
increased from patients without distant metastasis to that with secondary lesions 
(p<0.03, Figure 4.23).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.23 Twist1 protein expression in MSS CRC. A, the rate of stromal–
negative Twist1 expression increase from Stage I/II to stage III and significantly to 
stage IV; B the rate of stromal–negative Twist1 expression significantly increase 
with local invasion; C,D Twist1 stromal expression significantly increase with nodal 
and distant metastasis.  
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Figure 4.22 Twist1 
protein expression in 
CRC tissues according 
to MS-status. MSS CRC 
show a significantly 
higher frequency of 
stromal pattern respect 
to MSI ones. 
P=0.015 
P=0.04 
P<0.001 P<0.03 
P=0.007 
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The correlation between patients’ survival was also assed. Survival analysis was 
performed for Disease Specific Survival (DSS) and Disease Free Survival (DFS). 
As shown in Figure 4.24, the  Kaplan-Meier curves displayed that patients with 
MSS TWIST1-negative and MSI CRC had similar DSS and DFS, while the DSS 
and DFS of MSS CRC patients were worse for those with stromal-only TWIST1+ 
than for those with Twist1- cancers (p=0.01 and 0.02, respectively). Moreover, also 
the presence of Twist1 in both tumor and stroma correlated with a poor DSS as 
compared to Twist1-negative CRC (p=0.03 DSS), although the difference as to 
disease recurrence did not reach the statistical significance (DFS, p=0.11).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.24 A Disease Specific Survival (DSS) of CRC patients according to 
Twist1 expression (T&S Tumor and Stroma positivity, S Stromal positivity). Patients 
with T&S and S only positivity have a significant poor survival respect to those 
Twist1- (p=0.02 and p=0.01 respectively); B Disease Free Survival (DFS) of CRC 
patients according to Twist1 expression (T&S Tumor and Stroma positivity, S 
Stromal positivity). Patients with S Twist1+ have a significant lower survival than 
those Twist1- (p=0.03). 
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4.14 Chromosome 7 aneuploidy can be traced in both epithelial 
cancer cells and in stromal, Twist1 positive cells. A pilot study. 
Following immunohistochemistry for Twist1, we moved to perform fluorescent in 
situ ibridization (FISH) in CRC specimens by molecular cytogenetic analysis by 
using a specific DNA probe complementary to the centromer of chromosome 7. 
Of two Twist1 positive, MSS CRC samples analyzed, one (pT3N1) was identified 
as unstable for the chromosome 7.  
FISH revealed that the glandular neoplastic cells had different number of signals 
for chr 7, ranging  from 1 to 4 as shown in Figure 4.25. Of ten fields evaluated 
focusing our attention on stromal Twist1 positive cells, we found that one Twist1 
immunopositive cell in the stromal compartment, far from the neoplastic epithelial 
cells, had chr 7 trisomy, resembling a pattern saw in the neoplastic cells (Figure 
4.25). None of the other stromal cells positive or negative for Twist1 expression 
shared the same chromosomal alteration. 
Besides intrinsic limitations, this is the first experiment ever depicting the same 
cytogenetic clonal alteration in cancer cells and in the surrounding 
microenvironmental cells.  
Twist1 positive cells in the tumor microenvironment are likely a mixture of activated 
mesenchymal cells with a normal kariotype hiding neoplastic cells undergone EMT 
and Twist1 activation.    
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Tumor 
Stroma 
Figure 4.25 A Brighfield 
image showing Twist1+ cells 
(dark grey, Red Box) in the 
stromal compartment; B 
Spectrum Green image 
showing signals for CEP7  
(white points), Green box 
highlights Twist1+ cells in 
the stromal compartment 
with 3 signals for CEP7; C 
Merge image (DAPI (blue) 
and CEP7 (green)). 
Neoplastic cells in the 
glandular structure show 
aneuplody for Chromosome 
7 (from 1 to 4 signals of 
CEP7,green), the same 
Chromosome 7 umbalance 
is shared by the  Nucleus of 
Twist1+ cell in the stromal 
compartment (3 signals for 
CEP7 (red box)).  
A 
B 
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4.15 CT26 mouse cells expressing Twist1: a murine model to 
study in vivo EMT 
 
One of the cardinal points to study EMT in vivo is the identification of a suitable 
murine cell line that has a clear mesenchymal phenotype, consistent with the EMT 
program.  Looking for such a model, we focused on CT26 cell-line, which is 
syngenic top Balb/c mice, has a high metastatic potential and a marked 
fibroblastoid morphology (Figure 4.26). 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.26 Murine CRC CT26 and human CRC CoLo741 cells share the same 
mesenchymal morphology (20x Objective) 
 
The mesenchymal signature of CT26 was documented by qRT-PCR, showing also 
in CT26 cells the expression of the same markers associated with the 
mesenchymal phenotype of the human CRC cell line Colo741, coupled with the 
absence of the master epithelial marker E-cadherin. Both cell lines expressed 
Twist1, SIP-1, N-cadherin and Vimentin. Eventually, the levels of Twist1 and N-
Cadherin mRNA detected in CT26 were higher than those found in Colo741, and at 
the meantime a lower expression of SIP1 and Vimentin was proper to CT26 
(Figure 4.27). By W.B analysis we confirmed the presence of Twist1 and N-
cadherin and Vimentin and contemporary the absence of E-cadherin protein. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.27 A mRNA expression of EMT associated markers in CT26 and 
CoLo741 cells (by qRT-PCR); B Protein expression pattern of mesenchymal and 
epithelial markers in CT26 and CoLo741 cells (by Western Blotting) 
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In vitro, GFP-transfected CT26 cell were morphologically indistinguishable from 
Balb/c mouse embryonic fibroblast (MEF), but by taking advantage of GFP 
expression, we can distinguish the two cell lines (Figure 4.28). 
 
 
Figure 4.28 A Phase Contrast microscopy image of CT26-GFP co-cultured with 
MEF; B GFP image of co-cultured CT26-GFP (green arrow) with MEF (black 
arrow). Both two cells of embryonic different origin share the same mesenchymal 
morphology. 
 
4.16 Tracking local invasion and lymph-node metastasis of GFP-
transfected CT26 cells in an orthotopic murine model of EMT 
colorectal cancer 
 
For our study we maximized the resemblance of the human disease by orthotopic 
rectal inoculation of the mesenchymal CRC murine cell-line CT26, GFP-
transfected, in syngenic Balb/c mice. 
All the five mice injected with CT26-GFP cells developed rectal adenocarcinoma of 
about 0.5 cm of dimension. After 28 days from the trans-anal injection, mice were 
sacrificed and tumors collected, together with liver, kidneys and the mesenteric 
lymph-nodes.  Hematoxylin-eosin histological analysis of the tumor samples 
showed a poorly differentiated adenocarcinoma growing in the sub-mucosa 
(Figure 4.29), invading the muscular layer, and extending to the perivisceral 
adipose tissue. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.29 Rappresentative CT26 
Tumor mass growing in the sub-
mucosa of mouse rectum, stained 
for GFP (by immunohystochemistry)  
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By immuno-histochemical staining for GFP, the local invasive properties of 
mesenchymal cancer cells was magnified (Figure 4.30), revealing the presence of 
GFP+ CT26 cells in the adipose tissue.  
In addition elongated GFP-positive neoplastic cells were identified in the stromal 
compartment (Figure 4.30) recapitulating the same location of Twist1+ cells in 
human malignancies.  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.30 A CT26-GFP cells (Brown) invading the adipose tissue (20x 
objectives); B CT26-GFP with an elongated cytoplasm and nucleus (black arrow) in 
the tumor stromal compartment (40x objective), C CT26 GFP+ (purple) expressing 
Twist1 (Brown) 
 
In accordance with their in vitro features, CT26-GFP cells maintained Twist1 
expression while growing and invading nearby tissues in vivo (Figure 4.30).  
One of the six lymph-nodes collected displayed an altered morphology. By 
immunohistochemistry neoplastic GFP immunopositive cells as shown in Figure 
4.31 were localized within the deranged lymph-node.  At 28th day none of the 
distant organs were affected by neoplastic colonization.  
 
 
 
 
 
 
 
 
Figure 4.31 A, Haematoxilin-eosin staining of a deranged mesenteric lymph-node; 
B CT26-GFP+ cells in the deranged mesenteric lymph-node (black arrow), (by 
immunohistochemistry) 
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5. DISCUSSION and CONCLUSIONS 
Metastatic progression is the main cause of death in CRC cancer patients. 
Metastasis is the final point of a multistep-process in which neoplastic cells become 
able first to invade the surrounding tissues (invasion), second to reach and 
trespass into vessels (intravasation), third to travel in the blood-stream, to come out 
from the endothelium (extravasation), to reach and colonize a secondary organ 
(colonization), and finally to growth therein as a distant metastasis (metastasis).  
The successful ending of each step is necessary to achieve the dissemination of 
tumor cells from the primary site to a distant organ. Today several models imply 
that  neoplastic epithelial cells are able to cross all these events by acquiring a new 
morphology and phenotype through the early developmental mechanism of 
epithelial to mesenchymal transition (EMT)[8,247,248,250,251,253,310]. EMT is a 
mechanistic approach to explain a phenomena derived from murine model, but till 
now only postulated in human carcinogenesis. The term EMT refers to a complex 
molecular and cellular programme by which epithelial cells shed their differentiated 
characteristics, including cell adhesion, planar and apical-basal polarity, and lack of 
motility, to acquire mesenchymal features, including motility, invasiveness and a 
heightened resistance to apoptosis[6,11,318,256].  The EMT inducers are a class 
of pleyotropic transcription factors whose main role is the direct and indirect 
regulation of the E-cadherin expression coupled with the transcriptional activation 
of mesenchymal programs affecting proliferation, motility and survival.[258,265, 
274] 
Most trascriptional inducers of EMT, identified as bona fide; belong to the Snail, 
Zeb and bHLH families (SNAI1, SLUG or SNAI2, TWIST1, ZEB1, ZEB2 or SIP1, 
TCF3, TCF4, Goosecoid,  KLF8 and FOXC2)[6,275,321,325,328,363,380]. It was 
observed that these transcription factors cooperate into the induction of EMT, 
despite their redundant/different roles in distinct cellular models and in tumors 
arising in different organs. Accumulating observations display that some of the 
EMT inducers alone are responsible of the phenotypical switch by up-regulating the 
other markers, as demonstrated for SNAI1 at the onset of transition induced by 
TGF-beta [306,321,382,406]. However, specific and non redundant roles for each 
transcription factor in a hierarchical EMT functional cascade remain to be identified, 
as it remains their association to a potentially stabilized EMT state. Finding of an 
EMT stable cell-line to study the network between the major transcription factor 
regulators of the EMT, is fundamental to our better understanding of the 
background of epithelial to mesenchymal-transition. In fact, the limitations of the full 
comprehension of the EMT process is mainly due to the lack of an in vitro model of 
a natural and stable EMT state . Currently, all the experimental approaches, as 
recapitulated by Moreno-Bueno et Coll. [438], rely on the study of A) cell-culture 
systems of monolayer-3D cultured cells in a transient induced status of EMT or B) 
of cells in a stable state of EMT promoted by the ectopic expression of one of the 
EMT transcription factors. Clearly, both these approaches cannot fully replicate 
what happens in vivo.  
First section: Cellular and functional studies. With our work, to our knowledge, 
we identify and characterize for the first time a mesenchymal CRC cell-line arising 
from an epithelial tumor, CoLo741, which is in a stable state of EMT. Moreover our 
model, as cultured in basal condition, contrast the vision that EMT could be only 
induced by interactions between cancer cells and environmental elements, and 
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support the hypothesis that also EMT arises as a manifestation of genetic or 
epigenetic alterations, other than of a paracrine or autocrine stimuli.  
Human CRC cancer cells CoLo741 cells reflect the theoretical model of EMT by 
switching all the epithelial markers in mesenchymal ones and retaining a spindle-
like morphology, more similar to a fibroblast than to an epithelial tumor cell line. 
Colo741 cells lost the ability to form spheroid structure, as they prefer to detach 
each other, rather adhering to plates, as done by fibroblasts. According to the 
concept of cancer EMT as a transposition of the embryiogenic program of 
differentiation, resulting in the conversion of epithelial cells to mesenchymal 
derivatives during development and adulthood, appears that CoLo741 cells have 
reached the final/stable step of the transdifferentiation as in the organs 
development.  
Comparing Colo741 to other 16 epithelial CRC cells we can approach the 
modelling of the activation of the EMT program according to their  gene-expression 
profile. While EMT is till now considered as activated by the expression of one of 
the previous described transcription factors, here we report that most CRC cell-
lines expressed at least one of these transcription factors, without changing their 
epithelial expression profile and morphology.  
In our cell panel, reaching of the mesenchymal state occurs only by the 
simultaneously expression of at least 4 of the transcriptional regulator (Twist1, 
Zeb1, Sip1 and Slug). Till now the proposed EMT hierarchy supposes that SNAI as 
master regulator and inducer of the other factors. Our results in Colo741  re-
appraise this model, since these cells did not express SNAI1. 
Moreover SNAI1 was one of the genes more frequently expressed among by the 
other epithelial cell-lines. Our systematic assessment of known EMT markers in 
CRC cell-lines, shows that is not merely the qualitative expression of a given gene, 
but rather the sum of a set of transcriptional regulator to determine the revertion to 
a mesenchymal phenotype. Obviously we think that further studies are necessary 
to better explain the inter-relationships of each transcription factor within the EMT 
program, as well as their pleyotropic effects. Additionally, coming back to our 
cellular model we report that the gene expression profile appears to be different 
from the other cells. In fact, several genes directly or indirectly modulated by the 
EMT transcription factors, but absolutely related to this state, were up/down 
expressed only mirroring biological functions strictly related to the embryogenic 
development (i.e. ALX1-RUNX3-FOXD2 expression), to colon cancer metastasis 
(i.e. SPARC, MMP1), and improved resistance to cell-death (i.e. BCL2 and 
BCL2A1 expression).  
Despite our study is not extended to the evaluation of the post-trascriptional 
activation of SNAI1 protein, the absence of the transcript in Colo741, as paradigm 
of EMT, is a proof of evidence of the inefficacy or of the secondary role of SNAI1 
as main inducer of the EMT switch-on, a reason why our studies were focused on 
the transcriptional regulator Twist1, which can act independently of SNAI1 to 
repress E-cadherin [6] and to up-regulate N-cadherin [410] . 
Twist1 was for the first time identified as master regulator of EMT in a murine 
model of Breast cancer [6]. Its role in cancer metastatic progression was later 
demonstrated in several malignancies [410,424,325]. 
Starting from the gene expression profile we confirmed by qRT-PCR its significant 
expression in Colo741 and HCT116. These cell lines represent two models of 
different genetic instability in CRC. Colo741 is a prototypic cells with chromosomal 
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instability (CIN or microsatellite stable, MSS) while HCT116 of microsatellite 
instability (MSI). As stated, a mesenchymal phenotype was restricted to Colo741, 
despite Twist1 mRNA expression was seen in HCT116 too.  Evaluation of Twist1 
protein revealed that its expression is restricted to Colo741.  
The discrepancy between gene expression and the absence of Twist1 and 
associated  mesenchymal markers in  HCT116 is mainly related to the different 
genetic and epigenetic mutational pattern of MSI CRC with respect to their 
MSS/CIN counterpart.  
From the epigenetic point of view we demonstrate that a partial methilation of 
Twist1 affected HCT116. Moreover , MSI CRC due to the lack of mismatch repair 
system accumulate frameshift mutation inside genes with a short repetitive tract, 
resulting in unstable RNA transcripts, targeted for degradation through the 
nonsense mediated decay (NMD) machinery.  
In our study we found a shortened 3’-UTR in Twist1 is associated with an unstable 
transcript, by a mechanism involved in the regulation of translation of mRNA into 
protein  in MSI cancer cells. In line with these data,  instability of Twist1 transcript 
in HCT116  resulted in a lower level (2-fold) of protein even when we reproduced 
the same Twist1 mRNA level of CoLo741 by DNA de-methilation.  
Currently, we propose the impaired Twist1 expression in HCT116 as a paradigm of 
inefficient EMT in MSI cancers.  
Besides our discovery about epigenetic and genetic regulation of Twist1 
expression, several studies reported the activation of Twist1 by microenviromental 
stimuli and hypoxic conditions. Cytokines such as trasforming growth factor beta 
and tumor necrosis factor are considered environmental inducers of EMT.  
With this work we demonstrate that a short stimulation with  Hypoxia and TGF-beta 
increase Twist1 expression only in Colo741, but not in other cell-lines indicating 
that in vitro only clones prone to EMT are able activate the trascriptional machinery 
in response to microenvironment conditions. In other words, only cells with 
mesenchymal features are able to increase the EMT transcriptional pattern. 
Moreover other tested citokynes (such as IL-6, IL-1b, TNF-alfa and IFN-g) are not 
involved in the activation or enhancing of EMT in our CRC models.  
Taking together these results is conceivable that in vivo EMT is a phenomena 
restricted only to some clone which shared a mixture of epigenetic, genetic 
condition with an inclination to respond to external stimuli. In this view, not all the 
cells were able to undergone EMT. 
With respect to the MSI cells HCT116, our data are in agreement with those by 
Pino et al. In fact, besides our original observation concerning Twist1 DNA 
methylation and mRNA instability,  TGFBRII  frameshift mutation leads to  the un-
responsiveness towards its ligand TGFbeta [439].  
One of the central observations of our study is that, once we ectopically activated 
Twist1, its de novo expression in the context of an epithelial cell, such as SW480, 
was able,  to enhance migratory and invasive capability, together with a partial 
switch to the molecular mesenchymal phenotype, as testified by  the up-regulation 
of N-cadherin and Vimentin. At the same time we demonstrated that its ablation in 
mesenchymal cell Colo741 re-established an epithelial morphology, by directly 
affecting the expression of the epithelial cadherin. We also found that Twist1 
ablation induced the up-regulation of Zeb2 gene, likely a compensatory 
mechanism, but despite this increase migratory and invasive capability were at 
least 2-fold reduced as compared to the control. This experimental evidence 
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suggests that Twist1 expression is a signature of the mesenchymal activation, that 
its expression is necessary to maintain, or to successfully induce, the transition, 
and that its role principally affects the migratory and invasive capability of CRC 
cells. Ideally, acquisition of migratory capability should advantage Twist1 
expressing cells in dissociating and disseminating in the surrounding tissues, the 
prerequisite for complete at least the invasion step along the metastatic process. 
In fact when we analyze CRC specimens according to Twist1 protein expression 
we found not only the presence of immune positive cells in the tumor gland but also 
in the stromal compartment. Stromal Twist1 positives, share the expression of 
mesenchymal markers and are mainly located at the margin of degenerate tumor 
glands underlying degradation of basal membrane and indicating cells that can 
migrate away from the epithelial layer in which they originate.    
Second section: Human Tissues studies. Our study is the first that evaluates 
Twist1 expression in CRC, from transcript to protein expression,  according to the 
genetic instability of CRC.  
Genetic instability, may influence the prognosis. The clinical behaviour and 
enhanced survival benefit of MSI tumors is distinctive and not attributable to 
differences in therapeutic response. The molecular basis for the prognostic 
advantage due to the MSI status is not clearly established. Indeed it is proved that 
MSI cancers have a lower rate of metastastic progression compared to the MSS 
counterpart. For this reason appeared of interest to study the EMT, as mechanism 
of metastatic spread, in MSI and MSS CRC, taking advantage of  Twist1 signature 
for the mesenchymal switch.  
The first analysis performed by qRT-PCR in 78 CRC tissues compared to their 
normal mucosa, revealed that Twist1 expression was significantly higher in tumor 
samples and as our in vitro model showed (CoLo741 and HCT116), that Twist1 
was expressed at transcript level by both MSS and MSI CRC specimens.  
Higher mRNA levels of MSS CRC were associated with more local invasive tumors 
and, as previously reported by Valdes-Mora Twist1 mRNA is significantly 
associated with nodal and distant metastasis [15].  
Other associations with clinical and pathological features were also found by 
studying Twist1 protein expression. As previously described in cellular models, 
mRNA was not sufficient to indicate the presence and efficacy of Twist1 protein. 
Considering tumor specimens as complex tissues, composed by many cells of 
different clonal origin, we found expression of Twist1 protein in different 
compartments. Clonality of Twist1 positive cells in the stroma does not reflect an 
epithelial origin as they express exclusively mesenchymal markers (Vimentin and 
α-SMA), but not FSP-1 marker and Desmin. Thus they are un-likely to represent a 
phenotypic product of fibroblasts, as expected to originate by the EMT that occur 
during the development of fibrosis in chronic inflammation (i.e., these cells are not 
expression of a so-called type 2-EMT). 
Twist1 immunoreactivty in stroma may reflect an activated compartment. 
Therefore, Twist1 positive cells either contribute to create a better microenviroment 
for the progression of colon cancer, either reflect the presence of neoplastic cells 
invading nearby tissues. These possibilities are not mutually exclusive and 
probably represent different stages of CRC evolution. In fact Twist1 stromal 
expression in MSS CRC was associated with local invasion, nodal and distant 
metastasis. Accordingly, even the rate of Twist1 positive cases in the stromal 
compartment was significantly higher in MSS than in MSI cancers. This lower rate 
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of stromal expression goes hand in hand with a better survival, and a similar 
survival of MSS patients which were negative for Twist1 protein and of those with 
MS CRC was detected. Due to the roles that Twist1 plays in CRC cells as to our 
findings, the association of its expression with a poor disease specific survival and 
disease free survival in MSS CRC fits with the current EMT model. In line with the 
model, Twist1 low expression rate in MSI CRC, due to different concomitant 
genetic and epigenetic alterations, would help to explain the low metastatic 
potential of these subset of cancers. 
It remains to be clarified whether Twist1 positive cells in the stroma compartment 
are tumor cells. This central point till now remains largely postulated, for this like for 
the other EMT main players (e.g, SNA1, ZEB1). None of the studies regarding 
EMT in human malignancies described or identify the clonal origin of stromal cells 
expressing EMT markers. Snai1 protein at tumor-stroma interface was associated 
with activated mesenchymal cells promoting the conversion of carcinoma cells to 
stromal cells [13]. The same was postulated for Twist1 stromal expression without 
give any experimental evidence [14].  
The lack of a suitable methodology to track the EMT neoplastic cells in the tumor 
tissues or in blood samples is currently the main and strongest criticism concerning 
the true existence of cancer EMT in humans. 
Coupled to our previous results, the cornerstone of our findings is that by the 
combination of immunohistochemistry and molecular cytogenetic (iFISH for CEP7) 
we can track stromal Twist1 immunopositive cells as of neoplastic origin. Twist1 
positive cells could be hide by the acquired morphology more similar to a fibroblast 
than an epithelial CRC cells. We have a snap-shot of the EMT status in a precise 
spatial and temporary context. 
Here we demonstrate with a preliminary study that at least one of the stromal cells 
expressing Twist1 shared the same chromosomal instabilty, unbalance of 
chromosome 7, of the tumor gland cells and also of our mesenchymal CRC model 
CoLo741. Chromosome 7 gain is a well documented phenomena associated with 
liver metastasis formation [72]. 
It remains to be more precisely established the role of these cells, according to 
EMT model as it has been proposed so far. To the best of our experimental 
evidences, we can suppose that epithelial cancer cells expressing Twist1 play a 
crucial role in the local tumor invasion. In fact, the enhanced migratory capability 
conferred by Twist1 expression could help these cells to complete invasion as first 
step of the metastatic process.  At the same time the chance of finding these cells 
in the stroma is likely correlated to the number of Twist1 positive cells in this 
compartment. As a general notion, the larger the number of Twist1 stromal cells, 
the higher the probability to identify neoplastic cells undergone to EMT and prone 
to metastasize. This reasoning would be in agreement with our associative 
evidence demonstrating the association between stromal Twist1 immunopositivity 
and poor survival in MSS CRC.  
Third Section: Animal model. In parallel our EMT murine model recapitulates the 
same behaviour. Once identified a mouse cell lines sharing the same EMT 
transcriptional background of mesenchymal CoLo741, this mesenchymal EMT cell 
once transplanted into BalB/c mouse invaded the surrounding tissues and the 
stroma compartment showing an elongated fibroblast-like morphology. As in 
human malignancies this EMT model of neoplastic cells gave nodal infiltration and 
(in the literature) liver metastasis[440]. 
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In summary, we demonstrate through Twist1 mesenchymal signature the 
presence of EMT neoplastic cells in the stroma of CRC tumors and we give a 
method to identify cells undergoing to EMT able to invade surrounding tissues. 
Altogether our results readdress the study of the stromal compartment from that of 
a mere recipient of non-neoplastic cells to an incubator of cancer EMT cells able to 
disrupt the surrounding tissues mimicking activated fibroblast. This finding is the 
experimental demonstration of postulated phenomena regarding the presence of 
EMT cells in human malignancies. 
Accordingly, Twist1 stromal expression in CRC as a signature of activated 
neoplastic EMT program correlates with cancer progression and poor patients’ 
survival. These findings re-address the study of tumor specimens from a classic 
epithelial view point to a mesenchymal and stromal one. From a clinical 
perspective, targeting Twist1 neoplastic cells in the stroma might give the chance 
to reduce or inhibit the metastatic process in human CRC, and to do that as first 
approach we provide a suitable murine EMT model to test the pharmacological 
interferences with this mechanism. 
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Appendix I Gene exclusively expressed by CoLo741 (by Microarray analysis) 
Symbol Entrez Gene Name Location Type(s) 
    
 ABCA5  ATP-binding cassette, sub-family A (ABC1), member 5  Plasma Membrane  transporter 
 ABCB5  ATP-binding cassette, sub-family B (MDR/TAP), member 5  Unknown  other 
 ABL2  v-abl Abelson murine leukemia viral oncogene homolog 2 (arg, Abelson-related gene)  Cytoplasm  kinase 
 ACP5  acid phosphatase 5, tartrate resistant  Cytoplasm  phosphatase 
 ADAMTS1  ADAM metallopeptidase with thrombospondin type 1 motif, 1  Extracellular Space  peptidase 
 ADCY1  adenylate cyclase 1 (brain)  Plasma Membrane  enzyme 
 AKAP12  A kinase (PRKA) anchor protein 12  Cytoplasm  transporter 
 AKT3  v-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma)  Cytoplasm  kinase 
 ALS2CR4  amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 4  Unknown  other 
 ALX1  ALX homeobox 1  Nucleus  transcription regulator 
 AMOTL1  angiomotin like 1  Plasma Membrane  other 
 AMPH  amphiphysin  Plasma Membrane  other 
 ANGPT1  angiopoietin 1  Extracellular Space  growth factor 
 ANTXR1  anthrax toxin receptor 1  Plasma Membrane  other 
 ARHGAP15  Rho GTPase activating protein 15  Unknown  other 
 ARHGEF9  Cdc42 guanine nucleotide exchange factor (GEF) 9  Cytoplasm  other 
 ASB4  ankyrin repeat and SOCS box-containing 4  Nucleus  transcription regulator 
 ATP6V0A4  ATPase, H+ transporting, lysosomal V0 subunit a4  Cytoplasm  transporter 
 ATP8B2   ATPase, class I, type 8B, member 2  Plasma Membrane  transporter 
 BBS5  Bardet-Biedl syndrome 5  Cytoplasm  other 
 BCHE  butyrylcholinesterase  Plasma Membrane  enzyme 
 BCL2  B-cell CLL/lymphoma 2  Cytoplasm  other 
 BCL2A1  BCL2-related protein A1  Cytoplasm  other 
 BEX4  brain expressed, X-linked 4  Cytoplasm  other 
 BICD1  bicaudal D homolog 1 (Drosophila)  Cytoplasm  other 
 BNC2  basonuclin 2  Nucleus  other 
 C10ORF90  chromosome 10 open reading frame 90  Unknown  other 
 C13ORF1  chromosome 13 open reading frame 1  Unknown  other 
 C14ORF132  chromosome 14 open reading frame 132  Unknown  other 
 C1S  complement component 1, s subcomponent  Extracellular Space  peptidase 
 C6ORF142  chromosome 6 open reading frame 142  Unknown  other 
 C7ORF38  chromosome 7 open reading frame 38  Unknown  other 
 C9ORF93  chromosome 9 open reading frame 93  Unknown  other 
 CA8  carbonic anhydrase VIII  Cytoplasm  enzyme 
 CADM1  cell adhesion molecule 1  Plasma Membrane  other 
 CAPN3  calpain 3, (p94)  Cytoplasm  peptidase 
 CARD16  caspase recruitment domain family, member 16  Unknown  other 
 CASP1  caspase 1, apoptosis-related cysteine peptidase (interleukin 1, beta, convertase)  Cytoplasm  peptidase 
 CCDC132  coiled-coil domain containing 132  Unknown  other 
 CCDC50  coiled-coil domain containing 50  Unknown  other 
 CCDC52  coiled-coil domain containing 52  Unknown  other 
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 CCPG1  cell cycle progression 1  Unknown  other 
 CD276  CD276 molecule  Plasma Membrane  other 
 CDH2  cadherin 2, type 1, N-cadherin (neuronal)  Plasma Membrane  other 
 CDK5R1  cyclin-dependent kinase 5, regulatory subunit 1 (p35)  Nucleus  kinase 
 CHFR  checkpoint with forkhead and ring finger domains  Nucleus  enzyme 
 CHST10  carbohydrate sulfotransferase 10  Cytoplasm  enzyme 
 CNPY3  canopy 3 homolog (zebrafish)  Unknown  other 
 CNTN3  contactin 3 (plasmacytoma associated)  Plasma Membrane  other 
 COL4A1  collagen, type IV, alpha 1  Extracellular Space  other 
 COL5A2  collagen, type V, alpha 2  Extracellular Space  other 
 CPB2  carboxypeptidase B2 (plasma)  Extracellular Space  peptidase 
 CPEB1  cytoplasmic polyadenylation element binding protein 1  Cytoplasm  other 
 CRISPLD1  cysteine-rich secretory protein LCCL domain containing 1  Unknown  other 
 CSGALNACT1  chondroitin sulfate N-acetylgalactosaminyltransferase 1  Cytoplasm  enzyme 
 CTNNB1  catenin (cadherin-associated protein), beta 1, 88kDa  Nucleus  transcription regulator 
 CTSF  cathepsin F  Cytoplasm  peptidase 
 CTSK  cathepsin K  Cytoplasm  peptidase 
 CYBRD1  cytochrome b reductase 1  Cytoplasm  enzyme 
 D4S234E  DNA segment on chromosome 4 (unique) 234 expressed sequence  Cytoplasm  other 
 DAB2  disabled homolog 2, mitogen-responsive phosphoprotein (Drosophila)  Plasma Membrane  other 
 DCLK1  doublecortin-like kinase 1  Cytoplasm  kinase 
 DDR2  discoidin domain receptor tyrosine kinase 2  Plasma Membrane  kinase 
 DGKI  diacylglycerol kinase, iota  Cytoplasm  kinase 
 DNAJB9  DnaJ (Hsp40) homolog, subfamily B, member 9  Nucleus  other 
 DNER  delta/notch-like EGF repeat containing  Plasma Membrane  transmembrane receptor 
 DOK5  docking protein 5  Plasma Membrane  other 
 DPYD  dihydropyrimidine dehydrogenase  Cytoplasm  enzyme 
 DPYSL4  dihydropyrimidinase-like 4  Cytoplasm  enzyme 
 DSCR8  Down syndrome critical region gene 8  Unknown  other 
 DUSP10  dual specificity phosphatase 10  Nucleus  phosphatase 
 DYNC2H1  dynein, cytoplasmic 2, heavy chain 1  Cytoplasm  other 
 EDNRB  endothelin receptor type B  Plasma Membrane  G-protein coupled receptor 
 ELOVL2  elongation of very long chain fatty acids (FEN1/Elo2, SUR4/Elo3, yeast)-like 2  Cytoplasm  enzyme 
 EMP1  epithelial membrane protein 1  Plasma Membrane  other 
 ENG  endoglin  Plasma Membrane  other 
 ENTHD1  ENTH domain containing 1  Unknown  other 
 EPB41L3  erythrocyte membrane protein band 4.1-like 3  Plasma Membrane  other 
 EPHA4  EPH receptor A4  Plasma Membrane  kinase 
 EPM2A  epilepsy, progressive myoclonus type 2A, Lafora disease (laforin)  Cytoplasm  phosphatase 
 EVI2A  ecotropic viral integration site 2A  Plasma Membrane  transmembrane receptor 
 F2R  coagulation factor II (thrombin) receptor  Plasma Membrane  G-protein coupled receptor 
 FAH  fumarylacetoacetate hydrolase (fumarylacetoacetase)  Cytoplasm  enzyme 
 FAM101B  family with sequence similarity 101, member B  Unknown  other 
 FAM120C  family with sequence similarity 120C  Unknown  other 
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 FAM126A  family with sequence similarity 126, member A  Cytoplasm  other 
 FAM70A  family with sequence similarity 70, member A  Unknown  other 
 FAP  fibroblast activation protein, alpha  Cytoplasm  peptidase 
 FBLN5  fibulin 5  Extracellular Space  other 
 FBXO32  F-box protein 32  Cytoplasm  enzyme 
 FCRLA  Fc receptor-like A  Plasma Membrane  other 
 FERMT3  fermitin family homolog 3 (Drosophila)  Cytoplasm  enzyme 
 FGD4  FYVE, RhoGEF and PH domain containing 4  Cytoplasm  other 
 FHL1  four and a half LIM domains 1  Cytoplasm  other 
 FHOD3   formin homology 2 domain containing 3  Unknown  other 
 FLRT2  fibronectin leucine rich transmembrane protein 2  Plasma Membrane  other 
 FMN1  formin 1  Nucleus  transporter 
 FMN2  formin 2  Unknown  other 
 FN1  fibronectin 1  Plasma Membrane  enzyme 
 FOXF2  forkhead box F2  Nucleus  transcription regulator 
 FSTL5  follistatin-like 5  Extracellular Space  other 
 GAS7  growth arrest-specific 7  Cytoplasm  transcription regulator 
 GCNT2  glucosaminyl (N-acetyl) transferase 2, I-branching enzyme (I blood group)  Cytoplasm  enzyme 
 GHR  growth hormone receptor  Plasma Membrane  transmembrane receptor 
 GJC1  gap junction protein, gamma 1, 45kDa  Plasma Membrane  transporter 
 GLI3  GLI family zinc finger 3  Nucleus  transcription regulator 
 GLUD1  glutamate dehydrogenase 1  Cytoplasm  enzyme 
 GNB4  guanine nucleotide binding protein (G protein), beta polypeptide 4  Plasma Membrane  enzyme 
 GNG2  guanine nucleotide binding protein (G protein), gamma 2  Plasma Membrane  enzyme 
 GPM6B  glycoprotein M6B  Plasma Membrane  other 
 GPR143  G protein-coupled receptor 143  Plasma Membrane  G-protein coupled receptor 
 GPR37  G protein-coupled receptor 37 (endothelin receptor type B-like)  Plasma Membrane  G-protein coupled receptor 
 GPR85  G protein-coupled receptor 85  Plasma Membrane  G-protein coupled receptor 
 GPRC5B  G protein-coupled receptor, family C, group 5, member B  Plasma Membrane  G-protein coupled receptor 
 GREB1  GREB1 protein  Cytoplasm  other 
 GTF2H1  general transcription factor IIH, polypeptide 1, 62kDa  Nucleus  transcription regulator 
 GYG2  glycogenin 2  Unknown  enzyme 
 GYPC  glycophorin C (Gerbich blood group)  Plasma Membrane  other 
 HEY1  hairy/enhancer-of-split related with YRPW motif 1  Nucleus  transcription regulator 
 HHAT  hedgehog acyltransferase  Cytoplasm  enzyme 
 HIST1H4B  histone cluster 1, H4b  Nucleus  other 
 HIVEP2  human immunodeficiency virus type I enhancer binding protein 2  Nucleus  transcription regulator 
 HLA-DMA  major histocompatibility complex, class II, DM alpha  Plasma Membrane  transmembrane receptor 
 HOXC9  homeobox C9  Nucleus  transcription regulator 
 HRASLS  HRAS-like suppressor  Cytoplasm  other 
 HRK  harakiri, BCL2 interacting protein (contains only BH3 domain)  Cytoplasm  other 
 HS6ST2  heparan sulfate 6-O-sulfotransferase 2  Extracellular Space  enzyme 
 HSD17B14  hydroxysteroid (17-beta) dehydrogenase 14  Unknown  enzyme 
 ICAM1  intercellular adhesion molecule 1  Plasma Membrane  transmembrane receptor 
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 ICK  intestinal cell (MAK-like) kinase  Cytoplasm  kinase 
 IFFO1  intermediate filament family orphan 1  Unknown  other 
 IFI16  interferon, gamma-inducible protein 16  Nucleus  transcription regulator 
 IFI44  interferon-induced protein 44  Cytoplasm  other 
 IGF1R  insulin-like growth factor 1 receptor  Plasma Membrane  transmembrane receptor 
 IGSF11  immunoglobulin superfamily, member 11  Unknown  other 
 IKIP  IKK interacting protein  Cytoplasm  other 
 IL17D  interleukin 17D  Extracellular Space  other 
 IL24  interleukin 24  Extracellular Space  cytokine 
 IL6R  interleukin 6 receptor  Plasma Membrane  transmembrane receptor 
 IRF4  interferon regulatory factor 4  Nucleus  transcription regulator 
 JAM3  junctional adhesion molecule 3  Plasma Membrane  other 
 KATNAL1  katanin p60 subunit A-like 1  Unknown  enzyme 
 KIF13A  kinesin family member 13A  Cytoplasm  transporter 
 KYNU  kynureninase (L-kynurenine hydrolase)  Cytoplasm  enzyme 
 LAMA1  laminin, alpha 1  Extracellular Space  other 
 LAMA4  laminin, alpha 4  Extracellular Space  enzyme 
 LAMP2  lysosomal-associated membrane protein 2  Plasma Membrane  enzyme 
 LDOC1  leucine zipper, down-regulated in cancer 1  Nucleus  other 
 LHFP  lipoma HMGIC fusion partner  Unknown  other 
 LIN7B  lin-7 homolog B (C. elegans)  Cytoplasm  other 
 LINS1  lines homolog 1 (Drosophila)  Unknown  other 
 LOC100128202  hypothetical protein FLJ25694  Unknown  other 
 LONRF2  LON peptidase N-terminal domain and ring finger 2  Unknown  other 
 LRGUK  leucine-rich repeats and guanylate kinase domain containing  Unknown  other 
 LUM  lumican  Extracellular Space  other 
 LY96  lymphocyte antigen 96  Plasma Membrane  other 
 LYPD1  LY6/PLAUR domain containing 1  Plasma Membrane  G-protein coupled receptor 
 LYST  lysosomal trafficking regulator  Cytoplasm  transporter 
 LZTS1  leucine zipper, putative tumor suppressor 1  Nucleus  transcription regulator 
 MAFB  v-maf musculoaponeurotic fibrosarcoma oncogene homolog B (avian)  Nucleus  other 
 MAGEA1   melanoma antigen family A, 1 (directs expression of antigen MZ2-E)  Plasma Membrane  other 
 MAGEA10  melanoma antigen family A, 10  Unknown  other 
 MAGEC2  melanoma antigen family C, 2  Plasma Membrane  other 
 MAGEE1  melanoma antigen family E, 1  Plasma Membrane  other 
 MATN2  matrilin 2  Extracellular Space  other 
 MCC  mutated in colorectal cancers  Unknown  other 
 MCOLN3  mucolipin 3  Cytoplasm  ion channel 
 MCTP1  multiple C2 domains, transmembrane 1  Unknown  other 
 MCTP2  multiple C2 domains, transmembrane 2  Unknown  other 
 MDFIC  MyoD family inhibitor domain containing  Nucleus  other 
 MDFIC  MyoD family inhibitor domain containing  Nucleus  other 
 MEF2A   myocyte enhancer factor 2A  Nucleus  transcription regulator 
 MEF2D  myocyte enhancer factor 2D  Nucleus  transcription regulator 
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 MGC9913  hypothetical protein MGC9913  Unknown  other 
 MLANA  melan-A  Plasma Membrane  other 
 MMP1   matrix metallopeptidase 1 (interstitial collagenase)  Extracellular Space  peptidase 
 MOXD1  monooxygenase, DBH-like 1  Cytoplasm  enzyme 
 MSRB3   methionine sulfoxide reductase B3  Cytoplasm  enzyme 
 MTMR9  myotubularin related protein 9  Unknown  phosphatase 
 MYLK  myosin light chain kinase  Cytoplasm  kinase 
 MYO5A  myosin VA (heavy chain 12, myoxin)  Cytoplasm  enzyme 
 NAV2  neuron navigator 2  Nucleus  other 
 NAV3  neuron navigator 3  Unknown  other 
 NDN  necdin homolog (mouse)  Nucleus  other 
 NEDD4L  neural precursor cell expressed, developmentally down-regulated 4-like  Cytoplasm  enzyme 
 NEFL  neurofilament, light polypeptide  Cytoplasm  other 
 NLGN1  neuroligin 1  Plasma Membrane  enzyme 
 NNMT  nicotinamide N-methyltransferase  Cytoplasm  enzyme 
 NOV  nephroblastoma overexpressed gene  Extracellular Space  growth factor 
 NOX4  NADPH oxidase 4  Cytoplasm  enzyme 
 NR3C1  nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)  Nucleus  ligand-dependent nuclear receptor 
 NR4A2  nuclear receptor subfamily 4, group A, member 2  Nucleus  ligand-dependent nuclear receptor 
 NR4A3  nuclear receptor subfamily 4, group A, member 3  Nucleus  ligand-dependent nuclear receptor 
 NRCAM  neuronal cell adhesion molecule  Plasma Membrane  other 
 OLFML2A  olfactomedin-like 2A  Unknown  other 
 OLIG2  oligodendrocyte lineage transcription factor 2  Nucleus  transcription regulator 
 OSTM1  osteopetrosis associated transmembrane protein 1  Plasma Membrane  other 
 PAG1  phosphoprotein associated with glycosphingolipid microdomains 1  Plasma Membrane  other 
 PAX3  paired box 3  Nucleus  transcription regulator 
 PCDH20  protocadherin 20  Unknown  other 
 PCDHB5  protocadherin beta 5  Plasma Membrane  other 
 PCLO  piccolo (presynaptic cytomatrix protein)  Cytoplasm  transporter 
 PCTK2  PCTAIRE protein kinase 2  Cytoplasm  kinase 
 PDGFD  platelet derived growth factor D  Extracellular Space  growth factor 
 PDK4  pyruvate dehydrogenase kinase, isozyme 4  Cytoplasm  kinase 
 PDZRN3  PDZ domain containing ring finger 3  Extracellular Space  other 
 PELO  pelota homolog (Drosophila)  Nucleus  other 
 PFTK1  PFTAIRE protein kinase 1  Nucleus  kinase 
 PGBD1  piggyBac transposable element derived 1  Unknown  enzyme 
 PHACTR1  phosphatase and actin regulator 1  Cytoplasm  other 
 PKIA  protein kinase (cAMP-dependent, catalytic) inhibitor alpha  Unknown  other 
 PKNOX2  PBX/knotted 1 homeobox 2  Nucleus  other 
 PLD1  phospholipase D1, phosphatidylcholine-specific  Cytoplasm  enzyme 
 PLEKHA8  pleckstrin homology domain containing, family A  member 8  Unknown  other 
 PLEKHO1  pleckstrin homology domain containing, family O member 1  Plasma Membrane  other 
 PLSCR4  phospholipid scramblase 4  Plasma Membrane  enzyme 
 PLTP  phospholipid transfer protein  Extracellular Space  other 
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 PLXNC1  plexin C1  Plasma Membrane  other 
 PNMA2  paraneoplastic antigen MA2  Nucleus  transporter 
 POU3F2  POU class 3 homeobox 2  Nucleus  transcription regulator 
 POU3F2  POU class 3 homeobox 2  Nucleus  transcription regulator 
 PPM1E  protein phosphatase 1E (PP2C domain containing)  Nucleus  phosphatase 
 PPP2R3A  protein phosphatase 2 (formerly 2A), regulatory subunit B'', alpha  Nucleus  phosphatase 
 PREX1  phosphatidylinositol-3,4,5-trisphosphate-dependent Rac exchange factor 1  Cytoplasm  other 
 PRKACB  protein kinase, cAMP-dependent, catalytic, beta  Cytoplasm  kinase 
 PRKD1  protein kinase D1  Cytoplasm  kinase 
 PRUNE2  prune homolog 2 (Drosophila)  Unknown  other 
 PTPRM  protein tyrosine phosphatase, receptor type, M  Plasma Membrane  phosphatase 
 PTPRM  protein tyrosine phosphatase, receptor type, M  Plasma Membrane  phosphatase 
 QKI  quaking homolog, KH domain RNA binding (mouse)  Nucleus  other 
 RAB32  RAB32, member RAS oncogene family  Cytoplasm  other 
 RAB38  RAB38, member RAS oncogene family  Cytoplasm  enzyme 
 RHOBTB1  Rho-related BTB domain containing 1  Unknown  enzyme 
 RHOJ  ras homolog gene family, member J  Cytoplasm  enzyme 
 RHOQ  ras homolog gene family, member Q  Plasma Membrane  enzyme 
 RIMKLB  ribosomal modification protein rimK-like family member B  Unknown  other 
 RNF182  ring finger protein 182  Unknown  other 
 ROPN1B  ropporin, rhophilin associated protein 1B  Cytoplasm  other 
 RRP15  ribosomal RNA processing 15 homolog (S. cerevisiae)  Nucleus  other 
 RUNX3  runt-related transcription factor 3  Nucleus  transcription regulator 
 S100B  S100 calcium binding protein B  Cytoplasm  other 
 SAMD9L  sterile alpha motif domain containing 9-like  Unknown  other 
 SCFD2  sec1 family domain containing 2  Unknown  transporter 
 SEC22A  SEC22 vesicle trafficking protein homolog A (S. cerevisiae)  Cytoplasm  transporter 
 SEC22C  SEC22 vesicle trafficking protein homolog C (S. cerevisiae)  Cytoplasm  other 
 SEMA5A  sema domain,(semaphorin) 5A  Plasma Membrane  transmembrane receptor 
 SEMA6A  sema domain, (semaphorin) 6A  Plasma Membrane  other 
 SEMA6D  sema domain,(semaphorin) 6D  Plasma Membrane  other 
 SGCD  sarcoglycan, delta (35kDa dystrophin-associated glycoprotein)  Cytoplasm  other 
 SH3TC1  SH3 domain and tetratricopeptide repeats 1  Unknown  other 
 SHOX2  short stature homeobox 2  Nucleus  transcription regulator 
 SLAIN1  SLAIN motif family, member 1  Unknown  other 
 SLAMF7  SLAM family member 7  Plasma Membrane  other 
 SLAMF9  SLAM family member 9  Extracellular Space  other 
 SLC25A13  solute carrier family 25, member 13 (citrin)  Cytoplasm  transporter 
 SLC47A1  solute carrier family 47, member 1  Unknown  other 
 SLFN12  schlafen family member 12  Nucleus  enzyme 
 SMCR8  Smith-Magenis syndrome chromosome region, candidate 8  Unknown  other 
 SNAI2  snail homolog 2 (Drosophila)  Nucleus  other 
 SNAP25  synaptosomal-associated protein, 25kDa  Plasma Membrane  transporter 
 SNCA  synuclein, alpha (non A4 component of amyloid precursor)  Cytoplasm  other 
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 SNCA  synuclein, alpha (non A4 component of amyloid precursor)  Cytoplasm  other 
 SNRPN  small nuclear ribonucleoprotein polypeptide N  Nucleus  other 
 SOX10  SRY (sex determining region Y)-box 10  Nucleus  transcription regulator 
 SOX6  SRY (sex determining region Y)-box 6  Nucleus  transcription regulator 
 SPARC  secreted protein, acidic, cysteine-rich (osteonectin)  Extracellular Space  other 
 SPESP1  sperm equatorial segment protein 1  Cytoplasm  other 
 SPG20  spastic paraplegia 20 (Troyer syndrome)  Cytoplasm  other 
 SPP1  secreted phosphoprotein 1  Extracellular Space  cytokine 
 SPRYD5  SPRY domain containing 5  Unknown  other 
 SRPX  sushi-repeat-containing protein, X-linked  Cytoplasm  other 
 SSH1  slingshot homolog 1 (Drosophila)  Cytoplasm  phosphatase 
 SSX2IP  synovial sarcoma, X breakpoint 2 interacting protein  Plasma Membrane  other 
 ST3GAL6  ST3 beta-galactoside alpha-2,3-sialyltransferase 6  Cytoplasm  enzyme 
 ST6GALNAC3  ST6  Cytoplasm  enzyme 
 STK32B  serine/threonine kinase 32B  Unknown  kinase 
 STX7  syntaxin 7  Plasma Membrane  transporter 
 SULT1C2  sulfotransferase family, cytosolic, 1C, member 2  Cytoplasm  enzyme 
 SYNM  synemin, intermediate filament protein  Cytoplasm  other 
 SYT14  synaptotagmin XIV  Unknown  transporter 
 TAF9B  TAF9B RNA polymerase II, TATA box binding protein (TBP)-associated factor, 31kDa  Nucleus  transcription regulator 
 TBX2  T-box 2  Nucleus  transcription regulator 
 TCHP  trichoplein, keratin filament binding  Cytoplasm  other 
 TIMP3  TIMP metallopeptidase inhibitor 3  Extracellular Space  other 
 TM4SF18  transmembrane 4 L six family member 18  Unknown  other 
 TMEM108  transmembrane protein 108  Unknown  other 
 TMOD2  tropomodulin 2 (neuronal)  Cytoplasm  other 
 TMSB15A  thymosin beta 15a  Cytoplasm  other 
 TNFAIP3  tumor necrosis factor, alpha-induced protein 3  Nucleus  other 
 TNFAIP3  tumor necrosis factor, alpha-induced protein 3  Nucleus  other 
 TNS1  tensin 1  Plasma Membrane  other 
 TPM3  tropomyosin 3  Cytoplasm  other 
 TRIB2  tribbles homolog 2 (Drosophila)  Plasma Membrane  kinase 
 TRIM63  tripartite motif-containing 63  Nucleus  enzyme 
 TRPM1  transient receptor potential cation channel, subfamily M, member 1  Plasma Membrane  ion channel 
 TTYH2  tweety homolog 2 (Drosophila)  Unknown  ion channel 
 TUSC3  tumor suppressor candidate 3  Extracellular Space  enzyme 
 TWISTNB  TWIST neighbor  Unknown  other 
 TYR  tyrosinase (oculocutaneous albinism IA)  Cytoplasm  enzyme 
 UGGT2  UDP-glucose glycoprotein glucosyltransferase 2  Cytoplasm  enzyme 
 VANGL2  vang-like 2 (van gogh, Drosophila)  Plasma Membrane  other 
 VEPH1  ventricular zone expressed PH domain homolog 1 (zebrafish)  Nucleus  other 
 VLDLR  very low density lipoprotein receptor  Plasma Membrane  transporter 
 VPS53  vacuolar protein sorting 53 homolog (S. cerevisiae)  Cytoplasm  other 
 WASF3  WAS protein family, member 3  Cytoplasm  other 
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 WDR91  WD repeat domain 91  Unknown  other 
 WIPF1  WAS/WASL interacting protein family, member 1  Cytoplasm  other 
 ZBTB38  zinc finger and BTB domain containing 38  Nucleus  transcription regulator 
 ZEB2  zinc finger E-box binding homeobox 2  Nucleus  transcription regulator 
 ZFP82  zinc finger protein 82 homolog (mouse)  Nucleus  other 
 ZNF134  zinc finger protein 134  Nucleus  transcription regulator 
 ZNF148  zinc finger protein 148  Nucleus  transcription regulator 
 ZNF280B  zinc finger protein 280B  Nucleus  other 
 ZNF329  zinc finger protein 329  Unknown  other 
 ZNF331  zinc finger protein 331  Nucleus  other 
 ZNF347  zinc finger protein 347  Nucleus  other 
 ZNF354C  zinc finger protein 354C  Nucleus  other 
 ZNF426  zinc finger protein 426  Nucleus  other 
 ZNF480  zinc finger protein 480  Nucleus  other 
 ZNF512B  zinc finger protein 512B  Nucleus  other 
 ZNF542  zinc finger protein 542  Unknown  other 
 ZNF654  zinc finger protein 654  Unknown  other 
 ZNF655  zinc finger protein 655  Nucleus  other 
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Appendix II Genes exclusively not expressed by CoLo741 (By Microarray 
analysis) 
Symbol Entrez Gene Name Location Type(s) 
    
 ABLIM1  actin binding LIM protein 1  Cytoplasm  other 
 AKR1A1  aldo-keto reductase family 1, member A1 (aldehyde reductase)  Cytoplasm  enzyme 
 ANXA3  annexin A3  Cytoplasm  enzyme 
 ASS1  argininosuccinate synthetase 1  Cytoplasm  enzyme 
 C19ORF33  chromosome 19 open reading frame 33  Nucleus  other 
 CD24  CD24 molecule  Plasma Membrane  other 
 CDH1  cadherin 1, type 1, E-cadherin (epithelial)  Plasma Membrane  other 
 CENPV  centromere protein V  Nucleus  other 
 DSG2  desmoglein 2  Plasma Membrane  other 
 FUT4  fucosyltransferase 4 (alpha (1,3) fucosyltransferase, myeloid-specific)  Cytoplasm  enzyme 
 KLF4  Kruppel-like factor 4 (gut)  Nucleus  transcription regulator 
 KRT19  keratin 19  Cytoplasm  other 
 MALL  mal, T-cell differentiation protein-like  Plasma Membrane  other 
 ME1  malic enzyme 1, NADP(+)-dependent, cytosolic  Cytoplasm  enzyme 
 MYO5C  myosin VC  Unknown  other 
 PERP  PERP, TP53 apoptosis effector  Plasma Membrane  other 
 PLA2G16  phospholipase A2, group XVI  Nucleus  other 
 SLC27A2  solute carrier family 27 (fatty acid transporter), member 2  Cytoplasm  transporter 
 SLC38A1  solute carrier family 38, member 1  Plasma Membrane  transporter 
 ST14  suppression of tumorigenicity 14 (colon carcinoma)  Plasma Membrane  peptidase 
 TSTD1  thiosulfate sulfurtransferase (rhodanese)-like domain containing 1  Unknown  other 
 VAMP8  vesicle-associated membrane protein 8 (endobrevin)  Plasma Membrane  other 
        
 
 
